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Experiments were designed to confirm the existence in bloodstream 
forms of T.b.brucei of a small, but significant, proportion of supplied glucose 
being metabolised through an oxidative pentose phosphate pathway leading to 
provision of ribose-5-phosphate which is subsequently incorporated into RNA. 
The experiments also confirmed the existence of some de novo synthesis of 
pyrimidine bases, but not purines.
Phosphoribosyl pyrophosphate (PRPP) is the essential substrate for 
supply of the ribose moiety in the biosynthesis of purine and pyrimidine 
nucleotides. It occupies a unique position connecting the major metabolic 
pathways of the pentose phosphate shunt and nucleotide synthesis.
Phosphoribosylpyrophosphate synthetase (ATP:D-ribose-5’-phosphate 
pyrophosphotransferase, PRPP synthetase,EC 2.7.6.1) is the sole enzyme 
responsible for the formation of PRPP and so its presence was investigated in 
bloodstream forms of T.brucei. The enzyme was detected in bloodstream forms 
and the cultured procyclic forms of T.brucei by an adapted form of assay 
measuring the PRPP-conversion of [8 -^C ] Hypoxanthine to [^ C ]  5'-IMP in the 
presence of hypoxanthine-guanine phosphoribosyltransferase. The specific 
activity of the enzyme in the crude extracts of bloodstream forms was calculated 
to be 0.125 nmoles PRPP formed/min/mg cell protein.
The enzyme from the bloodstream form was partially purified and 
characterised and its properties compared to those PRPP synthetases from other 
sources.
The partially purified enzyme was found to have a Michaelis constant for 
D-ribose-5'-phosphate of 0.027mM. MgATP^- acts as an inhibitor at high 
substrate concentrations, with Km of 0.063mM and Ki of 0.250mM. Although 
inorganic phosphate did not seem significantly to stabilise the enzyme during 
storage at 4°C, glycerol at 20% (v/v) concentration increased its stability with 
time. There was no activity with other triphosphates except dATP which gave 
75% of the activity with ATP.
XVI
Gel filtration studies showed that the partially purified enzyme has a 
molecular weight of -180,000. Using subcellular fractions provided by Dr. F. R. 
Opperdoes, PRPP synthetase activity was found mainly in the cytosolic fraction, 
albeit with a sedimentation behaviour that indicated a very high molecular 
weight. This dichotomy was resolved when it was found that the molecular 
weight of the enzyme in crude extracts, prepared similarly to that used for the 
localisation study, was in excess of 600,000. The formation of high molecular 




The word 'parasite', derived from ancient Greek, means one frequenting 
the tables of the rich and earning welcome by flattery. It includes examples of all 
the known infectious agents such as viruses, bacteria, fungi, protozoa and 
helminths, which at some time during their life cycle intimately associate with 
the infected host, even though the host may not be flattered and the infectious 
agents may not be exactly welcome (Wang, 1983). In further contrast to the 
above definition, the parasites of most medical importance are sitting at the 
tables of the poor and causing 3 billion people malnutrition, blindness, debility, 
disfiguration, and death in the tropics and subtropics and to domesticated animals 
all over the world. The cost of parasites in terms of human misery and economic 
loss is incalculable.
The medical importance of trypanosomiases and leishmaniases is 
emphasised by the inclusion of African and South American trypanosomiases 
and leishmaniases as two target diseases of the World Health Organisation 
Programme for the Research and Training in Tropical Diseases (TDR) sponsored 
by the World Bank and the United Nations Development Programme (Trigg, 
1979). For both diseases vector control is either very expensive or impractical 
and drugs are either toxic or unavailable since pharmaceutical companies turned 
their backs on these diseases as potential sources of revenue (Molyneux and 
Ashford, 1983).
1.1. Introduction to trypanosomes.
Trypanosomes are parasitic protozoa that cause several serious diseases 
of humans and domestic animals in tropical Africa and South America. The 
family Tiypanosomatidae consists of a great variety of genera that infect birds, 
mammals (!Trypanosoma, Leishmania), fish, amphibia, insects {Crithidia spp.), 
and even plants. Many have complex life cycles that may comprise both 
extracellular and intracellular forms. Transmission to the vertebrate host always 
takes place via blood-sucking vectors, such as flies, bugs, fleas, or leeches. The
classification of the genus Trypanosoma is shown in figure 1.1. The two main 
groups of the genus reflect the mode of transmission by the insect vector, the 
Stercoraria (faecal transmission) and the Salivaria (salivary transmission).
Over the last two decades these parasitic protozoans have attracted much 
attention because they combine a number of peculiarities. The five main 
structural features characteristic of trypanosomes are shown in figure 1.2 and are:
(1) a single flagellum,
(2) a complex skeletal array of subpellicular microtubules,
(3) glycosomes,
(4) a single mitochondrion associated with
(5) a dense network of DNA called kinetoplast (Fairlamb, 1982).
The forms in the life cycle of the kinetoplastid flagellates are brought 
about by the migration of the kinetoplast-flagellum complex within the body 
(Vickerman, 1976), as shown in figure 1.3. The leishmanial parasites possess 
only two forms in their life cycles; amastigotes in the cells of the lymphoid 
macrophage system of a mammal or lizard and promastigotes in the gut of the 
vector which is a sand-fly (Diptera, Phlebotomidae). Leishmania species cause 
serious diseases in man. The typical infection is cutaneous but in many species, 
the parasites may invade subcutaneous or deeper tissues causing hideous and 
permanent disfiguration. The most serious disease, Kala azar, involves the 
macrophages of organs such as liver. The main species of Leishmania that affect 
man are Lmexicana, LJbraziliensis, Lxropica and L.donovani (Cox, 1982).
1.2. African trypanosomes.
Salivarian trypanosomes cause African sleeping sickness in humans 
(T.b.rhodesiense and T.b.gambiense), nagana in cattle (J'.b.brucei, T.b.vivax, 
T.b.congolense), surra in horses and camels (T.b.evansi) and dourine in horses 
(T.b.equiperdum).
Recent estimates suggest that 45 million people are exposed to the risk of 








SECTION 1: Salivaria 
SUB-GENUS: Trypanozoon 
SPECIES: Trypanosoma brucei brucei
Trypanosoma brucei rhodesiense 
Trypanosoma brucei gambiense 
for example.
SECTION 2: Stercoraria 
SUB-GENUS: Schizotrypanum 
SPECIES: Trypanosoma cruzi.
Figure 1.1. The classification of Trypanosomes (according to Cox, 1982 ; 
Molyneux and Ashford, 1983).
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Figure 1.2. The gross morphology of T.b.brucei (intermediate bloodstream 
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Figure 1.3. Different forms of trypanosomes according to kinetoplast-nucleus 





year (De Raadt, 1976), but serious outbreaks in Cameroon, the Sudan and 
Uganda have increased the annual incidence to at least 20,000 (Goodwin, 1985). 
The 1985 Ugandan epidemic caused by the rhodesiense form of the disease and 
the outbreaks in the Southern Sudan since the 1970s of the gambiense form 
illustrate the profound effects of the breakdown of diagnostic and surveillance 
facilities brought about through civil unrest
The three forms of the Trypanozoon subgenera, Tb.rhodesiense,
T.b.gambiense and Tb.brucei, are thought to be identical both morphologically 
and biochemically (Hoare, 1964), but some biochemical differences may exist, 
particularly in their infectivity to man; T.bbrucei being unable to survive in the 
human bloodstream due to a component of human serum, thought to be a high- 
density lipoprotein, which causes this trypanosome to lyse (Rifkin, 1978) . 
Infection with Tb.gambiense gives rise to the chronic form of the disease while 
an infection with Tb.rhodesiense follows a more acute course (Wakelin, 1984).
The first sign of the acute form of sleeping sickness is a swollen, rubbery 
chancre at the site of infection or frequently a more general oedema of the face. 
Some weeks following infection a fever develops, irregular and intermittent in 
nature, more intense in the acute form of the disease. Other symptoms of general 
malaise include headache, pains of the joints, loss of weight, insomnia and 
anaemia. It is the invasion and destruction of the central nervous system that 
makes the disease invariably fatal. Invasion of the central nervous system is 
accompanied by epileptic fits, loss of apetite, and eventual death due to 
respiratory failure, altered heart rhythm and beat or by secondary infections 
caused by the immunosuppressive activity of the trypanosomes.
Animal trypanosomiasis (nagana) is a serious obstacle to human welfare, 
because it causes severe nutritional and economic problems. Over three million 
cattle die each year from various forms of the disease, and the rearing of 
domestic cattle, sheep and goats is impossible in 10 million square kilometers of 
Africa which is the habitat of the tsetse fly {Glossina spp.).
1.3. South American trvpanosomes.
The most important South American trypanosome is T.cruzi. At least 20 
million people in South America are infected with T.cruzi\ in Brazil alone the 
annual incidence of new cases of Chagas' disease is estimated at 120,000. Young 
children are particularly likely to die in the acute febrile stage, whereas adults 
tend to survive to the chronic phase of the disease, in which parasite damage to 
the heart muscle causes congestive heart failure and autonomic nervous tissue 
damage causes dilatation of the oesophagus and colon. Other stercorarian 
parasites of importance include, T.lewisi of rats, Txheileri of cattle and 
T jnelophagium of sheep.
1.4. Life cvcle of T.b.brucei.
Tb.brucei is cyclically transmitted from mammal to mammal by the 
insect vector, the tsetse fly, during feeding (see figure 1.4).
Different developmental stages of the life cycle have markedly different 
morphology and biochemical activity. When an infected tsetse fly bites an 
uninfected human or animal, metacyclic forms are injected with the fly’s salivary 
secretions. These forms develop into trypomastigote forms and migrate to the 
bloodstream. Bloodstream trypomastigotes show considerable variation in 
morphology (pleomorphism), ranging from slender to stumpy forms. Stumpy 
forms are non-dividing and are thought to be a preadaptation necessary for 
survival in the insect midgut After a blood meal from an infected animal, short 
stumpy forms develop into procyclic trypomastigotes which ultimately migrate 
to the fly's salivary glands to complete the cycle (Fairlamb, 1982).
1.5. Life cvcle of T.cruzi.
T.cruzi is transmitted by reduviid bugs. Development in the insect vector 
takes place in the gut, the infective trypomastigote form occuning in the hind 
gut. Transmission of these parasites to vertebrates takes place when infected 
faeces of the vector come into contact with broken skin or mucous membranes,
9Figure 1.4. The life cycle of T.b.brucei, with emphasis on the relative sizes of 
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particularly of the eye or by blood transfusions (Fairlamb, 1982). These non­
dividing forms either penetrate new host cells, particularly muscle, or are 
ingested during a blood meal by an uninfected reduviid bug. The life cycle of 
T.cruzi is shown in Figure 1.5.
1.6. The morphology of trypanosomes.
The cyclically transmitted trypomastigotes which occur in the 
bloodstream and tissues of infected animals and man vary widely in size and 
shape, from short stumpy, about 12|im long, to long slender, about 30pm long. 
The trypanosomes are surrounded by a plasma membrane or plasmalemma 
approximately 2-4nm in total width, similar in appearance to that of other animal 
cells. Underlying the plasma membrane there is a series of pellicular 
microtubules which are believed to be of cytoskeletal function and present in 
both the vertebrate and invertebrate forms of Trypanosoma and Leishmania 
(Mdlyneux and Ashford, 1983). Ultrastructural studies suggest that desmosome- 
like structures attach the plasma membrane to the flagellar membrane (figure 
1.2) and sliding of the flagellar microtubules seem to cause the plasma 
membrane to undulate (Smyth, 1976).
An unusual feature of African trypanosomes is the possession of a single 
mitochondrion which undergoes striking changes during the various stages of the 
life-cycle. The mammalian form of trypanosome contains a simple 
mitochondrion which is unbranched with few tubular cristae, while the insect 
form has a fully-developed mitochondrion with numerous plate-like cristae 
(Vickerman, 1965; Fairlamb, 1982). Within the single mitochondrion, a 
characteristic organelle, the kinetoplast, is located. It is made up of a complex 
network of interlocked circular DNA molecules, representing up to 30% of the 
total cellular DNA (Opperdoes, 1985).
In the mammal, all trypanosomes are invested with a compact, 
homogeneous layer of identical glycoprotein molecules, the surface coat, 12- 












Figure 1.5. The life cycle of T.cruzi (Fairlamb, 1982).
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1969; Whitfield, 1979). The 52-69 kDa glycoprotein comprising this coat 
stimulates a powerful immune response on the part of the host, which is evaded 
by switching from expression of one surface glycoprotein to expression of 
another. Antigenic change entails the exposure of new epitopes on the N- 
terminal portion of the glycoprotein polypeptide. When the trypanosomes are 
injected by the fly into the host the majority possess glycoprotein coats of a 
single kind, the homotype. Trypanosomes belonging to one variable antigen type 
(VAT) express the same variant-specific glycoprotein (VSG) gene. A minority of 
this population however have antigenically-different coats or heterotypes by 
VSG switching. The immune system of the host quickly responds to the 
homotype by raising IgM-type antibodies which results in agglutination and 
complement-mediated lysis of the homotype (Cox, 1982). Sacrifice of the 
homotype allows a heterotype to grow up to take its place in the next 
parasitaemic peak characteristic of the undulating parasitaemia of trypanosome 
infections. A single TJbrucei cell has a repertoir of VATs based on about a 
thousand VSG genes which represents between five and ten percent of the total 
genetic capacity of the trypanosome (Donelson and Turner, 1985).
1.7. The Glvcosome.
Glycosomes are microbody-like organelles unique to all of the 
Trypanosomatidae with no mammalian counterpart (Opperdoes, 1988).They are 
homogeneous in size, with an average diameter of 0.27pm. A normal bilayer 
membrane, which is 6-7nm thick, surrounds the contents of the glycosome. On 
average a bloodstream trypanosome contains 240 glycosomes, which represent 
between 4.3% (Opperdoes et al. , 1984) and 8% (Bohringer and Hecker, 1975) of 
its total volume and a similar percentage of its protein content (Misset et al.,
1986; Opperdoes et al. , 1984). Seventy percent of the glycosomal protein has 
been found in the matrix, whereas the remainder seems to be associated with the 
membrane (Opperdoes et al. , 1984). There are a limited number of polypeptides 
which are associated with the bloodstream-form glycosome; the major poly­
13
peptides have all been identified as the subunits of the glycolytic enzymes, which 
together account for more than 87% of the glycosome’s total protein (Aman et 
aLy 1985; Misset, et al. , 1986). In the procyclic stage the relative abundance of 
the glycosomal polypeptides differs significantly, and a few additional 
polypeptide bands have been found (Hart et al, , 1984). The total amount of 
polypeptides is still very limited.
The glycosome contains several enzymes of glycolysis and glycerol 
metabolism as well as enzymes involved in such diverse pathways as carbon 
dioxide fixation, pyrimidine biosynthesis, ether-lipid biosynthesis, and purine 
salvage (Figure 1.6, Opperdoes, 1990).
Only trace amounts of DNA were detected in glycosomal fractions, and 
there has been no indication of a glycosome-specific class of DNA (Opperdoes et 
al. , 1984). Current evidence suggests that glycosomal proteins are encoded in 
the nucleus and synthesised on free polysomes (Hart et al. , 1987). Import into 
the glycosomes occurs within minutes of synthesis without apparent cleavage of 
a signal peptide or other post-translational modification (Hart et al. , 1987). No 
single unifying signal for import of glycosomal enzymes has been identified, 
although Wierenga et al. (1987) proposed that the 'hot spots' characteristic of 
those enzymes, might serve as topogenic signals for import into the glycosome. 
These 'hot spots' are two localised net positively charged clusters of amino acids, 
approximately 40 A apart, found on the surface of the proteins.
Opperdoes and Borst (1977) suggested that the glycosomal membrane 
acts like a selective permeability barrier to the bulk of the phosphorylated 
glycolytic intermediates and proposed that specific translocaters for DHAP, G-3- 
P, PGA, and Pi facilitate their diffusion over the membrane. An alternative 
explanation is that the single unit membrane of the glycosome acts as a simple 
diffusional barrier to both metabolites and coenzymes as well as maintaining a 
locally high concentration of glycolytic enzymes to account for the high 
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Figure 1.6. Enzymes biochemically localised in glycosomes of the 
Trypanosomatidae (Opperdoes, 1990).
1.8. The glvcolvtic pathway in trypanosomes.
The changes in morphology seen during the lifecycle of the trypanosome 
are associated with its ability to adapt its respiratory pathway to the prevailing 
conditions of its environment.
Owing to the absence of a functional mitochondrion, the bloodstream 
form of T.brucei is entirely dependent on glycolysis for its production of energy 
(Grant and Fulton, 1957). Because this form lacks significant polysaccharide 
reserves or high-energy phosphate stores such as creatine phosphate or 
polyphosphates, it relies entirely on an exogenous source of carbohydrate 
(Opperdoes et al. , 1976b). Glucose is the preferred energy source but fructose, 
mannose and glycerol can also support motility and respiration (Ryley, 1962).
The African trypanosome, as exemplified by T.bruceU has an extremely 
high rate of glycolysis (85 nmole glucose are consumed per minute per milligram 
cell protein). Under an aerobiosis, one glucose molecule can generate only two 
ATP molecules, with two pyruvate molecules excreted into the host bloodstream 
as the only end product (Grant and Sargent, 1960; Fairlamb and Bowman, 1980). 
This low energy yield makes it necessary to have such a high glycolytic rate 
(Brohn and Clarkson, 1980). Von Brand (1951) calculated that the amount of 
glucose consumed was equivalent to 50-100% of the dry weight of a cell per 
hour. One mole of oxygen is utilised per mole of glucose (Ryley, 1956) and 
experiments with [^C]glucose have shown that 83% of the glucose carbon can 
hi recovered as pyruvate and 9% as glycerol (Grant and Fulton, 1957).
The high glycolytic rate, 50 times that in the mammalian host, is made 
possible not only by the abundant glucose supply in the host blood 
(approximately lmg per ml, 5mM; Whitfield, 1979), but also by the clustering of 
rrost of the glycolytic enzymes in the glycosomes of the parasite (Opperdoes and 
Borst, 1977).
After the trypanosome's transformation from bloodstream form to insect 
sage its consumption of glucose occurs at a much lower rate (22.5 nmol glucose 
ptr minute per milligram of protein) (Bienen et al. , 1983). The transition is
accompanied by the synthesis of certain enzymes of the tricarboxylic acid (TCA) 
cycle, such as isocitrate dehydrogenase, malate dehydrogenase (Kilgour, 1980), 
and a-oxoglutarate oxidase (Flynn and Bowman, 1973). Glucose is now 
converted to succinate, acetate and CC>2, which are the main end products 
excreted. The oxidative metabolism of amino acids (especially proline) by the 
functional Krebs cycle and the respiratory chain serves as the major source of 
energy in this stage of the life cycle. Proiine is present at concentrations up to 
150mM in the insect where it serves as a source of energy for flight (Bursell,
1966).
Glucose metabolism in the bloodstream form trypanosome differs from 
glycolysis in other eukaryotes in a number of respects: (a) Lactate dehydrogenase 
is absent (Dixon, 1966), and therefore the reducing equivalents generated in 
glycolysis are indirectly reoxidised by molecular oxygen via a dihydroxyacetone 
phosphate (DHAP):glycerol 3-phosphate (G-3-P) shuttle plus a cyanide- 
insensitive mitochondrial oxidase: G-3-P oxidase.
(b) Under aerobic conditions, pyruvate is the sole end product of glycolysis and 
is excreted into the host's bloodstream, (c) Under anaerobic conditions glucose is 
quantitatively converted into equimolar amounts of pyruvate and glycerol, which 
are excreted (Fairlamb et al. , 1977) and for every molecule of glucose 
consumed, one ATP molecule is produced. A similar situation arises under 
aerobic conditions in the presence of the metal-chelating agent 
salicylhydroxamic acid (SHAM), which acts as an inhibitor of a- 
glycerophosphate oxidase, producing an effect which stimulates anaerobiosis 
(Evans and Brown, 1973; Opperdoes et al. , 1976b). It is the coupling of the 
Embden-Meyerhof pathway to the unique L-glycerol-3-phosphate oxidase 
system (Grant and Sargent, 1960) which maintains oxidation-reduction balance 
and adequately accounts for the carbon flow and energy balance under aerobic 
conditions (Opperdoes et al. , 1976a).
Under anaerobic conditions equimolar amounts of pyruvate and glycerol 
are produced (Grant and Fulton, 1957; Brohn and Clarkson, 1980) by a
mechanism which is generally accepted to follow the Embden-Meyerhof 
pathway although reservations have been expressed as to its limitations (Ryley, 
1962; Opperdoes et al. , 1976b). The compartmentalisation of a number of 
glycolytic enzymes in the glycosome has been used to explain the anaerobic 
pathway converting glucose to equimolar pyruvate and glycerol while giving a 
net yield of ATP (Opperdoes and Borst, 1977). Hammond and Bowman (1980) 
have shown that glycerol formation may proceed within the glycosomal 
compartment of the trypanosome cell via reversal of the glycerol kinase reaction 
resulting in ATP synthesis by L-glycerol-3-phosphate-dependent 
phosphorylation of ADP. This thermodynamically unfavourable reaction may 
proceed due to efficient compartmentation of the trypanosome cell leading to 
high local concentrations of G-3-P. This factor coupled with glucose 
phosphorylation from G-3-P-dependent ATP formation would allow this reaction 
to proceed in the direction of ATP generation (Kohler, 1982).
nuclear magnetic resonance (NMR) studies of anaerobic glycolysis 
in T.brucei spp. have confirmed that the end-products of glucose metabolism 
were glycerol and pyruvate together with alanine and dihydroxypropionate 
(Mackenzie et al. , 1983). In agreement with Grant and Fulton (1957), the 
NMR data obtained by Mackenzie et al. (1983) showed that C-l of [1-^C]- 
glucose is incorporated into the C-l (= C-3) of glycerol to the extent of 2 to 1 
over C-3 of pyruvate. However, in contrast to the early studies, the same 
incorporation (66 %) of C-6 of [6-^C]glucose into C-3 of pyruvate, alanine, and 
2,2-dihydroxypropionate (collectively) over C-l,3 of glycerol was found 
(Mackenzie et al., 1983). Comparison of whole-cell and acid-lysate high 
resolution ^C  NMR spectra concluded that pyruvate may be initially formed 
bound to a macromolecular species and that 10% of pyruvate produced was 
transaminated to alanine in vivo. For Scheme 1 in figure 1.7 (Mackenzie et al., 
1982) to hold, the rates of formation of glycerol from DHAP and pyruvate from 
GAP would need to be equal and greater that the rate of the triose phosphate 
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Figure 1.7. Embden-Meyerhof glycolytic pathway showing the fate of C-l (•) 
and C-6 (fc) of glucose in T.b.brucei bloodstream forms. Equilibrium (a) denotes 
the triosephosphate isomerase reaction. P in a circle represents phosphate. 
Abbreviations: G-6-P, glucose-6-phosphate ; FDP, fructose-1,6-diphosphate; 
GAP, glyceraldehyde-3-phosphate; DHAP, dihydroxyacetone phosphate; G-3-P, 
L-glycerol-3-phosphate; 1,3-DPGA, 1,3-diphosphateglycerate (Mackenzie etal. , 
1982).
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Mackenzie et al. (1983), that there is rapid equilibration in the triose phosphate 
isomerase reaction, adds to the discrepancy between the results obtained by the 
different workers.
These observations together with the equimolar production of glycerol 
and pyruvate provide compelling evidence that Scheme 1 (figure 1.7) does not 
give a true picture of anaerobic glycolysis and that an alternative pathway must 
exist
These observations cannot be reconciled by the high degree of 
compartmentation in Tbrucei spp. as no transmembrane processes were 
involved. This was due to the inhibition of the promitochondrial G-3-P-oxidase 
under anaerobic conditions which caused the concentration of cytosolic DHAP to 
rapidly diminish and inactivated the putative specific translocator for DHAP in 
the DHAP-G-3-P shuttle (Visser et al. , 1981). Some of the glycolytic enzymes 
associated with glycosomes, for example, D-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), are present also in the cytosol, where they are 
represented by a different isoenzyme (Opperdoes et al. , 1986; Misset et al. , 
1987).
One theoretical alternative involves the transphosphorylation between 
glycerolphosphate and a hexose monophosphate, avoiding the loss of one 
phosphate per glucose in Scheme 1 (figure 1.7), when glycerolphosphate is 
hydrolysed to glycerol and inorganic phosphate. Another alternative involves the 
splitting of a hexosemonophosphate into a triosephosphate and a triose. This 
would create a hydrogen acceptor (the triose) to re-oxidise NADH without the 
investment of a phosphate. Both pathways would allow glycolysis to operate 
anaerobically with a yield of one phosphate per glucose, rather than the 2 
phosphates per glucose obtained aerobically. However, the enzymes catalysing 
such reactions have not been reported in trypanosomes.
Glucose has to pass the plasma membrane, the cell-sap and the 
glycosomal membrane before it can be phosphorylated by hexokinase.
Gruenberg et al. (1978), suggested that the entry of D-glucose into the cell might
be the rate limiting step in glycolysis, and Nwagwu and Opperdoes (1982) came 
to the same conclusion in their studies of the regulation of glycolysis in TJbrucei. 
Comparison of the kinetic constants of D-glucose metabolism with those for 6- 
deoxy-D-glucose transport, by Eisenthal et al. (1989), has shown that transport 
across the plasma membrane was likely to be the rate-limiting step of glucose 
utilisation. The very high transport rate of glucose into the cell is required to 
match the high metabolic capacity of these organisms.
1.9. The pentose phosphate pathway of glucose metabolism.
It is generally recognised that the pentose phosphate pathway (PPP) 
fulfills two main functions in metabolism, the formation of ribose 5-phosphate 
(R5P) for nucleotide and nucleic acid synthesis and the generation of NADPH as 
a source of reducing equivalents for biosynthetic reactions. In addition, other 
intermediates of the pathway such as erythrose 4-phosphate or sedoheptulose 7- 
phosphate may be needed by certain microorganisms for the manufacture of 
aromatic amino acids or the incorporation into cell wall glycolipids respectively 
(Srinivasan et al. , 1955; Eiderls and Osborn, 1971).
The pathway was formulated in its classical form as a cycle by Horecker 
and Mehler (1955). The sequence of reactions is shown in Scheme 2 (figure 1.8) 
in which six molecules of hexose phosphate traverse the cycle with the formation 
of six molecules of carbon dioxide and six molecules of pentose phosphate. 
These six molecules of pentose phosphate are converted into four molecules of 
hexose phosphate and two molecules of triose phosphate. The two triose 
phosphate molecules may be condensed together by aldolase to form hexose 
bisphosphate, which can be split by a phosphatase, forming another molecule of 
hexose monophosphate and a molecule of inorganic phosphate. Thus, the six 
molecules of hexose phosphate entering the cycle emerge as five molecules of 
carbon dioxide derived exclusively from C-l of glucose 6-phosphate.
Although originally presented as the ’pentose phosphate cycle’, it has 
gradually become clear that the ’cycle' can operate as two separate pathways. The
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Figure 1.8. Distribution of carbon atoms after passage of six molecules of 
hexose phosphate through the classical pentose phosphate pathway (Axelrod,
1967).
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'oxidative branch' generates pentose phosphate and NADPH via the two 
dehydrogenases at the start of the pathway. The non-oxidative branch 
equilibrates the pentose phosphates with the hexose phosphates of glycolysis via 
the remaining enzymes of the pathway, in particular transketolase (TK) and 
transaldolase (TA) (Spydevold et al. , 1978). Pentose phosphate formed by the 
oxidative branch and not further utilised is converted back to hexose phosphate 
by the non-oxidative branch and re-enters the glycolysis pathway.
The 'classical' pathway, as formulated by Horecker and Mehler (1955) 
leads to the redistribution of the carbon atoms of hexose phosphate illustrated in 
scheme 3 (figure 1.9; Axelrod, 1967)
1.10. Pentose phosphate pathway in T.bruceL
As early as 1957, Grant and Fulton showed that bloodstream forms of the 
African trypanosomes metabolised isotopically labelled glucose by a classical 
glycolytic pathway. The pentose phosphate pathway in which the C-l of glucose 
is evolved as CO2 did not appear to be significant under the conditions used, 
since only 0.6% of [l-^C]glucose and 0.7% of [3,4-^C]glucose was evolved as 
^CC>2. This is in contrast to T.cruzi, where there is a marked differential release 
of ^CC>2 from [l-^C]glucose and [6- -^C]glucose of 28% and 5.2%, 
respectively (Bowman etal.y 1963).
Ryley (1962), demonstrated the presence of low amounts of glucose 6- 
phosphate dehydrogenase activity in both cultured procyclic and bloodstream 
forms of T.b.rhodesiense. The significance of glucose 6-phosphate 
dehydrogenase was obscure in the apparent absence of the second enzyme 6- 
phosphogluconate dehydrogenase (Ryley, 1962). The absence of Mg^+ in the 
assay may have been a possible reason for the lack of detection of this enzyme, 
since recent screening of bloodstream and cultured procyclic forms of T.brucei 
has shown that they contained glucose 6-phosphate dehydrogenase, 6- 
phosphogluconolactonase, 6-phosphogluconate dehydrogenase, ribose 5- 
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activities (>0.5 nmole.min" .^mg cell protein'*) of ribulose 5-phosphate 3'- 
epimerase and transketolase (Cronin et al. , 1989).
It seems probable that only the procyclic forms are capable of relying on 
the non-oxidative branch of the classical PPP to cycle carbon between pentose 
and hexose phosphates in order to produce glyceraldehyde 3-phosphate as a net 
product of the pathway. Both forms lack the key gluconeogenic enzyme, 
fructose-bisphosphatase. Consequently, procyclic forms are incapable of 
returning any of the glyceraldehyde 3-phosphate produced in the PPP to glucose 
6-phosphate, and neither form is able to engage in gluconeogenesis. In addition, 
neither form had detectable activities of the key enzymes of the Entner- 
Doudoroff pathway, 6-phosphogluconate dehydratase and 2-keto-3-deoxy-6- 
phosphogluconate aldolase (Ryley, 1962; Cronin etal. , 1989).
The results of Cronin et al. (1989) clearly demonstrated that both cultured 
procyclic and bloodstream forms of T.brucei contain the enzymic capacity to 
metabolise glucose via the oxidative segment of the classical PPP in order to 
produce R5P for the synthesis of nucleic acids and reduced NADP for other 
synthetic reactions.
The importance of the PPP in the production of most of the NADPH used 
for biosynthetic processes is not relevant to parasites. Trypanosomes get their 
NADPH by the action of malic enzyme, so the only essential role of the pathway 
is to produce pentose for nucleic acid synthesis as in HeLa cells (Reitzer et al. , 
1980). The cellular growth rate of HeLa cells was proportional to the rate of 
pentose phosphate synthesis. In rat adipose tissue both the PPP and malic 
enzyme provide the NADPH requirement of these cells (Gumaa et al. , 1973).
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1.11. Alternative routes for ribose-5-phosphate synthesis.
In addition to the PPP formation of R5P, other routes also exist by which 
ribose phosphates are formed:
(a) Direct phosphorylation of pentoses.
Direct phosphorylation of pentoses may lead either to ribose-5-phosphate, 
or to other pentose-5-phosphates from which it can be derived. Three such 
reactions are listed below:
Ribose + A TP > Ribose-5-P + ADP.
Ribulose + ATP > Ribulose-5-P + ADP.
Xylulose + ATP ----- > Xylulose-5-P + ADP.
All three enzymes have been reported in various microorganisms, and 
low activities have also been found in animal tissues such as liver and thyroid.
(b) Phosphoribomutase reaction.
Ribose-5-phosphate can be formed from ribose-1-phosphate by the action 
of the enzyme phosphoribomutase:
Ribose- 1-P <----- > Ribose-5-phosphate.
This reaction can also be catalysed by phosphoglucomutase and has been 
studied by Klenow and Emberland (1955).
Ribose-1-P can also originate from the phosphorolysis of nucleosides 
through the action of nucleoside phosphorylases, as shown below:
Nucleoside + Pi <------> Ribose-1-P + Base.
Mg2*
1.12. Carbohydrate metabolism in T.cruzi.
The substrates utilised and the catabolic pathways present in the 
mammalian forms of T.cruzi are similar to those of culture forms of the organism 
and are quite distinct from those of the bloodstream forms of the African 
trypanosomes (Rogerson and Gutteridge, 1979). Culture, blood and intracellular 
forms of T.cruzi have a high rate of endogeneous oxygen uptake and probably
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utilise amino acids and carbohydrates as their exogenous energy sources 
(Rogerson and Gutteridge, 1980).
The culture epimastigote forms can survive incubation in Krebs-Ringer 
solution without added glucose for 24 hours. The rate of respiration decreases by 
about 40% of its initial rate but motility is maintained. About 6|imol of oxygen 
are utilised by 10  ^epimastigotes over a 24 hour period, equivalent to about 5% 
of the dry weight of the organisms (Rogerson and Gutteridge, 1980). During 
starvation triglyceride reserves are broken down to free fatty acids and a certain 
amount of protein degradation also takes place (Oliveria et al. , 1977).
Glycolysis functions in all forms as the levels of hexokinase, 
phosphofructokinase and pyruvate kinase are high. Both epimastigote and 
trypomastigote forms of T.cruzi further metabolise pyruvate to acetate, succinate 
and carbon dioxide and their mitochondria contain a full complement of 
cytochromes and TCA cycle enzymes (Gutteridge and Rogerson, 1979; Marr, 
1980).
The two primary enzymes in the pentose phosphate pathway, glucose 6- 
phosphate dehydrogenase and 6-phosphogluconate dehydrogenase have been 
demonstrated (Raw, 1959; Cannata and Cazzulo, 1984) in T.cruzi cells. Lack of 
conversion of R5P into lactate by cell homogenates of T.cruzi epimastigotes led 
Raw (1959) to the conclusion that the shunt pathway was inoperative. Bowman 
et al. (1963) and Mancilla and Naquira (1964) investigated ^CC>2 and ^C- 
glycerol formation from [2-^C]-, [6-^C]- and [U-^C]-glucose by whole cells 
and showed that the pentose phosphate pathway contributed 28% and 42% 
towards glucose catabolism in the Peruvian and Tulahuen strains respectively 
(Mancilla and Naquira, 1964). Terminal catabolism of glucose undoubtedly 
occurs via the tricarboxylic acid cycle, but as with the pentose phosphate shunt, 
the quantitative contribution of the cycle appears to differ between different 
strains of T.cruzi (Mancilla and Naquira, 1964).
1.13. 5-Phosphoribosvl-a-1 -pyrophosphate (PRPP).
The discovery of PRPP took place in 1955 in two independent 
laboratories, by Komberg, Lieberman, and Simms in St Louis, Missouri, and by 
Remy, Remy, and Buchanan in Cambridge, Massachusetts. The structure of 
PRPP is shown in figure 1.10(a).
PRPP is the essential substrate for supply of the ribose moiety in the 
biosynthesis of purine, pyrimidine, and pyridine nucleotides (Henderson and 
Paterson, 1973). It occupies a unique position connecting the major metabolic 
pathways of the pentose phosphate shunt and nucleotide synthesis. In 
microorganisms and plants, it is also a precursor for tryptophan (Yanofsky, 
1956), and histidine biosynthesis. In animal cells, PRPP also participates in the 
synthesis of ribonucleotides of imidazoleacetic acid (Gots, 1957), quinolic acid 
(Wyngaarden, et al. , 1958), and histamine (Preiss and Handler, 1957). Because 
of its involvement in such a great number of metabolic pathways, the amount of 
PRPP in a bacterial cell (the PRPP pool) varies depending on growth conditions 
(Sadler and Switzer, 1977).
PRPP is formed from ribose-5-phosphate (R5P) and adenosine-5- 
triphosphate (ATP) by PRPP synthetase (ATP: D-ribose-5-phosphate 
pyrophosphotransferase, EC 2.7.6.1) according to the following equation:
Mg2+,Pi
R5P + ATP <-------> AMP + PRPP
The equilibrium constant (Keq) for the PRPP synthetase reaction was 
estimated by Switzer (1969), and found to have an average value of 28.6 at pH 
7.5,5 mM MgCl2 and 37° C.
As PRPP is an essential precursor for a number of divergent metabolic 
pathways it is likely that synthesis of this compound is tightly controlled by 
feedback mechanisms. Switzer (1967) and Atkinson and Fall (1967) have 
indicated that feedback inhibition of bacterial PRPP synthetase does occur and 
the latter workers have shown that the activity is regulated by the relative 
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enzymatic activity is modulated by many effectors: Mg^ and inorganic 
phosphate as activators; and ADP, 2,3-bisphosphoglycerate, or GDP as 
competitive or noncompetitive inhibitors (Becker et al. , 1979).
From a mechanistic viewpoint, the enzyme is interesting because it 
bridges the gap between other nucleotide-utilising enzymes. Kinases are 
involved in mechanisms where nucleophilic attack occurs at the y-phosphoms 
and nucleotidyl transferases are involved in mechanisms where nucleophilic 
attack occurs at the a-phosphorus of ATP. PRPP synthetase is a pyrophospho- 
kinase; nucleophilic attack occurs at the p-phosphorus, and an intact 
pyrophosphoryl group is transferred from ATP to R5P (Miller et al. , 1975). The 
reaction is one of two such known. The second pyrophosphokinase known 
catalyses the conversion of thiamine to thiamine pyrophosphate (Snyder and 
Speck, 1939).
1.14. The de novo pathway of purine nucleotide biosynthesis.
Purines are formed in vivo by the synthesis of first the imidazole ring then 
the pyrimidine ring. Using partially purified enzymes from pigeon liver, 
Buchanan and his co-workers were able to unravel the steps in the enzymic 
synthesis of inosinic acid, the first product formed with a complete purine ring 
structure (Buchanan, 1961). The reactions involved in purine de novo synthesis 
are shown in figure 1.11.
The basic precursors of the purine skeleton are shown in figure 1.10(b). 
The ability to synthesise the purine ring system de novo is by no means a 
universal biochemical capacity. All the protozoan parasites studied thus far 
appear to be unable to synthesise purines de novo (Wang, 1982). Trypanosomes 
resemble those mammalian cells, for example, heart muscle (Liu and Feinberg, 
1971), platelets (Sixma et al. , 1976) and mature erythrocytes (Gerlach et al. , 
1965), which cannot synthesise purines de novo and possess high affinity uptake 
systems for adenosine. Purine metabolism studies in bloodstream forms of 
African trypanosomes have shown that purine bases label the nucleotide pools
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Figure 1.11. Enzymes involved in the biosynthesis of Inosine 5- 
monophosphate (Mahler and Cordes, 1968).
Enzyme activities: A, ribose-5-phosphate pyrophosphokinase; M, phosphoribo- 
syl-diphosphate amidotransferase; N, phosphoribosyl-glycinamide synthetase; O, 
phosphoribosyl-glycinamide formyltransferase; P, phosphoribosyl-formylglycin- 
amide synthetase; Q, phosphoribosyl-aminoimidazole synthetase; R, phospho- 
ribosyl-aminoimidazole carboxylase; S, phosphoribosyl-succinocarboxamido- 
aminoimidazole synthetase; T, adenylosuccinate lyase; U, phosphoribosyl- 
aminoimidazole-carboxamide formyltransferase; V, IMP cyclohydrolase.
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more efficiently than ribonucleosides (Fish et a l., 1982b). Although the last two 
enzymes of the de novo pathway are known to be present in the mature 
mammalian erythrocytes, PRPP amidotransferase, the first enzyme, appears to be 
missing (Fontenelle and Henderson, 1969).
Fish et al. (1982a), incubated bloodstream forms of T.b.gambiense and 
T.b.rhodesiense with [U-^C] radiolabelled formate, glycine or serine and found 
no detectable incorporation of radiolabel into any of the purine ribonucleotides. 
This suggested the absence of any de novo purine synthesis. De novo purine 
synthesis does not occur in procyclic forms of T.b.gambiense (Fish et al., 1982b), 
as well as in none of the major morphological forms of T.cruzi, the amastigote, 
trypomastigotes and epimastigotes (Gutteridge et al., 1979).
1.15. The de novo pathway of pyrimidine nucleotide biosynthesis.
A central distinction between the metabolic routes leading to the 
formation of purine and pyrimidine nucleotides is the timing of the formation of 
the N-glycosidic bond. In contrast to the purine biosynthetic pathway, the 
complete pyrimidine nucleus is synthesised prior to its attachment to R5P; the 
key intermediate introduced into the N-glycosidic linkage is orotic acid, uracil-4 
carboxylic acid, which contains the pyrimidine nucleus. Dihydro-orotic acid is 
formed by the cyclisation of the reaction product of aspartic acid and carbamyl 
phosphate (Crosbie, 1960). Glutamine, ATP, HCO3' and aspartate were 
recognised as the precursors of particulate atoms of the orotate ring (Reichard 
and Lagerkvist, 1953), as shown in figure 1.10(c).
There are 6 enzymes involved in the pyrimidine de novo nucleotide 
biosynthetic pathway which is summarised in figure 1.12. All 6 enzymes of 
pyrimidine biosynthesis de novo have been detected in homogenates of the 
culture promastigote form of L.m.amazonensis, the blood trypomastigote form of 
T.brucei and the culture epimastigote, blood trypomastigote and intracellular 
amastigote forms of T.cruzi (Gutteridge and Gaborak, 1979).
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Figure 1.12. Reactions involved in the synthesis of Uridine-5'-Phosphate 
(Cohen, 1965).
The subcellular distribution of pyrimidine biosynthetic enzymes in 
members of the Kinetoplasdda is different to that described for other species 
studied to date (Hammond et al. , 1981). The intracellular location for the 
enzymes of UMP synthesis in (a) Kinetoplasdda and (b) mammals is shown 
diagramatically in figure 1.13 (Hammond and Gutteridge, 1982).
1.16. Salvage pathways for purine and pyrimidines.
Parasites rely on their environment to provide a source of purines. In the 
absence of de novo synthesis, it is not surprising to rind elaborate systems for 
absorption and interconversion of existing purines. The latter are the so-called 
'salvage' pathways, widely distributed in parasites.
Gutteridge and Davies, (1981), detected substantial incorporation of 
radiolabelled purine bases and nucleosides but not nucleotides into nucleic acids. 
Cell-free homogenates of all three main forms of T.cruzi contained a range of 
phosphoribosyltransferases, aminohydrolases, kinases, hydrolases and 
phosphorylases which are involved in the salvage mechanism of purines. The 
properties of these purine phosphoribosyltransferases were studied by Gutteridge 
and Davies (1981,1982) who showed that phosphoribosyltransferase was the 
sole activity involved in hypoxanthine salvage and also played a major role in 
adenine and guanine salvage. They also demonstrated that in the culture 
epimastigote forms of T.cruzi purine phosphoribosyltransferase activity involves 
two separate enzyme proteins with different subcellular distribution. One, active 
with adenine as substrate and is found in the cytosol; the other, active with both 
hypoxanthine and guanine, occurs in the glycosomes.
It has been shown by James and Bom (1980), that bloodstream forms of 
T.b.brucei can take up various nucleosides and bases with different apparent 
order of salvage efficiency to T.b.gambiense and T.b.rhodesiense (Fish et al. , 
1982a,b). The order of salvage efficiency for purine bases and their respective 
nucleosides in T.b.gambiense and T.b.rhodesiense is: adenine>hypoxanthine>
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Figure 1.13. Diagram of the intracellular location for the enzymes of UMP 
synthesis in (a) Kinetoplastida and (b) mammals (Hammond and Gutteridge, 
1982).
guanine>xanthine, with the order of purine bases of adenine and hypoxanthine 
reversed in T.b.rhodesiense (Fish etal., 1982a,b). Although the incorporation of 
labelled purine bases into the nucleotide pool is generally more efficient than that 
of ribonucleosides, the rate of uptake of adenosine in bloodstream forms of 
T.b.brucei is much greater than that of the other purines and purine nucleosides, 
the uptake of which decreased in the order adenine, inosine, guanosine and 
hypoxanthine (James and Born, 1980). The concentration of adenosine is very 
low (lO '^-lO '^ M) in normal plasma (Miyazaki et al. , 1974). However, there is 
evidence of a rapid turnover of adenosine in the nucleotides of erythrocytes in 
normal blood (Adams and Harkness, 1973; Henderson and LePage, 1959; Mager 
et al. , 1967) so that a source normally accessible to red cells could presumably 
also be available to trypanosomes in the blood; there is evidence that purines, 
mainly nucleosides, are continuously released from various tissues including 
myocardium (Rubio and Berne, 1969). It is probable also that the destructive 
effect of trypanosomal infections on the tissues increases the concentration of 
adenosine and other purines in the extracellular fluids where they can be utilised 
by the parasites (James and Born, 1980).
Phosphoribosyltransferases catalyse the formation of purine and 
pyrimidine nucleotides from the free base and PRPP as follows:
Base + PRPP <------ > base nucleotide + PPi
Nucleoside phosphorylases catalyse the formation of nucleosides from 
the bases and R IP  as follows:
Base + R IP  <------ > base nucleoside + Pi
The nucleosides are converted to nucleotides through the action of an appropriate 
kinase:
Ribonucleoside + ATP -----> nucleotide + ADP
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Two successive kinase reactions convert mononucleotides into the actual 
precursors of RNA, the nucleoside triphosphates:
ATP ADP ATP ADP 
NMP <— > NDP <—-> NTP 
Mg2+ Mg2+
These transphosphorylation reactions are readily reversible since the 
breakage of each phospho-anhydride bond in the substrate results in the 
formation of another such bond in the product.
The biochemical transformations converting inosine 5-phosphate 
(inosinic acid) to adenosine 5-phosphate (adenylic acid) and guanosine 5- 
phosphate (guanylic acid) are indicated in figure 1.14.
Figure 1.15 summarises the enzymes involved in purine salvage in 
T.cruzi, T.brucei, and Lmexicana (Davies e ta l . , 1983; Fish et al. , 1982a).
Hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) plays an 
important part in the reutilisation of purines by liver and other tissues (Pritchard 
et al. , 1970). In man, HGPRTase deficiency leads to Lesch-Nyhan syndrome, a 
rare inherited disorder that is characterised by overproduction of uric acid and 
neurologic abnormalities including a compulsive form of self-mutilation 
(William and Wyngaarden, 1983).
As regards pyrimidines, Trypanosoma spp. are reliant equally on salvage 
and on de novo synthesis. All enzymes of UMP production via the salvage 
pathway are soluble. Uridine salvage in the Kinetoplasdda involves 
phosphorolysis to form uracil, catalysed by uridine phosphorylase and not by 
uridine kinase. Uridine kinase has not been detected in any of the Kinetoplasdda, 
yet is detectable in rat liver (Hammond and Gutteridge , 1982). It is quite likely 
therefore that uridine salvage involves phosphorolysis to form uracil, catalysed 
by uridine phosphorylase, which may then be converted to UMP by uracil 
phosphoribosyltransferase (Jaffe, 1961). The lack of detection of both uracil 
phosphoribosyltransferase and uridine kinase in the amastigote form of T.cruzi 
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Figure 1.15. Enzyme activities involved in purine salvage pathways of the 
Tiypanosomatidae (Henderson and Paterson, 1973).
Enzyme activities: (1) phosphoribosyltransferase; (2) nucleoside kinase; (3) 
nucleoside hydrolase; (4) nucleoside phosphorylase; (5) adenine aminohydrolase;
(6) adenosine aminohydrolase; (7) guanine aminohydrolase. The dotted lines 
indicate that enzyme is absent in one or more of the organisms.
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than the epimastigote and trypomastigote forms (Gutteridge and Gaborak, 1979). 
In contrast mammalian cells salvage uracil preferentially by first forming uridine 
by uridine phosphorylase and then converting this to UMP by uridine kinase 
(Hochstadt, 1974).
Cytosine phosphoribosyltransferase activity in trypanosomes is expressed 
by uracil phosphoribosyltransferase (Hammond and Gutteridge, 1984). Because 
nucleosides are converted to nucleotides through kinases, bases through 
phosphoribosyltransferases and because thymine and uracil could first be 
converted to nucleosides, cytosine and uracil bases are interconvertable, and 
uracil alone could supply all the pyrimidine requirements of the cell.
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1.17. Control and treatment of African trypanosomiasis.
Currently the most effective method of control of African 
trypanosomiasis is the avoidance of the tsetse fly by the movement of human 
populations to tsetse-free areas or reducing tsetse fly-man contact by control of 
the size and distribution of the population. The methods of vector elimination 
under investigation include, alterations of the habitat, pesticide application, 
genetic and biological control, conical fly traps and physiological interference 
such as interference with insect growth regulators which inhibit chi tin synthesis 
(Molyneux, 1982). Wild game acts as a parasitic reservoir and the measures to 
conserve these species have made the control of trypanosomiasis a more difficult 
problem. Several drugs are available (Ethidium, Anthrycide sulphate, Berenil, 
Samorin) for the treatment of trypanosomiasis in infected animals. Substantial 
resistance of certain T.brucei strains has developed to all of the available drugs 
except Berenil with serious complications to prophylaxis and treatment - 
especially of relapse infections (Molyneux and Ashford, 1983).
The incidence of nagana could be reduced by the exploitation of the 
trypanotolerance of some breeds of cattle. These cattle, primarily humpless 
taurine breeds, are smaller than the more commonly kept zebu and not such 
prolific milk-producers. It remains for long-term breeding programmes to 
combine the most desirable characteristics of the various breeds (Molyneux and 
Ashford, 1983).
Sleeping sickness due to Tb.rhodesiense has been reported in all the 
following countries of Eastern Africa, Burundi, Ethiopia, Kenya, Malawi, 
Mozambique, Rwanda, Sudan, Tanzania, Uganda, Zambia and Zimbabwe. 
T.b.gambiense overlaps with the distribution of T.b.rhodesiense in the region of 
the East African complex of great lakes, particularly the northern shores of Lake 
Victoria in Uganda. Currently the most active foci of Tb.gambiense are in 
Cameroon, Congo, Ivory Coast, Southern Sudan, Uganda and Zaire. In Nigeria 
extensive vector control activities directed against the animal disease have made 
an impact on the number of human cases reported, and a vector control
programme combined with treatment has practically eradicated TJb.gambiense 
sleeping sickness in Kenya and Tanzania (Molyneux and Ashford, 1983).
Constant monitoring and rapid treatment of people living in areas in 
which trypanosomiasis is endemic have prevented serious outbreaks of the 
disease in recent years. The early stages of sleeping sickness in men are 
controlled by suramin and occasionally by pentamidine and berenil although the 
former is used mainly for chemoprophylaxis (see Figure 1.16). None of these 
drugs will cross the blood-brain barrier and so control of the late stages of the 
disease in which invasion of the CNS occurs rests with arsenicals such as 
tryparsamide and Melarsoprol (MelB, Arsobal) with undesirable side effects. No 
drug is in routine use to prevent transmission during blood transfusion.
Melarsoprol remains the best available drug for any stage of sleeping 
sickness. The drug itself causes a mortality of up to 10% due to fatal side effects. 
It has been found to be highly inhibitory to T.b.brucei pyruvate kinase (Bowman 
and Flynn, 1976; Flynn and Bowman, 1974), but further studies by Van 
Schaftingen et al. (1987) suggest that this may not be so. These workers 
proposed that the drug blocks the formation of Fru(2,6)P2 through inhibition of 
PFK 2. The way by which melarsen oxide causes cell lysis remains to be 
identified.
The shortness of the treatment period for pentamidine is its main 
advantage over suramin, where the full course takes weeks. Pentamidine works 
well in both prophylactic and treatment modes against the Rhodesian disease. It 
appears to exert its effect on nucleic acid biosynthesis, possibly by binding to 
DNA by a non-intercalative mechanism due to its positive charge at 
physiological pH (Newton, 1974). Selectivity appears to be due to differential 
permeability between host and parasite: trypanosomes contain a pentamidine 
transport system which raises the intracellular concentration of the drug to many 
times the plasma concentration (Damper and Patton, 1976).
Suramin, a highly-polar sulphated-naphthylamide is a competitive 
inhibitor of glycerophosphate oxidase with respect to a-glycerophosphate. The
42
N*SO
N H - C '
NM
CO
c o - n h  n *soCM
NH
CO











H O C H 2
H O  O H
O H
h o c h 2
H O  O H
Figure 1.16. Structures of commonly used drugs against African 
trypanosomiasis.
I = Suramin, II = Melarsoprol, HI = Pentamidine, 
IV = Allopurinal ribonucleoside, V = Formycin B.
drug is administered intravenously and slowly taken up by the trypanosome by 
endocytosis in the form of a plasma-protein-bound complex (Gutteridge, 1985). 
Its effectiveness is limited by its inability to cross the blood-brain barrier 
(Meshnik, 1984).
Some recent studies of the polyamine metabolism in T.brucei have shed 
some light on the possible rational design of antitrypanosomal agents, a- 
Difluoromethyiornithine, a "suicidal inhibitor" of ornithine decarboxylase, cured 
T.b.brucei infection in mice when administered in drinking water at 0.5%
(Bacchi et a l . , 1980) and was shown to inhibit ornithine decarboxylase in intact 
T.b.brucei cells at a 10 times higher potency than its inhibition of mammalian 
ornithine decarboxylase. Putrescine, spermine and spermidine can reverse the 
antitrypanosomal activity of difluoromethylornithine (Nathan e ta l . , 1981). A 
combination of the drug with the DNA cleaver bleomycin has a synergistic effect 
on T.b.brucei\ the combination therapy can cure advanced CNS trypanosomiasis 
in mice. The rational basis behind this antitrypanosomal activity can probably be 
explained by the joint interference of rapid DNA replication and cell division in 
T.b.brucei.
In a recent issue of New Scientist (Coghlan, 1990), it was reported that 
after a long delay of two years, the Food and Drug Administration in the U.S.A. 
approved difluoromethylornithine, to treat T.b.gambiense trypanosomiasis, which 
is more common in West and Central Africa. It has no effect on T.b.rhodesiense 
infections. The main drawback of the drug is that it must be administered 
intravenously. This requires medical supervision which increases the cost of 
treatment and restricts its use to specialised centres rather than in the villages 
where it is mostly needed. Trials conducted with about 600 patients suffering 
from advanced trypanosomiasis in Congo and Ivory Coast, have shown that the 
drug has no serious side effects.
This is one example of the recent progress in rational approaches to 
antitrypanosomal chemotherapy. Most of the research is being carried out in 
academic institutions worldwide and the biochemical and molecular biology
expertise currently available render the prospect of new drug development very 
promising. The aim of these research groups is to discover an enzyme or a 
unique pathway which exists in the trypanosome and not the host and to inhibit 
its activity causing a fatal blow to the parasite (Morello, 1988)
One of the chief obstacles to the design of antitrypanosomal drugs is that 
although the bloodstream form is free, i.e. it is not intracellular and does not 
occupy an immunologically privileged site, it is able to evade the host's immune 
system. This is due to the existence of rapidly changing repertoirs of VATs 
(serodemes). This property has made the prospect of vaccinating against African 
trypanosomiasis a daunting if not impossible one (Barry, 1989). Therefore, an 
attempt to develop antitrypanosomal drugs must rely on other biochemical 
differences between trypanosomes and their mammalian hosts.
1.18. Control and treatment of Chagas' disease.
The lack of a registered drug with chemoprophylactic properties is a 
serious deficiency, especially in areas where there are large potential reservoirs 
of infection. Any progress in eradication such as vector control and better 
housing, is often rapidly undone by reinfection from such reservoirs.
Two drugs, a 5-nitrofuran derivative (Nifurtimox, Bayer 2502) and a 2- 
nitroimidazole, (Benznidazole, Radanil) (see Figure 1.17) are used to treat both 
acute and chronic phases (Gutteridge, 1985). These drugs have such severe side 
effects that the full recommended course is rarely completed. The development 
of more acceptable alternatives has been hampered by the carcinogenic and 
mutagenic properties of the most promising nitro-compounds (Molyneux and 
Ashford, 1983).
The development of a vaccine against T.cruzi has been , until now, 
unsuccessful. Educational campaigns, especially among young people, are 
becoming a very useful way to combat the disease (Schofield, 1985). Gentian 
violet is the chemical currently used to treat transfusion blood. Its main
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Figure 1.17. Structures of Nifurtimox, Benznidazole and Crystal Violet 
(Gentian Violet).
disadvantage is the colouring of blood and the staining of patient’s tissues. It has 
no side effects and is very effective.
Differences in the metabolism of purines between T.cruzi and the 
mammalian host have been utilised for the development of a rational approach to 
the chemotherapy of Chagas' disease (Marr et a l., 1978; Berens et a l., 1981). 
T.cruzi cannot synthesise purines de novo and depend exclusively on salvage 
pathways for their purine supply. Some of the purine salvage enzymes appear to 
have a more relaxed substrate specificity than the host enzymes (Gutteridge and 
Davies, 1981).
The pyrazolopyrimidine base allopurinol (4-hydroxypyrazolo [3,4-a] 
pyrimidine, HPP, a structural analogue of hypoxanthine is activated by 
hypoxanthine phosphoribosyltransferase to the ribonucleotide-5-monophosphate 
(HPPR-MP). HPPR-MP is aminated to 4-aminopyrazolopyrimidine 
ribonucleotide (APPR-MP) and subsequently phosphorylated to the triphosphate 
form and incorporated into RNA inhibiting the parasite's growth in vitro (Marr et 
a l., 1978; Avila et a l., 1981). The metabolic transformation of allopurinol in 
T.cruzi and human erythrocytes is presented in figure 1.18. Allopurinol is a 
relatively nontoxic drug which has been used in humans for many years as a 
treatment for gout, by inhibiting the enzyme xanthine oxidase in the production 
of uric acid. Allopurinol does not inhibit human hypoxanthine-guanine 
phosphoribosyltransferase and, thus, does not cause Lesch-Nyhan type 
syndrome, known to be associated with the enzyme deficiency. Although T.cruzi 
infected mice treated with this drug showed significant increases in survival 
times when compared with controls (Avila and Avila, 1981), some T.cruzi 
strains are not responsive to this type of compound, which suggests that 
metabolic differences are present between the different strains (Marr et al. ,
1978; Avila et a l., 1981,1984). This raises doubts as to the efficacy of these 
drugs to treat Chagas* disease in man. More recently, allopurinol ribonucleoside 
and another inosine analogue, formycin B has been tested against Leishmania 
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Figure 1.18. Structure of hypoxanthine and metabolic transformation of 
allopurinol in Trypanosoma cruzi (Morello, 1988).
Enzyme activities : (1) succino-AMP synthetase; (2) succino-AMP-lyase.
identify differences in metabolic pathways in the parasite which are distinct from 
the mammalian host in order to develop new antichagasic chemicals so badly 
needed.
Aims of the research project
1. To determine the existence of a functional pentose phosphate pathway in the 
bloodstream form of T.b.brucei by studying the differential labelling of RNA in 
trypanosomes incubated with [^C]glucose labelled at C-l and C-6 positions, 
and to investigate whether the label is incorporated into the base and/or ribose 
moieties of RNA.
2. To purify, characterise and describe the physiological role of the enzyme 
PRPP synthetase in T.b.brucei, with particular emphasis on its localisation and 
possible interaction with other metabolic pathways, such as the salvage of 
nucleosides and bases and the pentose phosphate pathway in view of the 
presence of intracellular compartments in T.b.brucei.
CHAPTER 2
INCORPORATION OF RADIOLABEL INTO 
TRYPANOSOMAL RNA USING DIFFERENTIALLY 
LABELLED [14C] GLUCOSE
2.1. Introduction.
A vast amount of knowledge has accumulated about the metabolism of 
glucose via the glycolytic pathway in African trypanosomes (see review by 
Opperdoes, 1987).
Very little is known about alternative routes of glucose metabolism in 
trypanosomes. The metabolism of glucose via the oxidative pentose phosphate 
pathway has been shown by Grant and Fulton in 1957 and Fairlamb and 
Opperdoes in 1986 not to be a major pathway in T.brucei. In 1962, Ryley 
reported the presence of glucose-6-phosphate dehydrogenase in T.brucei but was 
unable to detect 6-phosphogluconate dehydrogenase or Entner-Doudoroff 
pathway activity. The fate of 6-phosphogluconate was considered problematic 
until recently, when Cronin et al. in 1989, showed the presence of most of the 
enzymic components of the oxidative pentose phosphate pathway, including 6- 
phosphogluconate dehydrogenase.
In recent years there has been a lot of indirect evidence for the existence 
of an active pentose phosphate pathway in trypanosomes. Preliminary results 
from this laboratory (Hunt et a l., 1986), on incorporation of label into cells 
incubated with differentially labelled [^C]glucose indicated that a total RNA 
fraction had a labelling pattern that was consistent with provision of pentose 
from an oxidative pentose phosphate pathway. Other work that suggests the 
operation of an oxidative pentose phosphate pathway includes: (a) 
Phosphoribosyltransferase activities for adenine, hypoxanthine and guanine was 
present in bloodstream forms of T.brucei (Davies et a l. , 1983) which require 
PRPP as substrate which must have originated from a pentose phosphate 
precursor, (b) Procyclic forms of T.gambiense and bloodstream forms of both 
T.gambiense and T.rhodesiense were unable to synthesise purines de novo and 
suggested the operation of an interconverting purine salvage pathway based on 
the metabolic fate of isotopically labelled purine bases, nucleosides and various 
precursors (formate, glycine, serine and glucose) for purine nucleotide 
biosynthesis (Fish et al. 1982a, 1982b). The identification of the enzymes of de
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novo pyrimidine synthesis in various species of trypanosomes suggests this 
hypothesis (Hammond and Gutteridge, 1984).
Substrates utilised and catabolic pathways present in mammalian forms 
of T.cruzi are similar to those of culture forms of T.cruzi and are quite distinct 
from those of the bloodstream form of T.brucei (Rogerson and Gutteridge, 1979). 
In 1959, Raw demonstrated the presence of the two primary enzymes of the 
pentose phosphate pathway, glucose-6-phosphate dehydrogenase and 6- 
phosphogluconate dehydrogenase and Mancilla and Naquira in 1964, showed 
that the pentose phosphate pathway contributes significantly towards glucose 
catabolism but the proportion varied with different strains used.
The following experiments confirmed the existence in bloodstream forms 
of Tbrucei and in epimastigote forms of T.cruzi of a small, but significant 
proportion of supplied glucose being metabolised through an oxidative pentose 
phosphate pathway leading to provision of ribose-5-phosphate which is 
subsequently incorporated into RNA.
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2.2.0. Materials.
Potassium dihydrogen orthophosphate, magnesium sulphate, potassium 
chloride, ethylenediaminetetraacetic acid (EDTA) disodium salt, sodium 
hydroxide, hydrochloric acid, perchloric acid, sulphuric acid, tris(hydroxy- 
methyl)aminomethane hydrochloride (Tris-HCl), Orcinol (3,5 dihydroxytoluene), 
Sarkosyl NL 30, formic acid, glacial acetic acid and D-glucose were Analar 
grade from BDH Chemicals Ltd, Poole, England.
Sucrose, glycerol, orthophosphoric acid, trichloroacetic acid and sodium 
chloride were Analar grade from Fisons pic., Loughborough, England.
Heparin (grade I, porcine intestinal mucosa) sodium salt, Antifoam A 
emulsion (30 % aqueous emulsion, a 100 % active silicone polymer with anionic 
emulsifiers), isoamyl alcohol, ferric chloride (anhydrous) were purchased from 
Sigma Chemical Company, St Louis, Mo., U.S.A.
Ribonuclease (RNAse), glucose oxidase (GOD) and peroxidase (POD) 
were also purchased from Sigma. GOD was supplied as a lyophilised powder 
containing -80% protein, with specific activity, 146 units mg'*, where 1 unit is 
the amount of enzyme required to convert 1 nmole of glucose to gluconic acid 
and peroxide min-* at pH 5.1 and a temperature of 35°C. POD, R.Z.1.1, was 
supplied as a salt-free powder with specific activity of 95 units mg"*, where one 
unit is the amount of enzyme required to convert lmg of pyrogallol to 
purpurogallin and peroxide in 20sec at pH 6.0 and at a temperature of 20°C. The 
R.Z. is a measure of the haemin content of a peroxidase preparation.
Caesium chloride Analar grade (99.9 % minimum) was obtained from 
Rose Chemicals Ltd, London, England.
Ethanol, methanol and diethyl ether were supplied by James Burrough, 
England.
Anion exchanger diethylaminoethyl cellulose (pre-swollen DE-52) and 
cellulose filter papers 3MM (2.4 cm Diameter) were purchased from Whatman 
Ltd, Maidstone, Kent, England.
Anion exchange resin, Dowex 1-X8 (200-400 mesh) chloride form was 
purchased from Bio-Rad Laboratories, Richmond, Ca., U.S.A.
Optiphase ’Safe' Scintillation fluid was purchased from Pharmacia 
Biosystems Ltd, Milton Keynes, Bucks., England.
Sabre sterile hypodermic needles, 0.8 mm x 40 mm, were used for 
infection and bleeding into Gillette 20 ml plastic disposable syringes.
Pasteur pipettes and micro-haematocrit tubes were purchased from 
Bilbate, Daventry, England.
2.2.1. Radiochemicals employed.
Stocks of [U-*^C]glucose (270mCi mmole"*), [l-*^C]glucose (3 and 
55.6mCi mmole"*) and [6-*^C]glucose (58.5mCi mmole"*) were purchased 
from Amersham International pic., Buckinghamshire, England.
The nominal activities of radiolabelled glucose in the incubations were 
calculated from the specific activities of the stock solutions purchased and the 




Adult male or female, Wistar and/or Sprague-Dawley rats of 200-800 g 
weight, were bred and supplied by the University of Bath animal house.
B. Earasitig forms used,
1. Bloodstream form of Trypanosoma brucei brucei.
Stocks of clones of long slender bloodstream forms of T.b.brucei strain 
EATRO 427-12/ICI-060 were kindly supplied by Dr. Paul Voorheis, Trinity 
College, Dublin, Ireland, and stored as frozen stabilates at -70°C.
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2. Culture forms of Trypanosoma cruzi.
These were cultured and prepared by Tim Sharpington, London School of 
Hygiene and Tropical Medicine, London. The axenic culture contained RPMI 
medium suplemented with HEPES, trypticase, Hemin, glutamine, 10 % fetal calf 
serum and the antibiotics penicillin and streptomycin. The strain supplied was 
strain X10-1 and the culture medium seeded at a cell density of 1-2 x 10  ^cells 
ml"* and incubated at 28°C. All procedures that involved live cells were carried 
out in plastic tubes under sterile conditions at the London School of Hygiene and 
Tropical Medicine to avoid infection.
2.3.0. Buffers and reagents.
2.3.1. Krebs-Ringer phosphate buffers.
2.3.2. Krebs-Ringer phosphate buffer (KRP).





The pH was adjusted to 8.0.
2.3.3. Krebs-Ringer phosphate buffer with sucrose and glucose (KRPSG).
Glucose lOmM (freshly added)
Sucrose 3 % (w v"*) (freshly added)
2.3.4. Glucose incubation buffer.
KRP buffer containing 0.15 % (w v"*) bovine serum albumin (Sigma 
fraction V), pH 8.0 and 20jil antifoam per 40ml buffer.





Sarkosyl 1 % (w v"*) (added after pH adjustment)




The pH was adjusted to 8.0.
2.4.3. Sodium chloride-sodium citrate buffer (SSC buffer).
NaCl 1.5M
Sodium citrate 150mM
The pH was adjusted to 7.0.
2.4.4. Chloroform reagent,
CHCI3:3 methyl-1 -butanol (24:l,v v~ )^
2.4.5. Phenol.
Phenol:water (80 %,w w"*), dissolved on a hot-plate in a fume cupboard 
and redistilled.
2.4.6. Orcinol reagent.
Orcinol 1.0 % (w v"*)
FeCl3 0.5 % (w v'1)
This was made up to the required volume with concentrated HQ.
2.5.0. Methods*
2.5.1. Preparation of glassware and reagent sterilisation.
Glassware which was used with crude and purified nucleic acid 
preparation and analysis was autoclaved at 150°C for 70min. Plasticware and 
solutions were sterilised at 121°C for 30min. This procedure denatured the 
ubiquitous RNAse activity found even on fingertips.
Gloves were used whenever handling of RNA and radiochemicals was 
involved.
2.5.2. Preparation of acid washed filter papers.
The Whatman 3MM filter papers were washed with 20 % (w.v"*) 
trichloroacetic acid in a beaker for 30min and rinsed with diethyl ether, followed 
with ethanol and dried. The papers were marked on one side with an HB pencil.
2.5.3. Preparation of COo-free water.
CC>2-free water was prepared by vigorously boiling 500ml water with 10- 
15 anti-bumping granules on a hot plate. After lOmin, the water was cooled 
having been stoppered with a tube filled with sodalime.
2.5.4. Preparation and storage of T.b.brucei stabilates.
Heparinised blood from a severely infected rat (10^ cells ml"* blood) was 
cooled on ice and glycerol was slowly added by gentle stirring with a glass rod to 
10-15 % (w v~*). About 20|il of blood was drawn by cappillary action into glass 
cappillary tubes and both ends sealed using the blue part of a Bunsen burner 
flame.
The glass cappillary tubes were very slowly cooled to -40°C by slowly 
introducing them into a flask of liquid-nitrogen fridge using a specially designed 
apparatus which fits into the neck of the liquid-nitrogen container. After 3-4
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hours the stabilates were immersed in liquid-nitrogen where the cells retained 
their viability and infectivity for at least several years.
The contents of one or more tubes were suitably diluted in KRPSG 
isotonic buffer and injected intraperitoneally into an uninfected rat at a density of 
1-3 10? cells per 200-400g rat.
2.5.5. Counting of trypanosomes.
The number of active mobile trypanosomes was determined using the 
chamber of an improved Neubauer haemocytometer (depth 0.1mm, volume of 
chamber 0.1 mm )^ and the 40x objective of a Zeiss light microscope. The 
chamber is divided into 25 squares with a total area of 1.00 mm .^
The cells in five, squares were counted. If N equals the number of the 
cells in the five squares, Nx5 equals the number of the cells in the chamber.
O.lOmmxl.OOmm  ^= O.lmm^
A volume of 0.1 mm  ^contains Nx5 cells (if the cell suspension has been diluted 
this value must be multiplied by the dilution factor).
A volume of 1000mm(1.0ml) contains:
(N x 5 x dilution factor x 1000) / 0 . 1 = N x 5 x  dilution factor x 10  ^cells.
2.5.6. Preparation of anion-exchanger DE-52.
The pre-swollen microgranular ion exchanger DE-52 was equilibrated 
with KRP buffer in the ratio of lOOg of pre-swollen adsorbent to 1.51 of KRP 
buffer.The adsorbent was allowed to settle for 20min and the supernatant, 
containing the fines, was sucked off. This was repeated five or six times and the 
sediment was resuspended in KRP buffer and the pH adjusted to 8.0 with HC1. 
This was stored in the cold room and used as required.
2.5.7. Preparation of the DE-52 column.
The column was prepared freshly on the day of trypanosome harvest.In a 
20ml syringe, glass wool was placed over the hole and sufficient DEAE cellulose 
up to 8- 10ml. The column was equilibrated with several volumes of KRPSG 
buffer.
2.5.8. Harvesting of trvpanosomes.
The infection of the rat was allowed to proceed for 72 hours. The rats 
were anaesthetised using diethyl ether and bled into 20ml syringes containing 
lml of heparin solution (200 units ml'^) in KRP buffer. Bleeding was carried out 
by insertion of the hypodermic needle into the bifurcation of the common iliac 
artery. Between 10 and 15ml blood was recovered from a 200g rat
2.5.9. Purification of trvpanosomes.
The trypanosomes were separated from the blood by differential 
centrifugation at lOOOg at 4°C in an IEC CENTRA-3R refrigirated centrifuge 
and purified by the method of Lanham and Godfrey, (1970).
The blood was centrifuged for 5min at lOOOg, at 4°C and the supernatant 
was discarded and the trypanosomes, which separated as a white layer above the 
red cells, were removed as completely as possible by means of a Pasteur pipette 
into KRPSG buffer. The trypanosome suspension was again centrifuged, the 
upper layer being collected and the small lower layer of contaminating red cells 
discarded. The process was repeated until most of the blood elements were 
removed.
Platelets, residual red blood cells and white blood cells were separated 
from the trypanosomes on the basis of the surface charge of many species of 
trypanosomes being less negative than that of the blood cells of rats and mice in 
the pH range 6-9 (Lanham, 1968).
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The trypanosomes were purified by passage through a column (8-10ml) 
of DEAE-cellulose (Whatman DE-52) pre-equilibrated with KRPSG buffer at 
4°C. The trypanosomes eluted from the column as a milky suspension with 
KRPSG buffer and washed once with KRPSG buffer. They were counted and 
kept on ice until required.
2.5.10. Glucose utilisation bv bloodstream form of T.b.brucei in vitro.
Incubations were carried out at 37°C in a four-port 250ml flask in 36ml
of stirred incubation buffer while gassing with pre-humidified air. The gas 
outflow was bubbled through 5ml of 1M NaOH in order to trap the evolved CO2.
The incubation volume was brought up to 40ml by addition of 4x10^ 
cells in 4ml KRPSG buffer to give a final concentration of glucose of ImM and a 
cell density of 10  ^cells ml"*.
At certain time intervals , aliquots of 200|il were removed and lOfil 
diluted lOOx in incubation buffer and the number of viable cells estimated. The 
remaining aliquot was quickly spun on a microfuge and the supernatant suitably 
diluted for glucose estimation.
2.5.11. Assay for Glucose estimation.
A modified version of the method of Bergmeyer (1974) was employed.
The buffer-enzyme mixture used for this assay contained 5.13mg/150ml 
GOD and 1.58mg/150ml POD in 98mM potassium phosphate buffer, pH 7.2.
To 150ml of the above buffer, 0.6ml of an o-dianisidine dihydrochloride 
solution containing lOmg ml"* was added to form the assay reagent
Aliquotes of incubation mixture were spun at lOOOg for 5min and 
volumes of 25-50|il were made up to 0.5ml with water in test tubes. 5.0ml of 
assay reagent were added and the tubes were incubated at room temperature for 
45min. The absorbance of the samples was measured against a blank (0.5ml of 
incubation buffer without any glucose plus 5.0ml of assay reagent) at 436nm 
with a 1cm light path in a Philips PYE-Unicam SP6-450 UV/VIS Spectrophoto­
meter. The glucose concentration was determined by comparison of the 
spectrophotometer readings with a standard curve prepared with glucose 
concentrations 0 to 20mg per 100ml. The maximum linear range of the assay is 
15mg glucose per 100ml.
2.5.12. Incubation of T.b.brucei cells with r*jciglucose.
The experimental set up was similar to the glucose utilisation system the 
only difference being that radiolabelled glucose was added to the flask. An 
aliquot of the incubation mixture was removed for the estimation of total glucose 
added.
After 25min a further 200|il. sample was taken and the contents of the 
flask transferred to 4 pre-cooled centrifuge tubes. The cells were pelleted at 
1000# at 4°C for 5min. The supernatant was carefully poured off and the cells 
resuspended in a total of 8ml of KRP buffer and respun. The cell pellet was 
resuspended in 1ml of sterile KRP buffer and lysis of the cells was achieved with 
the addition of 4ml extraction buffer containing Sarkosyl detergent
2.5.13. Incubation of T.cruzi cells with r14C1 glucose.
The incubation set-up was effectively that of the T.brucei, the difference 
being the absence of unlabelled glucose. The trypanosomes were introduced into 
the incubation medium in KRP buffer so the only glucose present in the system 
was the radioactive [^C ] glucose added directly to the flask. The final 
concentration of glucose was approximately 8.7|iM. According to von Brand 
(1961), these cells survive for long periods in the absence of glucose and can 
metabolise proteins and fatty acid reserves. Bovine serum albumin was also 
excluded, the incubation time extended to 150min and the incubation carried out 
at 28°C. All other procedures were exactly the same as for T.brucei cells.
2.5.14. Estimation of radioactivity of an aqueous sample.
A constant ratio of 1:10 (v v"*)of aqueous sample to scintillation fluid 
was used and a final volume of 5ml counted in 50ml super polypropylene vials 
for 10min per vial The LKB Wallac 1217 Rackbeta liquid scintillation counter 
had a window of 0-156 KeV. As the counting efficiency of [^C] counting was 
£95% all counts in cpm were not converted into dpm.
2.5.15. Estimation of the evolution of label as r14Cl(XK
An aliquot of 50pl from the 1M NaOH through which the gas outflow 
was passed was diluted lOx with water and twice the usual volume of 
scintillation fluid added in order to get a clear sample for counting. The vials 
were counted for lOmin each and the total counts of [^C ] in the CO2 estimated 
after multiplying the counts from the 50|il aliquot (corrected for background 
radioactivity using a water blank with the same ratio of sample to scintillation 
fluid) by the dilution factor of 100.
2.5.16. Nucleic acid extraction.
Nucleic acid extraction and mass protein removal were carried out 
simultaneously with phenol and chloroform reagent according to Pryke et al. 
(1979).
The cell preparation was stirred, 2m 1 phenol and 2ml chloroform reagent 
were added and the mixture gently stirred for 5min and then centrifuged at 800g 
for 5min in a glass tube. The top (aqueous) layer and the white interface were 
removed and re-extracted with 4ml chloroform reagent in a glass tube with 
quick-fit stopper for 5min. After spinning as before, the top layer was taken for 
two further extractions with chloroform reagent. The final top layer was used to 
prepare the caesium chloride density gradient
2.5.17. RNA purification - CsCl density gradient centrifugation.
To the nucleic acid extraction volume, one-tenth volume of SSC buffer 
was added and solid CsCl 1.3:1 w v"* was added.
The solution was placed in Beckman quick-seal ultracentrifuge tubes 
(5.2ml max volume per tube) and sealed by melting after carefully balancing 
against each other (less than 50mg difference).
The tubes were spun at 200,000# for 18 hours at 15°C in a vertical rotor 
(VTi 65) in a Beckman L5-65 ultracentrifuge. After deceleration without brake 
the top of the tube was sliced off with a razor blade and drained of liquid using a 
sterile Pasteur pipette. The RNA pellet which was clearly visible down the wall 
of the tube was allowed to dry and was resuspended in a small volume of sterile 
TE buffer. The suspension was made up to 0.4 M NaCl and 2 volumes of ethanol 
(absolute ethanol at -20°C) were added. The solution was stored overnight at 
-70°C. The RNA was recovered by centrifugation at 20,000# for 10 min at 2°C. 
The pellet was resuspended in a small volume of sterile TE buffer and aliquots 
taken for RNA determination, radioactivity estimation and acid hydrolyses.
2.5.18. Orcinol method for RNA determination.
The Orcinol method of Schneider (1957) was employed.
Volumes of RNA (75-150|jJ) were diluted to 0.5ml with TE buffer in 
duplicate. 0.5ml perchloric acid (72% v/v) and 1ml of Orcinol reagent were 
added and mixed. The test tubes were heated in a boiling water bath for 20min. 
After cooling, the absorbance at 660nm was measured against a reagent blank. A 
standard calibration curve was constructed using standard RNA (500|igmr^) in 
TE buffer at 0-100fil ml"* concentration in the assay. The assay was linear for up 
to at least 100 |ig mT*.
2.5.19. RNAse assay to confirm the radioactivity of RNA.
Ribonuclease (RNAse), from Aspergillus clavatus supplied as lyophilised 
powder containing about 5% protein was used. The activity was approximately
250,000 units mg"* protein, where one unit will produce acid soluble 
oligonucleotides equivalent to a DA25Q of 1.0 in 30 min at pH 7.5 at 37°C in a 
1.5ml reaction volume.
Excess RNAse (80 units ml"*) free from DNAse and protease activities 
was used in the presence of 100|iM PMSF. It was incubated with RNA for 2,5  
and 15 min at room temperature. The incubation buffer was 0.1 M acetate (pH 
5.0). Control tubes with no RNAse were also set up. At the set time intervals, 
aliquots of 20|il out of a reaction volume of 100 |il were placed onto acid pre­
washed filter papers and allowed to dry.
The filter papers (Whatman 3MM) were then washed 4 times with 5% 
TCA, once with ethanol and allowed to dry. Scintillation fluid (5ml) was added 
to each vial containing the filter paper and counted for 10 min.
The counts that remained on the filter papers represented the acid 
insoluble nucleic acid (RNA) that was not hydrolysed in the absence of RNAse 
in the control incubations.
2.5.20. RNA hvdrolvses.
A. RNA hydrolysis with sulphuric acid.
Half the RNA stored as ethanol precipitate at -70°C was resuspended in 
0.5 M H2SO4 and heated at 100°C for one hour. After cooling, the hydrolysate 
was subjected to anion-exchange column chromatography (See below).
According to Vischer and Chargaff (1948), this hydrolysis is mild 
enough to prevent the breakdown of the pentose sugar component and so allow 
its chromatographic separation and quantitation.
From this hydrolysis free purine bases were obtained in addition to the
ribose.
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B. RNA hvdrolvsis with perchloric acid.
The rest of the RNA was mixed with 70% perchloric acid and heated at 
100°C for 1 hour. The hydrolysate was diluted with two volumes of water and 
treated as for the sulphuric acid hydrolysate.
In this process, free pyrimidine bases were obtained while the ribose was 
charred.
2.5.21. Anion-exchange chromatography.
A formate Dowex 1-X8 column (mesh size 200-500) was prepared from a 
batch of chloride form by washing with 1 M NaOH followed by CC^-free water, 
followed by 3 M formic acid and CC^-free water. The column dimensions were 
20cmx0.7cm diameter.
The hydrolysate (sulphuric or perchloric) was loaded onto the column and 
the column washed with water. In the case of the sulphuric acid hydrolysate the 
water eluant contained the ribose, adenine and guanine and in the case of the 
perchloric acid hydrolysate, the water eluant contained cytosine and uracil only.
The sample and water were passed through the column by a peristaltic 
pump, at a rate of 1 ml min"*. The eluate tube was connected to a CECIL CE 272 
linear ultraviolet spectrophotometer, set at 260nm, which was connected to a 
Rikadenki electronic recorder. The eluate was collected into a round-bottom 
flask which fitted onto a vaccum rotor evaporator which was used in evaporating 
the formic acid.
2.5.22. Evaporation of the formic acid - Preparation for TLC.
The flask was attached to a rotor vaccum evaporator which was attached 
to an oil vaccum pump. The sample was in the flask which was immersed in a 
constant temperature water bath at 48°C. Water up to twenty times the volume 
was added at intervals during the evaporation of the formic acid. When neutrality 
was reached, the volume was reduced to 100pl and was spotted in a line five cm 
long 2cm from the bottom of the silica gel 60 coated glass plate 10 x 20 cm.
Mixture of markers adenine, cytosine, guanine, uracil and ribose, 5|ig each were 
spotted on either side of the eluate. The plate was developed at room 
temperature,about 22°C, in the following solvent, Acetonitrile : glacial acetic 
acid: ethanol: water (195 :15 : 2 :1 ; v : v : v : v). The plate was developed for 
2 1/2 hours and dried at room temperature.
2.5.23. Quantitation of bases and ribose.
The positions of the bases were viewed under U.V. light and they 
appeared as dark areas against the overall green background fluorescence of the 
plate.
The positions were marked with a pencil and the plate cut using a 
diamond cutter to remove the marker columns either side of the eluate.
The bands were scraped carefully and eluted with water overnight in 1ml 
per lx5cm^ area. The tubes were mixed occasionaly to aid elution. The silica 
was spun down in a bench centrifuge and the supernatant used for spectral 
characterisation and calculation of the concentration of the bases from their 
respective wavelength maxima in 0.1M HC1 after the subtraction of a TLC blank 
(Burton, 1969). An aliquot was taken for estimation of the radioactivity and the 
specific molar radioactivity of each base calculated.
Ribose was located on the plate by charring with sulphuric acid in 
methanol (5%, v v"*) using a Bunsen burner flame. This was only carried out on 
the marker columns to avoid quenching and to ensure the quantitative estimation 
of the ribose by an adapted Orcinol method (Mejbaum, 1939). The eluate ribose 
was scraped and a suitable blank included.
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The Rf value of each component was calculated as follows:
distance travelled by 
component
Rf  ----------------------------------  x 100
distance travelled by 
solvent
The Rf values for the four bases and the ribose are presented in Table 2.1. 
The specific activity of radioactivity was calculated from a small fraction 
of supernatant not used for the quantitation of the ribose.
2.5.24. Quantitative assay for ribose.
The method used is a variation of the assay for RNA, the difference being 
in that instead of perchloric acid, water was added. The calibration curve was 
constructed using standard ribose (0.1 mg ml"*) in water at 0-50 fig ml"* 
concentration in the assay. The assay was linear for up to 50 fig ml"*.
2.5.25. Estimation of the ribose content of RNA.
This estimation assumes that the four nucleic acid bases had equal 
distribution in the RNA. The relative molecular mass of RNA was then 












Table 2.1. Rf values of ribose and the four nucleic acid bases of RNA
obtained with pre-coated silica gel TLC plates using solvent 
acetonitrile : glacial acetic acid : ethanol: water (195 :15 : 2 :1, v/v)
The average relative molecular weight of a mononucleotide constituent of 
RNA is therefore equal to 339.45.
Ribose 150.0
150.00
% Ribose in RNA = --------------  x 100 = 44.19%
339.45
One 100 equivalents of RNA contain approximately 44.2 equivalents of
ribose.
2.6.0. Results*
2.6.1. Glucose utilisation bv bloodstream form of T.b.brucei.
The in vitro survival of the bloodstream form of T.b.brucei is dependent 
on a readily available carbohydrate supply (Fulton and Stevens 1945). Under the 
specified conditions of in vitro incubation of 4x10^ cells in 1 mM glucose, it was 
found (Figure 2.1) that all the glucose was metabolised within 40 minutes of 
incubation. Cell death started at a glucose concentration of -0.05 mM and after 
40 minutes -27% of the cells had died.
From this result it was decided that all subsequent incubations would end 
at 25 minutes after which -94% of the glucose supplied had been metabolised 
and all the cells were still viable.
2.6.2. Incubation of bloodstream form of Th.brucei with r14Cl glucose.
There was very little difference in the radioactivity of the incubation 
medium at the start and in the end of the incubation period with T.b.brucei This 
was due to the catabolism of radioactive glucose resulting in the extracellular 
excretion of radioactive products, mainly pyruvate and a small amount of 
glycerol (Grant and Fulton, 1957).
2.6.3. Incubation of cultured epimastigote form of T.cruzi with r14C1 glucose.
Carbohydrate metabolism in T.cruzi epimastigotes and blood 
trypomastigotes resembles that of the insect stage of T.b.brucei rather than that 
of the bloodstream form, in that carbon dioxide, succinate and acetate are 
produced as end-products (Bowman 1974).
Culture epimastigote forms of T.cruzi can survive incubation in Krebs- 
Ringer solution without added glucose for 24 hours. During starvation, 
triglycerides are broken down to free fatty acids and they appear to be the free 






















Figure 2.1. Glucose utilisation and survival of bloodstream TJbbrucei cells 
incubated at 37°C.
■ ■ Glucose concentration in the medium (mM)



















There was a bigger difference in the radioactivity of the incubation 
medium before and after the incubation than in the T.brucei incubations. This is 
because a larger fraction of the label was lost as *^ C0 2 *
2.6.4. Evolution of label in CC>2*
The incoiporation of labelled glucose into CO2 is presented in Tables 2.2 
and 2.3 for incubations with Tbbrucei and T.cruzi cells respectively
With T.bJ?rucei, in all the incubations, there was a small percentage 
incorporation of total label metabolised into CO2. There is a >10-fold difference 
in the total counts recovered in CO2 from [1-^C ] glucose than from 
[6-^C]glucose. An even greater percentage of total counts was recovered in 
CC>2 from the [U-^C]glucose incubation than from both the [l-^C]glucose and 
[6-^Cjglucose incubations added together.
With T.cruzi, the percentage of total counts recovered in CO2 was a lot 
higher than that with T.b.brucei in all the incubations. The highest incorporation 
was observed in the [1-^C] glucose incubation, where -14% of the total label 
supplied was recovered in CO2. This value was -2.5-fold higher than the value 
from [6-^C]glucose. In contrast with T.b.brucei, the percentage of total counts 
recovered in CO2 fr°m [U-^C] glucose metabolism was lower than that from the 
other two put together.
2.6.5. The incorporation of label intQ RNA and its ribose gompflnsnL
Table 2.2 presents the specific activities of RNA and ribose in the 
incubations of T.b.brucei with differentially labelled [^C ] glucose. The specific 
activities of ribose were almost equal to those of the RNA from which it was 
derived. The difference in the values could be due to incorporation of label into 
the nucleic acid components of the RNA, or also due to a consistent error in the 
estimation of the quantities of RNA and ribose. The specific activity of RNA 
from [6-^C] glucose was higher than that from the other incubations. The lowest 



























[U-14C] 5.976 1.494 2.151 0.360 6555 5790
5.160 1.290 1.863 0.340 4642 4383
12.143 1.518 4.095 0.340 3628 2986
[6-i4C] 5.089 1.272 0.051 0.010 10038 9485
5.723 1.430 0.034 0.006 11030 9903
[1-14C] 9.960 2,490 11.659 0.110 1690 1596
9.000 2.250 9.760 0.110 2023 1857
Table 2.2. Incorporation of labelled glucose into C 02 anc* specific activities of RNA and ribose from T.b.brucei following incubation of 





































uTt1£ 21.600 6.194 8.72 20.40 9.45 1.0010 1.46 0.236
u1VO 4.367 1.252 8.72 24.05 5.50 0.1690 0.23 0.186
[1-14C] 4.280 1.234 8.67 59.92 14.00 0.0957 0.12 0.100
Table 2.3. Incorporation of labelled glucose into CO2 and RNA from 150 minute incubation at 28° C of 4 x 10  ^cultured epimastigote 
T.cruzi cells.
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to correct for the different specific radioactivities of the labelled glucose in 
different experiments, the results were expressed as percentage molar 
incorporations (see Table 2.4), which were calculated as 100 x [specific activity 
of RNA (cpm jimole"^)/ specific activity of glucose (cpm jimole'^)]. The molar 
incorporations into ribose and RNA are approximately the same for each labelled 
glucose, and the amount of incorporation from [6-^C]glucose incubation is 
roughly half an order of magnitude higher than that from [1-^^C]glucose 
incubation. The percentage molar incorporation into ribose and RNA from [U- 
^C] glucose incubation is slightly less than half that from [6- glucose 
incubation.
The RNA results for three representative experiments with T.cruzi are 
presented in Table 2.3. Here the percentage molar incorporation of label into 
RNA from [U-^C]glucose incubation is -25% higher than from [6-^C]glucose 
incubation. The percentage molar incorporation into RNA from [6-^^C]glucose 
incubation is -20% higher than from [ l - ^ C ] g l u c o s e  incubation. These 
incubations were carried out using different amounts of glucose and in all the 
experiments almost all the label in the RNA was due to its ribose component.
2.6.6. The incorporation of label into the nucleic acid component of the RNA.
The data in Table 2.4 show that there was no incorporation of label into 
the purine bases of RNA in all the incubations of T.b.brucei. Although there was 
some incorporation of label into the pyrimidine bases, the values were very low 
and the contribution to the total label in the RNA is minimal. The quantities 
recovered were sufficient for accurate quantitation [Figures 2.2(1-4)] but the 
corresponding counts were too few for accurate determinations of specific 
radioactivity.
The data for the nucleic acid bases of T.cruzi RNA were also very low 
(percentage molar incorporation for pyrimidines <0.003) and they were 
considered too inaccurate to be presented. The purines were also slightly





supplied (x 10‘6) 
cpm/|imole
RNA Ribose Adenine Cytosine Guanine Uracil
[U-14C] 1.494 0.330 0.330 0 0.006 0 0.004
1.290 0.360 0.340 0 0.011 0 0.007
1.518 0.240 0.200 nd 0.008 nd 0.005
[6-14C] 1.272 0.790 0.740 0 0.003 nd 0.023
1.430 0.770 0.690 nd 0.025 nd 0.028
[1-14C] 2.490 0.068 0.064 nd 0.001 nd 0.003
2.250 0.089 0.082 0 0.002 nd 0.010
Table 2.4. Incorporation of labelled glucose into RNA and its components from T.b.brucei (See table 2.2). 
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Figure 2.2. Absorbance spectra of bases: (1) guanine; (2) adenine; (3) uracil; 
(4) cytosine; (5) RNA; yeast RNA ( • - • ) , tiypanosome RNA (a-a) and buffer 
blank ( -----).
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labelled (<0.1 %) and the lack of contamination could not be excluded and 
therefore the results are not presented.
2.6.7. RNAse assay to confirm the radioactivity of RNA.
All insoluble radioactivity was removed from a TCA precipitate 
incubated with RNAse (10|Xg ml"*) thus confirming that all the counts 
incorporated were in RNA.
The RNA yield from 4x10^ cells ranged between 600-1000 p.g in total for 
TJ?rucei, the same number of T.cruzi cells gave on average half the RNA yield. 
The absorbance spectra of yeast RNA and the extracted purified trypanosomal 
RNA are presented in Figure 2.2(5).
2.7. Discussion.
African trypanosomes like T.bruceiy are well adapted to life in the 
mammalian bloodstream. For their energy needs they rely entirely on glycolysis, 
which proceeds at a very high rate and leads to pyruvate excretion as the only 
end-product of aerobic glycolysis (see review by Brohn and Clarkson, 1978). 
Pyruvate cannot be further metabolised due to the absence of a functional 
tricarboxylic acid cycle (Fulton and Spooner 1959, Flynn and Bowman 1973) 
and the enzyme lactate dehydrogenase (Dixon 1966). In the absence of a readily 
metabolisable energy source TJbrucei rapidly lose motility and lyse due to the 
lack of energy stores, as noted by Ryley in 1962.
In the present work, the rate of glucose consumption was monitored with 
time so that the cells were incubated for the longest period required to consume 
as much of the glucose supplied without loss of viability to the trypanosomes. 
The cell viability was followed by the mobility of the cells under microscopic 
observation. Although total cell viability and motility was maintained over the 
incubation periods, no cell proliferation occurred, as was shown by the constant 
number of cells present. In these experiments the incubation media did not 
contain any labelled nucleic acid bases or precursors which could have served as 
raw materials in the turnover of the trypanosomal RNA. Any incorporation of 
radioactivity in that pool would have arisen from de novo biosynthesis of nucleic 
acid bases or ribose.
In all the incubations, there was no incorporation of label from [U- 
^C] glucose into the purine bases of the RNA, confirming the absence of de 
novo purine biosynthesis in T.brucei (Berens et al. , 1981). The functioning of 
various purine salvage pathways is therefore essential to the parasite's survival 
and growth in vivo. It was shown by James and Bom in 1980 that the 
bloodstream forms of T.brucei can take up various nucleosides and bases from 
the host's fluids and incorporate them into its own nucleic acid biosynthesis.
The epimastigotes of T.cruzi are also unable to biosynthesise purines de 
novo, as suggested in previous experiments by Gutteridge and Gaborak (1979).
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The required purine bases and nucleosides are salvaged from the host through the 
action of a range of phosphoribosyltransferases, aminohydrolases, kinases, 
hydrolases and phosphorylases (Gutteridge and Davies, 1981).
Incorporation of label from glucose into RNA must therefore have arisen 
from pyrimidine biosynthesis or via the pentose moeity. All six enzymes of de 
novo pyrimidine biosynthesis have been detected in homogenates of the blood 
trypomastigote form of T.brucei and the culture epimastigote form of T.cruzi 
(Gutteridge and Gaborak, 1979). Trypanosomes can also utilise salvage 
pathways for pyrimidine nucleotide synthesis (Hammond and Gutteridge, 1984). 
In all incubations the incorporation of label into the pyrimidines was very low. 
Because of this, and the low specific activities, no conclusions could be reached 
about the metabolic sourse of cytosine and uracil.
Previous work in this laboratory by Hunt et al. in 1986, had indicated the 
operation of a C-l oxidative pathway leading from glucose to RNA in T.brucei. 
Recent detailed study by Cronin et al. in 1989, has shown the presence of most 
of the enzymic components of this pathway, including 6-phosphogluconate 
dehydrogenase long thought to be absent due to Ryley's inability to detect it in 
1962.
Gutteridge and Gaborak (1979) have shown that none of the three forms 
of T.cruzi incorporated radiolabelled formate, bicarbonate, or glycine into the 
purines or their nucleic acids. Extracellularly supplied adenine and guanine were 
nevertheless incorporated into the nucleic acids as the respective nucleotides. 
Berens et al. (1981) used the sensitive technique of HPLC analysis of the soluble 
nucleotide pool of epimastigotes of T.cruzi to show that the observed incorporat­
ion of radioactivity in the nucleotide pool was not in the purine ring but in the 
ribose moiety. The demonstration that radioactivity from [U-^C]glucose was 
incorporated, as the ribose moiety, into purine and pyrimidine ribonucleotides 
showed that these compounds were being made under the experimental 
conditions and that T.cruzi possesses adequate pentose phosphate shunt activity 
to supply the ribose, as PRPP, necessary for biosynthesis of nucleotides from
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salvaged bases. Due to the overall low counts obtained with trypomastigotes of 
T.brucei, the experiments were extended to T.cruzi epimastigotes where at least 
the oxidative part of the pentose phosphate pathway has been identified by the 
presence of glucose-6-phosphate dehydrogenase and 6-phosphogluconate 
dehydrogenase activities (De Boiso and Stoppani, 1973).
The higher percentage of glucose released as ^CC>2 in all the T.cruzi 
experiments compared to T.brucei is consistent with the well-known fact that in 
T.cruzi epimastigotes carbohydrate oxidation is via glycolysis, followed by a 
complete tricarboxylic acid cycle (Rogerson and Gutteridge, 1979). The yields of 
^CC>2 from [1-^C]glucose and [6-^C]glucose of 14% and 5.5% respectively 
indicated that the hexose monophosphate shunt was contributing significantly to 
the metabolism of glucose. The yield of ^CC>2 from [U-^C]glucose of 9.45% 
was lower than that quoted by Bowman et al. (1963), of 32%, which could 
reflect the switching-on of different pathways due to a lower concentration of 
glucose supplied in the present experiments. The understanding of the different 
pathways of glucose metabolism which operated in these experiments would 
need more scrupulous investigation involving the isolation and degradation of 
ribose and other end-metabolites such as succinate and acetate produced through 
C02-fixation. In order to attempt any calculation of the contribution of the 
pentose carbon cycle in the metabolism of glucose the labelling pattern of the 
trioses and other end-metabolites should be known.
The ratio of the percentage molar incorporations of radiolabel from 
glucose into the RNA is the inverse from that in the *^ CC>2, consistent with the 
activity of the pentose phosphate pathway. The label from [U-^C]glucose is 
-25% higher than from [6- ^C]glucose. One might expect a lower result (5/6) if 
the only pathway was the pentose phosphate pathway, but the results suggest 
different pathways operating such as recycling of carbon and possible loss of C-6 
before pentose synthesis.
In the T.brucei experiments, the ratio of radiolabel recovered in ^ (X >2 
from [1-14C] and [6-14C]glucose is indicative of a very active pentose
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phosphate pathway. The higher ^CC>2 recovery from [U-^C]glucose indicates 
loss of label through decarboxylation of other carbons such as [3,4-^C] as has 
already been reported by Grant and Fulton in 1957.
There are formidable problems encountered in the attempt to calculate the 
contribution of the pentose phosphate pathway to the overall glucose metabolism 
using radiotracers. Most early attempts are discussed in reviews by Wood (1955), 
later refined by Katz and Wood (1960,1963), Katz and Rognstad (1967) and 
many others. These methods are based on estimates from determinations of the 
fate of the labels of specifically labelled glucoses in their metabolism to various 
metabolic products. The yields of in CO2 from labelled glucose are easily 
measured but are difficult to evaluate in terms of the metabolic pathways. All of 
the factors which affect the yields of in the triose phosphate come into play 
and superimposed on them are other factors. This is due to the fact that the 
pentose cycle yields CO2 directly from C-l of glucose via 6-phosphogluconate 
whereas the Embden-Meyerhof pathway yields none (Katz and Wood 1960). The 
principal purpose of the 1963 Katz and Wood paper was to consider procedures 
that utilise the yields of *^ CC>2 from [1-^C] and [6-^C]glucose as a measure 
of the contribution of the different pathways of metabolism. A number of 
assumptions are made which are not necessarily valid when applied directly to 
any given system.
The following expression is based on the assumptions that the glucose 
supplied in the Tbrucei experiments is solely metabolised via the Embden- 
Meyerhof pathway and the oxidative part of the pentose phosphate pathway. A 
second assumption is that the same amount of glucose supplied was metabolised 
in identical experiments irrespective of the label in the supplied glucose. Given 
that 94% of the glucose supplied in each case was metabolised in 25 minutes, the 
^CC>2 yields from [1-^C] and [6-^C]glucose were expressed as specific 
yields, designated as GICO2 and G6CO2, respectively.
In the [6- C]glucose:xperiment, the amount of glucose utilised was 
5.089xl07 cpm x 0.94, the yidd of '4C02 recovered was 0.051x10'' cpm.
0.051xl05




G1C02= ---------------------- = 0.01245
9.362xl07
As was shown by Katz and Wood in 1963, when glucose is metabolised 
entirely by the pentose phosphate pathway and the glycolytic pathway,
GlCO2 -G6C02 3PC
1-G 6C 02 1+2PC
where, PC is the fraction of the total glucose that is metabolised via the pentose 
phosphate pathway.
By substituting the values for the specific yields calculated and solving 
the expression for PC the value of 0.415% is reached. This is a small yet 
significant amount of glucose metabolised via the pentose phosphate pathway 
under the conditions of these in vitro experiments. The concentration of glucose 
in the system is likely to affect the relative contribution of the various pathways 
operating and since these experiments do not involve cell proliferation it is likely 
that under in vivo conditions the need for ribose for RNA synthesis will switch- 
on a higher pentose phosphate pathway involvement in the overall glucose 
metabolism of the bloodstream form of Tbrucei.
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In TbruceU a number of glycolytic enzymes present in the cytosol of 
other organisms are uniquely segregated in a microbody-like organelle, the 
glycosome, which they are believed to reach post-translationally after being 
synthesised by free ribosomes in the cytosol (Opperdoes et al., 1986).
Continuous and pulse-chase labelling experiments with procyclic 
trypomastigotes revealed that the enzymes have a half-life in the cytosol of about 
3 minutes or less, and then turn over rapidly in the glycosomes, with half-lives as 
short as 30 minutes (Hart et al., 1987). Some of the glycolytic enzyme activities 
associated with glycosomes such as TIM, GAPDH, PGK and ALDO all have 
cytosolic counterparts (Opperdoes et a/., 1986; Misset et al., 1987). Under 
aerobic conditions, the function of the glycosome is intimately associated with 
that of the mitochondrial glycerol 3-phosphate oxidase, so that the overall 
reaction catalysed within the glycosome is:
glucose + 2Pi + O2  > 2(3PGA) + 2H2O
The conversion of glucose to 3PGA proceeds with no net gain in ATP or 
NAD. The major function of the glycosome appears to be the rapid and efficient 
conversion of glucose or glycerol to 3PGA for ATP synthesis by pyruvate kinase 
in the cytosol. The reduced coenzyme, NADH, is indirectly re-oxidised by O2 
via the G3P-DHAP shuttle which involves speculation that specific translocators 
for DHAP, G3P, PGA, and Pi facilitate the diffusion of these phosphoiylated 
species through an otherwise impermeable glycosomal membrane (Opperdoes 
and Borst, 1977). The current available evidence discussed by Fairlamb (1989), 
supports the hypothesis that the glycosomal membrane acts as a barrier to 
diffusion, rather than a selectively permeable membrane.
The presence of cytoplasmic phosphoglucose isomerase in the 
bloodstream form of T.brucei is puzzling in view of the absence of transketolase 
in bloodstream forms (Cronin et al. , 1989), which is required in the metabolism 
of GAP to 3PGA in the incorporation of C-l of glucose into ribose. The results
of Table 2.2 suggest that czrbons 4, 5, and all of 6 find their way into the ribose 
since loss of carbons 1,2, aid 3 would explain the consistent lower molar 
incorporation from [U-^C] than from [6-^C ] into the RNA. Mackenzie etal. 
(1982) incubated bloodstream forms of T.b.gambiense with [l-^C]glucose and 
[1-^C]glucose and assessed intracellular metabolic processes by NMR 
spectroscopy. They found that there was under anaerobic conditions predominant 
incorporation of C-l of glucose into glycerol while there was complete 
randomisation of C-6 of glucose into glycerol and pyruvate. In later studies 
however, these workers (Mackenzie et al. , 1983) showed that there was a 2 to 1 
ratio in the incorporation of C-6 of [6- ^C]glucose into C-3 of pyruvate, alanine, 
and 2,2-dihydroxypropionate (collectively) over C-l,3 of glycerol. The 
observations of a number of scientists such as Mackenzie et al. (1982), cannot 
be reconcilled by the Embden-Meyerhof glycolytic pathway and an alternative 
pathway of glucose catabolism must exist Cronin et al. (1989), suggested that 
there could be a 2-carbon transfer independent of transketolase and 3'-epimerase 
activities which is yet unknown.
The complexity and indispensability of carbohydrate, mainly glucose, 
metabolism justifies research effort in evaluating the different pathways involved 
in the search of possible targets of chemotherapy against Trypanosomiases. The 
important result of this section of the present work has been the confirmation of 
the existence in the bloodstream forms of T.brucei, as well as in the epimastigote 
forms of T.cruzi, of a small, but significant, proportion of glucose metabolism 
through an oxidative pentose phosphate pathway leading to the provision of 
ribose moieties for subsequent incorporation into RNA.
CHAPTER 3
PRPP SYNTHETASE FROM T.B.BRUCEI.
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3.1. Introduction.
The experiments of the previous chapter have shown that ribose is 
synthesised and incorporated into the RNA pool of T.bbrucei cells during the in 
vitro incubation of the cells with differentially labelled [^ ^C] glucose. The supply 
of ribose-5-phosphate into purine, pyrimidine and pyridine nucleotides takes 
place uniquelly through the catalytic action of the enzyme PRPP synthetase.
It is well reported in the literature that trypanosomes salvage purine and 
pyrimidine bases from their environment through the action of various 
phosphoribosyltransferases which require PRPP as one of their substrates (Fish et 
al. , 1982a,b). It was therefore interesting to detect and characterise the enzyme 
uniquely responsible for formation of PRPP in trypanosomes. In this chapter, the 
various methods used in the detection, partial purification and characterisation of 
PRPP synthetase from bloodstream forms of T.b.brucei are presented. The results 
obtained are compared with results from PRPP synthetases from different 
sources.
The assignment of the last two enzymes of de novo pyrimidine 
biosynthesis as well as of the purine salvage enzyme HGPRTase to the 
glycosome (Opperdoes, 1990), made the investigation of the intracellular 
localisation of trypanosomal PRPP synthetase very interesting.
3.2.0. Materials,
Additional materials to those used in chapter 2 were supplied as presented
below.
Phenylmethylsulfonyl fluoride (PMSF), glycine, Brilliant Blue G 
(Coomassie Brilliant Blue G), High molecular weight marker proteins, 
triethanolamine hydrochloride, 2-mercaptoethanol, cupric chloride (dihydrate), 
nickel chloride (hexahydrate), ammonium chloride, streptomycin sulphate, 
N,N^r,N'-Tetramethylethylenediamine (TEMED), DL-Dithiothreitol (Cleland's 
reagent; DTT), 5-phosphorylribose-a-l-pyrophosphate (phosphoribosyl pyro­
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phosphate, PRPP, estimated purity 80-90% based on the orotate removal assay), 
orotidine-5-monophosphate (OMP), orotic acid, inosine-5-monophosphate 
(IMP), hypoxan thine, adenosine, N^N’-Methylene-bis-Acrylamide, 
triethanolamine, Triton X-100, Blue Dextran (average molecular weight of
2,000,000), carbonic anhydrase, alcohol dehydrogenase, ft-amylase, apoferritin, 
thyroglobulin, D-ribose-1-phosphate (cyclohexylammonium salt), D-ribose-5- 
phosphate (disodium salt), D-ribulose-5-phosphate (sodium salt), uridine-5- 
triphosphate (sodium salt), adenosine-5-diphoshate (sodium salt), 2- 
deoxyadenosine-5-triphosphate (disodium salt), cytidine-5-triphosphate (sodium 
salt), guanosine-5-triphosphate (sodium salt), inosine-5-triphosphate (sodium 
salt) were purchased from Sigma Chemical Company.
ATP (disodium salt) was purchased from Sigma and was purified from 
ADP and Pi contaminants using ion-exchange chromatography on a Dowex 1-X- 
8 (formate form) column, according to the method of Bartlett, 1959. The 
concentration of the eluted ATP solution was estimated from the extinction at 
259nm; the molecular extinction coefficient was taken to be 15.4x10^ at pH 7.0 
(Glynn and Chappell, 1964).
Inorganic Pyrophosphatase (Pyrophosphate phosphohydrolase, PPiase; 
EC 3.6.1.1) from Bakers Yeast purchased as lyophilised powder from Sigma, and 
kindly donated by Dr. W. Whish, Biochemistry Department, University of Bath. 
It was supplied as 100 units, 0.2 mg protein/vial and 520 units/mg protein. One 
unit will liberate lpmole of inorganic orthophosphate per minute at pH 7.2 at 
25°C.
Orotidine-5'-phosphate pyrophosphorylase and Orotidine-5'-phosphate 
decarboxylase, (OPRTase-ODCase; mixed enzymes) were also from Sigma. 
These were supplied as a crude powder from Yeast, which contained -50% 
buffer salts. Activity -0.2-0.3 Units per mg solid. [One Unit will catalyse the 
phosphorylation of lpmole of orotic acid to 5’-OMP, which is then 
decarboxylated to 5-UMP in one hr at pH 8.0 at 25°C, in a PRPP system].
HGPRTase purchased from Sigma was supplied as 1,000 mUnits. The white 
powder was dissolved in lnl water and aliquotes of 80pl stored at -20°C.
Acrylamide, magneaum chloride (hexahydrate), sodium azide, 
ammonium persulphate, Brcmophenol Blue, Eriochrome black T (Solochrome 
black), ammonia solution (sp. gravity 0.88g/cm^), Tris(hydroxymethyl)- 
methylamine, butan-l-ol, zinc chloride, cobalt chloride (hexahydrate), sodium 
dodecyl sulphate (SDS), calcium chloride (hexahydrate), manganous chloride 
(tetrahydrate), polyethylene glycol (20,000) from BDH Chemicals Ltd.
Dialysis tubing (membrane), visking size 1-8/32" from Medicell 
International, London, U. K .. Ion-exchange paper DE-81 filter discs (2.3 cm 
diameter) from Whatman Ltd. Thin Layer Chromatography Polygram cel 300 
PEI (0.1mm) pre-coated plastic sheets from Camlab Ltd., Duren, Germany. 
Cibacron Blue F3G-A from Ciba-Geigy, Basel, Switzerland.
Bio-Rad protein assay (dye reagent concentrate) and Vertical slab gel 
apparatus (Proteam TM 11) from Bio-Rad Laboratories, GmbH, Munchen, 
Germany.
Millipore disc filters (0.2[im and 0.45|im pore size) and Millipore 
multifiltration apparatus from Millipore Coiporation, U.S.A.
Sepharose 6B, Sephadex G-25 (PD 10) columns and Fast Protein Liquid 
Chromatography (FPLC) HiLoad 16/60 Superdex 200 column from Pharmacia 
Biosystems Ltd.
Ammonium sulphate, sodium carbonate (anhydrous), urea from Fisons 
Scientific Apparatus, Loughborough, U. K. Silicon carbide (SiC) was Grade C6- 
F400 from The Carborundum Co., Manchester, England.
3.2.1. Radiochemicals employed.
Radioactive orotic acid, [6-^C]orotate, was purchased from ICN Flow, 
High Wycombe, U. K . , with specific activity of 61mCi/mmole (50jiCi in 1ml).
Radioactive hypoxanthine, [8-^C]hypoxanthine 
(specific activity of 55mCi/mmole; 50|iCi as white powder) ,and [G- 
■^H]hypoxanthine (specific activity of 1.32Ci/mmole; lmCi as white powder) 
were purchased from Amersham International pic.
3.2.2. Organisms used.
The bloodstream form of T.b.brucei was prepared and purified as 
described previously. The cultured procyclic cells were cultured and supplied by 
Maijan Kasraeian, Biochemistry Department, University of Bath. These cells 
were grown from a frozen stock of procyclic T.brucei strain EATRO-427, 
originally supplied by Dr. W. Gibson (Tsetse Research Centre, Langford, 
Bristol). Growth was at 26°C in SDM-79 [Brun, R. and Schonenberger, M. 
(1979) Acta Trop. 36,289-292] supplemented with 10% (v/v) fetal calf serum, 
and cells were harvested by centrifugation at 600g and washed with phosphate 
buffered saline.
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3.3.0. Methods of assay for PRPP svnthetasc.
Phosphate protection buffer.





3.3.1. Orotate Removal Assay.
This assay was developed by Komberg et al. (1955). It involves two 
separate steps. In the first step (step 1) enzyme activity accumulates PRPP, which 
is converted to orotidylic acid and uridylic acid in the second step (step 2), by an 
enzyme preparation from yeast which contains OPRTase and ODCase activities. 
The disappearance of orotate in step 2 is followed spectrophotometrically. The 
disappearance of 1 Jimole of orotate (which is equivalent to the production of 1 
pinole PRPP) from the 1ml reaction volume, corresponds to a decrease in 
absorbance of 3.95 at 295nm.
The assay was slightly modified as follows:
Step 1 . PRPP Formation Step.
In 1 ml final reaction volume, the reaction mixture contained:
ATP 7.5mM
R5P 4mM
MgCl2 3mM (added after ATP and buffer)
KH2P04 95mM
DTT 0.2mM
Trizma base buffer lOOmM 
(pH 8.85)
and enzyme samples containing 1.25-1.45mg protein. 
The final pH was adjusted to 8.85 at 37°C.
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Incubation was carried out at 37°C and was stopped at 0,7.5, and 15min by 
heating at 100°C for 60sec.
The tubes were immediately cooled by plunging them into crushed ice 
and then stored overnight at -20°C. The thawed samples were centrifuged at 
4000xg for 15min at 2°C, and from the resulting clear supernatant fluid the PRPP 
produced in step 1 was measured in step 2.
Step 2 . PRPP Assay.




Tris-HCl buffer (pH 8.85 at 20°C) 20mM
4 Units of OPRTase-ODCase mixture (see materials).
0.3ml aliquot from step 1 incubation mixture.
The final pH was 8.0.
Care was taken to establish a constant absorbance reading before adding the step 
1 aliquot, which was introduced with rapid mixing. The decrease in absorbance 
at 295nm was followed in a spectrophotometer. The reaction came to completion 
when there was no more change in the absorbance (about 20min).
One unit of enzyme activity is defined as the amount catalysing formation 
of l(imole of PRPP per min under the conditions of the assay.
Step 2 was also used directly for enzymic assay of PRPP. In step 1 
reaction mixture R5P was omitted and replaced by 165nmole of PRPP in order to 
check the assay. Also blanks were included in which the R5P was substituted 
with water.




0.1M (pH 7.4) 
0.2mM
In order to standardise the Orotate Removal assay, rat liver enzyme was 
prepared and assayed acceding to the method of Bal6-Banga and Weber (1984).
Wistar rats (180-200g) were stunned, decapitated, and exsanguinated; the 
liver was quickly removed into a beaker with homogenisation buffer (see above) 
which had previously been weighed and embedded in crushed ice.
A ten percent homogenate from rat liver was prepared using a blender 
homogeniser (15sec). The homogenate was centrifuged at 100,000xg for 30min 
at 2°C in a Beckman L5-50 preparative ultracentrifuge. To 6ml of the resulting 
clear supernatant, 1.4g solid ammonium sulphate was added, resulting in 40% 
final saturation. After lOmin incubation at 0°C the precipitate formed was 
removed by centrifugation at 100,000xg for 15min at 2°C. The pellet was 
resuspended in 0.35ml of the homogenisation buffer and then centrifuged at 
l,500xg for 15min in a Sorvall type RC-5 superspeed refrigerated centrifuge. 
From the clear supernatant 25|il samples were assayed for PRPP synthetase 
activity.
3.3.2. Alternative forms of the orotate removal assay.
An alternative form of this assay was the production of [^C] 5f-OMP 
and [^C] 5-UMP from [6-^C] orotate and the separation of substrate and 
products by TLC. The solvent utilised was n-butanol: methanol: water ammonia 
(sp. gr. 0.88) ;60: 20: 20: 1, (v/v). The negatively charged products stayed nearer 
the origin (Rf values for OMP and UMP of 0.24 and 0.14 respectively) and the 
substrate, [6-^C]orotate, travelled with an Revalue of about 0.37.
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In this procedure, aliquots are spotted from an incubation mixture after 
the assay had been stopped by mixing the aliquot to 50% final concentration of 
ethanol and spotted on TLC plastic plates pre-coated with PEI-cellulose.
A carrier was spotted prior to the aliquot in order to aid the localisation of 
the substrate spot The carrier consisted of lOjil (lOmM stock) orotic acid. 
Suitable markers were run on either side of the test sample and the plates run for 
6 hours in a pre-equilibrated (3 hours) tank. After the plates were dried, the spots 
were viewed under U. V. light and the position of the spots marked with a soft 
pencil. The plates were then cut in 0.5x1 cm  ^strips and counted with 5ml 
'Optiphase' Safe scintillation fluid.
3.3.3. The coupling of PRPP synthetase to Hvpoxanthine-guanine 
phosphoribosvltransferase.
The assay was essentially that of Roth et al. (1974) but with some 
adaptations. In principle, the activity of PRPP synthetase was measured by the 
PRPP-conversion of radioactive hypoxanthine (^C  label on a carbon atom in the 
purine ring, or label on the hydrogen of carbon atom at position 8) to 
radioactive 5-IMP (label on same position as in hypoxanthine) in the presence of 
hypoxanthine-guanine phosphoribosyltransferase (Sigma).
TLC method.
The assay was essentially that of Roth et al. (1974). In this assay, the 
activity of PRPP synthetase was measured by the PRPP-conversion of [8- 
 ^^ C] hypoxanthine to [^C] 5'-IMP in the presence of hypoxan thine-guanine 
phosphoribosyltransferase. This coupling enzyme preparation introduced less 
protein in the assay and involved the production of one product compared to the 
two products of the orotate removal system.
The assay volume was 70pl
The assay system contained:
Components. |il added in the assay.






(1.9 |imole/ml; 1.32 Ci/mmole) 4
HGPRTase (1 munit/p.1) 2
Trypanosomal extract 10 or 20|il
Water up to 70jjI volume..
Suitable controls were included where R5P was omitted from the assay 
system for all the concentrations of enzyme assayed. PRPP (ImM stock) was 
also included in assay systems (as 2fil/assay) without any R5P, ATP and 
trypanosomal enzyme preparation added, as control.
After incubating for 0,15,45 and 150 minutes, lOpl samples were 
removed at each time point and mixed with lOjxl 95% ethanol and left on ice. 
After the addition of 5|il o f hypoxanthine (2.38mM) or IMP (0.1M) carrier 
solution, a 20|il sample w;as spotted on the plastic PEI-cellulose pre-coated 
plastic TLC sheets with suitable markers on each side. The plates were run in the 
same solvent as with the alternative orotate removal assay and processed in the 
same manner.
The Rf values for IMP and hypoxanthine were 0.014 and 0.297 
respectively. Strip blank had 30cpm and was subtracted from all strip cpm. The 
percentage of substrate converted to product was expressed as nmoles of PRPP 
produced over the time of incubation.
Detection of PRPP synthetase in bloodstream and cultured procvclic Xfrrtf cei 
cells.
The cells were resuspended in phosphate protection buffer and disrupted 
by sonication (see later on). The sonicate was spun at 20,000xg for 20 minutes at 
2°C and the resulting pellet resuspended in a small volume of the same buffer 
and both supernatant and pellet fractions assayed by the standard method for 
PRPP synthetase activity described below.
DE-81 filter method. Standard method.
Materials and methods*
Stock solutions prepared.
1. Potassium buffer 0.7M, pH 7.6





7. [8-^C]hypoxanthine 20|iCi/ml; 55mCi/mmole
The hypoxanthine was prepared by diluting the stock 5 times with water and 
filtering though a DE-81 disc.
8. IMP 0.1M
9. Adenosine 4mM in
20mM phosphate buffer, pH 7.6. 
The assay had a final volume of 70pl A cocktail containing the potassium 
phosphate buffer, magnesium sulphate, ATP, EDTA, hypoxanthine and 
HGPRTase was added as 22|il. Control assays had no R5P. Water was added to 
make the volume to 60pl and the mixture pre-incubated for 5 minutes at 43°C in 
a water bath.
A suitably diluted enzyme preparation (at 0°C) was added last in lOp.1 to start the 
reaction and the incubation mixture mixed with a whirly-mixer and transfered to 
a second water bath equilibrated at 37°C for 10 minutes.
Reaction mixture Final concentration in .ihs 7Qi4 of the assay,
Potassium phosphate, pH 7.6 20mM




HGPRTase 2munits in total.
R5P 2.87mM.
Enzyme preparation sufficient to give a linear relationship between reaction 
velocity and protein concentration was added last (see later on).
The reaction was stopped by placing samples in a boiling water bath for 
30 seconds. The samples were chilled on ice and 10}il of the IMP stock solution 
added prior to filtration. The samples were filtered 12 at a time using a Millipore 
multifiltration unit through DEAE paper discs (Whatman DE-81) which were 
soaked in 4mM adenosine solution in 20mM phosphate buffer, pH 7.6. The discs 
were washed with 50ml water and 10ml 95% ethanol. The filters were transfered 
in scintillation vials and immersed in 5ml scintillation fluid (Optiphase ’Safe’, 
LKB Ltd.). The counting time was 5 minutes for each sample.
3.3.4. .3?E.lransfer assay,
The assay was developed by Switzer (1969) and measures the transfer of 
radioactivity from [y-^PJATP to the product, PRPP, which is not adsorbable by 
charcoal. The labelled product is hydrolysed in acid to inorganic phosphate. 
Unreacted ATP and reaction product AMP are removed by adsorption by 
charcoal and centrifugation of the adsorbed complexes.
This assay is used in kinetic studies with highly purified enzyme. It is not 
suitable for use in crude extracts where there is interference from other enzymes, 
mainly those that involve ATPase-like activity. It is the most sensitive and rapid 
assay available for PRPP synthetase.
In this assay samples contain the following in a final volume of 0.5ml: 
lOOmM potassium phosphate (pH 8.0); lOmM MgC^; 2mM ribose-5-phosphate; 
1.4mM Na2ATP; O.lmM Na2EDTA; O.lmg of bovine serum albumin; 
[y_32p]ATP to give a specific activity of 100 to 200 cpm per nmole; and enzyme 
as specified.
After incubation for 30minutes at 37°C, the reaction was stopped by 
addition of 0.5ml of 5% (v/v) perchloric acid, and cooled on ice for at least 
lOmin. After mixing the stopped reaction mixtures with 0.3ml of 20% (v/v) acid- 
washed Norit (Zimmerman, 1963) and standing in ice for 10 to 15min, 0.2ml of a 
'carrier' composed of 5mg per ml of bovine semm albumin in 50mM sodium 
pyrophosphate, pH 7.0, was added and the substances were mixed vigorously. 
After centrifuging the tubes, 0.5ml of the clear supernatant fluid was removed for 
counting.
3.3.5. Methods of trvpanoscme disruption.
In order to optimise he yield and specific activity of PRPP synthetase 
from a given number of bloodstream forms of T.b.brucei, different well-known 
trypanosome disruption menods were attempted as described by Oduro et al. 
(1980a,b). The trypanosomes were purified from contaminating blood cells as 
described in chapter 2.
Bv sonication.
The disruption buffer used in this method was:




The cells were washed in the disruption buffer and resuspended at a 
density of 5x10** cells/ml. The cells were sonicated at 0°C at 40 Watts for 15 sec 
at each time and the process repeated 4-6 times with an interval of 30 sec.
The extent of disruption was followed by microscopic examination. The 
sonicated cells were spun at l,500xg for 10 min in a cooled centrifuge and the 
supernatant used for assaying for enzyme activity by the standard method.
Triton X-100.
Triton X-100 was added to the standard assay, at a final concentration of 
0.1% (v/v).
Bv freezing and thawing in the presence of Triton X-100 (0.1%. v/v).
The cells were resuspended in phosphate protection buffer with 0.1% 
(v/v) Triton X-100 and disrupted by 3 cycles of freezing (liquid N2) and thawing 
(37°C water bath). Homogenates were centrifuged at 20,000xg for 20 min at 2°C 
and the supernatant used as a source of enzyme activity.
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By grinding with Silicon Cirbide.
The disruption buffer used vith this method was:
Tris-HCl 25mM (pH 7.8)
PMSF 0.5mM (added freshly)
DTT l.OmM (added freshly)
KC1 150mM
EDTA l.OmM
Sucrose 250mM (added freshly)
5x10** cells were spun dowi on a bench centrifuge (900xg at 2°C) and suspended 
in 5ml disruption buffer. The cells were ground by hand with silicon carbide (5g 
silicon carbide per 1x10^  cells) in an ice-cold pestle and mortar until no more 
live cells were visible microscopically.
The disrupted cells were collected in centrifuge tubes and washed in the 
disruption buffer (lOOxg for 15 min at 2°C) till no more silicon carbide 
remained. At each washing stage the supernatants were pooled and then 
centrifuged for 20 min at 900xg at 2°C. The large-granular fraction used in the 
localisation studies was prepared from the 5,000xg (lOminutes at 2°C) 
supernatant To obtain a concentrated glycosome fraction, the supernatant was 
spun for a further 20 min at 14,500xg at 2°C. The pellet contained the 
glycosomes and was resuspended in a small volume of disruption buffer. 
Addition of Triton X-100 at a final concentration of 0.1% (v/v) released the 
glycosomal enzymes.
3.3.6. Determination of protein concentration.
The concentration of protein in all samples was determined using the dye- 
binding method of Bradford (1976). The so-called 'Bio-Rad' method is a quick, 
one-step simple reaction that is carried out at room temperature. The details of 
the assay are found in the Bio-Rad Protein Assay Instruction Manual, 1984).
Bovine serum albumin was used for the construction of the standard 















Figure 3.1. Standard callibration curve for the 'Bio-Rad* method of protein 
concentration estimation with Bovine serum albumin as standard in 1 ml final 
volume.
3.3.7. Determination of Magnesium concentration.
The magnesium concentration of the magnesium chloride stock solution 
was determined with Eriochrome Black T as indicator (Belcher and Nutten, 
1960).
The method required the following solutions:
1. Buffer solution.
54g of ammonium chloride were dissolved in 350ml of ammonia solution 
(sp. gravity 0.88) and diluted to 1 L with distilled water.
2. Eriochrome Black T indicator.
0.2g of the indicator was dissolved in 15ml of triethanolamine and 5ml of 
ethanol. (This solution will remain stable for about 1 month).
3. 0.1 M EDTA solution.
This was prepared by dissolving, 37.22 g of disodium EDTA (dihydrate) 
in 1L distilled water.
4. Test solution 1 M MgCl^
This was prepared by dissolving approximately 203.31 g MgCl2.6H20  
into 1L distilled water.
The method involved the titration of 550|i.l of the MgCl2 solution with 
50|il of buffer solution and 15 drops of lOx diluted indicator solution against the 
0.1 M EDTA solution in a 10ml biuret pipette until the wine-red colour changed 
to blue. Care was taken to approach the end-point slowly.
To neutralise from red-wine to clear blue solution, 4.85ml, 5.02ml, 5.1ml, 
5.02ml and 5.14ml of 0.1 M EDTA were required. On average, 5.028ml was 
used in the calculation of the accurate concentration of Mg^+ in the MgCl2 
solution as follows:
5.028ml x 0.1 M = 0.55ml x [Mg2*] M
[Mg2*] = 0.914 M solution instead of 1 M. The solution was divided in aliquots 
which were stored frozen at -20°C until required.
3.3.8. The partial purification of PRPP synthetase from T.brucei.
Ammonium sulphate precipitation.
A 20,000xg supernatant (20K sn) was subjected to sequential ammonium 
sulphate precipitation. A suitable amount of finely ground ammonium sulphate 
according to Dawson etal. (1969) was added slowly to the sample to bring it to 
the first 'cut'. The addition was carried out as the sample was continuously being 
stirred on ice, and after a further 15 minutes the sample was spun at 20Kxg for 
20 minutes in an MSE-18 High Speed centrifuge. The pellet was resuspended in 
a suitable small volume of phosphate protection buffer and ’desalted' on a small 
Pharmacia Sephadex G-25 gel filtration column, eluted with phosphate 
protection buffer. The eluate was then assayed for PRPP synthetase activity and 
protein concentration.
The volume of the decanted supernatant was measured accurately and 
sufficient solid ammonium sulphate added to bring the ammonium sulphate 
concentration to that of the next 'cut' and the procedure repeated as above until 
the highest ammonium sulphate concentration had been reached.
Streptomycin sulphate precipitation.
Streptomycin sulphate, 10% (w/v), was prepared freshly for each 
purification in water and chilled on ice. To the enzyme sample 0.1 volume of the 
streptomycin sulphate solution was added and the sample stirred for 15 minutes, 
centrifuged and the supernatant and resuspended pellet assayed for enzyme 
activity using the standard assay. A small volume of phosphate protection buffer 
was used for resuspending the pellet.
A further 0.2 volumes of streptomycin sulphate solution were added to 
the carefully measured 1% supernatant, and the procedure repeated.
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Heat precipitation.
A 5ml sample of the 20-40% ammonium sulphate resuspended pellet (20- 
40% AS P) was divided into five fractions of equal volume (1ml) and placed in 
glass tubes each containing a small stirring bar. Each tube was placed into a pre­
heated water bath of either 50° or 55°C for 5,10 or 15 minutes with continuous 
stirring with an immersible magnetic stirrer. After the desired heating time the 
tubes were chilled by immersion in ice-cold water and allowed to cool down 
prior to centrifugation at 20,000xg for 20 minutes at 2°C in a bench centrifuge. 
The supernatants were assayed and the specific activity and percentage recovery 
of units of PRPP synthetase from each system determined.
Coupling of Cibacron Blue F3G-A to Sepharose 6B.
To 150ml Sepharose 6B gel, 2.5g of Na2CC>3 in 50ml water and lg  Cibacron 
Blue F3G-A, and in 50ml water were added. After careful mixing, the suspension 
was incubated for 40 hours at 45°C with occasional stirring. The non-coupled 
dye was removed by extensive washing with distilled water on a Buechner filter. 
The gel was stored at 4°C in the presence of lg  sodium azide (NaNj).
Two column volumes were used for washing and equilibrating the 
column prior its use. The column was washed with 1M NaCl and 6M urea and 
equilibrated with phosphate protection buffer.
Routine partial purification procedure.
The trypanosome cells were routinely disrupted by three cycles of 
freezing and thawing and the extract allowed to incubate with Triton X-100 for 
15 minutes on ice. The extract was then spun at 20,000xg for 20 minutes at 2°C 
in a bench centrifuge and the supernatant brought up to 20% ammonium sulphate 
concentration. The 20% ammonium sulphate supernatant was then brought to 
40% concentration of ammonium sulphate and the pellet resuspended in a small 
volume of phosphate protection buffer with PMSF freshly added to it
The sample was hen heated for 5 minutes at 55°C in a water bath with 
continual stining. The fhal supernatant was dialysed overnight against 
phosphate protection buffer containing 20% (v/v) glycerol to get rid of the 
ammonium sulphate and to make the sample contain glycerol for extra stability. 
The sample was concentrated by polyethylene glycol (20,000) and stored at 4°C 
until required. The enzyne preparation was used up to a week since the day of 
preparation.
3.3.9. Methods to test the validity of the coupled-enzvme assay.
To test that the observed rates of production of [^C ] 5'IMP truly 
represent the rate of the PRPP synthetase-catalysed reaction, the variation in 
measured overall reaction rate with concentration of coupling enzyme was 
determined.
When conditions were found under which the rate of the overall reaction 
was proportional to the rate of the PRPP synthetase reaction, this was further 
checked by studying the initial rate as a function of PRPP concentration (protein 
concentration of a crude preparation) at the concentration of [*^C]Hypoxanthine 
in the assay and the number of units of coupling enzyme chosen.
Under steady-state conditions, the rate of the overall reaction, that is the 
rate of IMP formed per unit time, should be dependent on the rate of the PRPP 
synthetase reaction. Doubling the PRPP synthetase concentration, should double 
the cpm on the filter (i.e. the product of HGPRTase) if HGPRTase is in excess. 
Because in the coupled assay, the rate of HGPRTase depends on the rate of 
PRPP synthetase, all substrate from PRPP synthetase should be accessible to 
HGPRTase (or if not all, a constant steady-state concentration).
3.3.10. Localisation of PRPP synthetase in the bloodstream form of 
Trvnanosoma hrucei.
The subcellular distribution of PRPP synthetase in the bloodstream form 
of Trypanosoma brucei was investigated using fractions obtained from isopycnic
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sucrose gradient centrifugation of post-large-granule extract The fractions were 
kindly supplied and analysed by Dr.F.R.Opperdoes' research group in the 
International Institute of Cellular and Molecular Pathology, Brussels. The 
analysis of each fraction involved the assay of a number of marker enzymes 
whose subcellular localisation has already been accomplished
Materials and methods.
Growth, isolation and purification of the bloodstream trypomastigote 
forms of T.brucei stock 427 were conducted as described by Opperdoes et al. 
(1976a).
Organisms were disrupted by grinding with silicon carbide according to 
Toner and Weber (1972), using 0.25M sucrose, 25mM Tris-HG and ImM 
EDTA (pH 7.2) for homogenisation. The homogenates were fractionated into a 
nuclear fraction, a large-granule (mitochondria and microbody enriched) 
fraction, a small-granule fraction and the final supernatant as described by 
Opperdoes et al. (1977a).
For isopycnic centrifugation 7ml of a large-granule fraction (65.3 mg 
protein) was layered on top of a linear density gradient from 0.4-2.0 M sucrose 
containing ImM EDTA (sodium) and 25mM Tris-HG buffer (pH 7.4) which 
was prepared with a Beckman density gradient former and layered on top of a 2.5 
M sucrose cushion. The gradient was centrifuged in a E-40 automatic zonal rotor 
in a Beckman L2-65B ultracentrifuge at 30,000rpm for 17 hours at 6°C. The 
gradient was pumped out through a fine bore metal tube from the bottom of the 
centrifuge tube (Opperdoes et al. , 1977b) and stored in liquid nitrogen 
(Opperdoes and Borst, 1977).
The enzymatic analyses of the protein and marker enzymes in the 
fractions were carried out by the group in Brussels using the following published 
methods: alanine aminotransferase (Reitman and Frankel, 1957); a-mannosidase 
(Peters etal. , 1972); a-glucosidase (Barrett and Heath, 1977); acid phosphatase 
(Opperdoes et al. , 1977a); hexokinase (Bergmeyer, 1974); NADP-linked
isocitrate dehydrogenase (Ochoa, 1955); 3’-nucleotidase (Gottlieb and Dwyer, 
1983) and protein by the method of Lowry et al. (1951) with bovine serum 
albumin as standard
All 14 fractions were kindly transported from Brussels by Simon 
Jackman. They were each diluted 8-10 times in the following buffer,





Triton X-100 0.25% (v/v)
The activity of PRPP synthetase was measured using the standard assay 
(see methods section) on 10pl of the diluted sample of each of the 13 fractions 
supplied, including the homogenate fraction 14, representing the supernatant 
from the 5000xg large-granular fraction which was placed on the gradient. The 
PRPP synthetase activity of each fraction was measured in duplicate samples 
using three different protein concentrations in the assay. The mean average taken 
as activity/ml, munits PRPP synthetase/ml, was expressed as a percentage of the 
activity of the homogenate which was 100%.
3.3.11. Gelfiltration of PRPP synthetase from T.brucei.
Method,
Gel filtration was carried out with a prepacked HiLoad 16/60 Superdex 
200 Pharmacia fast protein liquid chromatography column using a mechanised 
Pharmacia fast protein liquid chromatography system. The column was 60cm 
high and 16mm in diameter and was equilibrated with 50mM potassium 
phosphate, pH 7.6; 6mM magnesium chloride, ImM EDTA (disodium salt) and 
2.5mM mercaptoethanol. The void volume of the column was determined with 
Dextran blue 2000 and calibrated with standard proteins of known molecular
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weight viz. carbonic anhydrase (29,000); bovine serum albumin (66,000); alcohol 
dehydrogenase (150,000); p-amylase (200,000); apoferritin (443,000) and 
thyroglobulin (669,000). MilliQ grade water was used throughout buffer 
preparation and all buffers and samples were pre-filtered through Millipore 
(0.2pm) filters. The column flow rate was 48ml/hour and 1ml fractions collected. 
The runs were carried out at room temperature. The activity of PRPP in the 
fractions was assayed in 10|il aliquots using the standard method.
Gel filtration was earned out on two enzyme preparations at different 
stages of purification.
Gel filtration of partially purified enzyme preparation.
The routine purification procedure was carried out and the dialysed 55°C 
heat fraction was concentrated to a 3ml volume with polyethylene glycol 
(20,000) and 200jil applied to the Superdex 200 column. The column was eluted 
in the equilibration buffer and the active fractions pooled. The pooled fractions 
were dialysed against water, concentrated with polyethylene glycol and gel 
electrophoresed.
Gel filtration of crude homogenate of T.brucei.
The crude homogenate was prepared by the grinding method of 
trypanosome disruption (see method section). The column was equilibrated in the 
disruption buffer, 25mM Tris-HCl (pH 7.2), ImM EDTA (disodium salt) and 
sucrose 0.25M. The 5,000xg (lOminutes at 2°C) supernatant was filtered through 
a 0.45 m Millipore filter which was pre-rinsed in the disruption buffer and a 2ml 




3.4.1. Drawbacks of theOrotate Removal Assay.
The assay is insensitive for activities below 2nmoles PRPP formed/min.
It requires the use of a sensitive spectrophotometer such as a Cary Model 118 CX 
recording spectrophotometer which was not available for the present work. The 
amount of protein in the assay was very high (>8mg) and the contribution at 
295nm of the absorbance of the protein (>2.6 absorbance units) in the OPRTase- 
ODCase preparation meant that small absorbance changes were impossible to 
detect or measure accurately due to the insensitive absorbance scale of the 
Unicam recording spectrophotometer employed.
This method failed to detect PRPP synthetase activity in trypanosomal 
extracts but was adequate for detection and quantitation of rat liver PRPP 
synthetase activity. This was measured in order to investigate whether the lack of 
activity with trypanosomal extracts was due to the assay failure or otherwise. The 
rat liver PRPP synthetase activity was estimated to be ~120-185nmoles/hr/mg 
protein. This result was slightly higher than that recorded in the Balo-Banga and 
Weber (1984) paper of 80-125nmoles/hr/mg protein.
When trypanosome extract was assayed in the presence of rat liver PRPP 
synthetase preparation, there was no difference to the activity of the same sample 
of rat liver enzyme preparation assayed on its own. This showed that there was 
no inhibitors of the mixed enzymes in step 2 of the assay in the trypanosome 
crude preparation. The spectrophotometric orotate removal assay was therefore 
abandoned and more sensitive radioactive assays employed instead.
3.4.2. Alternative form of Orotate removal assay.
Using this method it was possible to show that the trypanosome crude 
extract contained PRPP synthetase activity, due to the increasing number of 
counts accumulating at the product spots with increasing reaction time. A typical 
result of progressive accumulation of product with increasing incubation time is 
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Figure 3.2. Orotate removal assay. Accumulation of product with increasing 
time of incubation. A, B, C, and D correspond to time 0, 20, 60, and 180 minutes 
respectively. Strips 5-7, 9-11 and 14-18 correspond to [ 14C] 5'-UMP, [14C] 5'- 
OMP and [14C] orotate respectively. The amount of PRPP in the assay was 7 
nmoles in total in the 60 p.1 final assay volume.
Up to 20 strips were used for every assay which resulted in a great 
number of vials and counter time.
Although the separation of the substrate (orotic acid) and products (UMP 
and OMP) was adequate, the method was discontinued as it proved impractical. 
The alternative method tried employed the coupling of PRPP synthetase to 
HGPRTase.
3.4.3. The coupling of PRPP synthetase to Hvpoxanthine-guanine
phosphQrih.Qsyltran.sfgrass,
TLC method.
The results of a typical experiment are shown in Table 3.1. The counts 
present in the substrate (hypoxanthine) and product (IMP) strips of the TLC plate 
were expressed as percentages of the total counts of the assay applied to the TLC 
plate and marked as S and P respectively. Control assays were canied out with 
ommission of R5P from the assay. It can be seen that in all the assays and 
controls there was a progressive accumulation of radioactivity for P and a 
respective decrease in counts for S. There was double the amount of product 
formed at each incubation time as the amount of trypanosomal extract was 
doubled indicating that the overall reaction rate was proportional to the amount 
of PRPP synthetase present in the assay. The result obtained with the control 
assays indicated the presence of one or more other contaminating enzymic 
activity able to phosphorylate hypoxanthine without R5P and PRPP requirement
DE-SI filter method,
. Under assay conditions, over 95% of IMP was retained on the disc, while 
the hypoxanthine was not retained at all. The background was 0.3% of the total 
counts filtered through.
Table 3.1. TLC method of HGPRTase-coupled assay.
I l l
Assay Time of incubation (minutes) 
0 15 45 150
P
sn Cl + R5P
S
0.686 1.168 1.501 2.466 
97.630 96.229 97.630 95.123
P
sn Cl - R5P
S
0.778 1.041 1.174 1.390 
97.679 97.311 97.457 96.773
P
sn C2 + R5P
S
0.633 1.733 2.769 4.628 
97.126 95.979 95.111 93.573
P
sn C2 - R5P
S
0.973 1.453 2.175 2.382 
97.489 96.825 96.781 95.696
P and S represent the percentage of total counts present in each TLC strip as 
product ([^H]IMP) and substrate ([^H]hypoxanthine) respectively. Cl and C2 
are 10 and 20pl of trypanosomal 20K sn preparation respectively. Control assays 
were carried out in the absence of R5P in the assay.
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3.4.4. Different method? of trypanosome disruption.
From the results in Table 3.2 it was clear that there was very little 
difference in the yield and specific activity of the enzyme obtained by the 
different disruption methods. The disruption of the cells was routinely achieved 
by the freezing and thawing method in the presence of Triton X-100 at 0.1%
(v/v) final concentration
3.4.5. The partial purification of PRPP synthetase from T.b.brucei.
The different stages in the development of the partial purification 
procedure for trypanosomal PRPP synthetase are presented in Tables 3.3-3.5 
inclusive. The routine partial purification protocol was developed and is 
presented in Table 3.6. On average the recovery of enzyme units in the dialysed 
enzyme preparation was 56% and the purification ford achieved was about 73x 
that of the crude extract.
3.4.6. Removal of an endogeneous inhibitor from the crude extract.
It was observed that there was a greater yield than 100% on some steps in 
the purification procedure such as after the supernatant of the 0-40% ammonium 
sulphate 'cut' was removed. A similar increase in unit numbers recovered was 
achieved by dialysis of the 20K sn obtained after disruption of the cells by 
freezing and thawing and also after passing the 20K sn fraction through a 
Pharmacia Sephadex G-25 'desalting' column (Table 3.7). From those treatments 
it is possible to suggest that there is an endogeneous inhibitor present in the crude 
extract that has a small enough molecular weight to be retained by the gel 
filtration column.
113
Table 3.2. Results from different methods of trypanosome disruption. 













Sonicadon 0.976 4.488 0.462 0.103




0.331 2.120 0.371 0.175
Grinding (SiC) 1.397 2.164 0.229 0.106
Where Triton X-100 is included it was always at a final concentration of 
0.1% (v/v). The activity of PRPP synthetase is expressed in mUnits i.e. nmoles 
PRPP formed/minute using the standard assay.
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fold ( x )
Crude 4.66 47.53 4.52 0.095 100.00 1.00
20K sn 4.00 32.80 4.02 0.123 88.94 139
20KP 0.80 14.24 0.22 0.015 4.87 0.16
Ammonium sulphate resuspended pellets
0-15 % 3.50 10.250 0.33 0.032 7.19 0.34
15-25 % 3.40 8.630 4.79 0.555 105.97 5.84
25-35 % 3.60 4.360 3.82 0.876 84.51 9.22
35-45 % 3.50 3.900 0.82 0.209 18.03 2.20
45-55 % 3.40 0.386 0.02 0.041 0.35 0.43
These are the results of the initial 'cuts’ of ammonium sulphate (AS) tried. 
The standard assay was carried out on suitably diluted samples in phosphate 
protection buffer. Each pellet had been passed through a Sephadex G-25 
'desalting' column prior to assaying.
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fold ( x )
Crude 7.03 35.62 3.74 0.105 100.00 1.00




6.05 20.39 1.68 0.082 44.900 0.78
0-20 % 
P
3.00 0.19 0.01 0.053 0.270 0.50
20-40%
sn
6.00 20.20 0.07 0.003 1.870 0.03
20-40 % 
P
4.17 4.59 4.88 1.063 130.480 10.12
Streptomycin sulphate
0-1% sn 5.16 2.45 3.03 1.237 81.02 11.78
0-1% P 1.04 0.34 0.10 0.294 2.67 2.80
1-3% sn 3.50 0.73 2.61 3.575 69.79 34.05
1-3% P 0.38 0.02 0.01 0.500 0.27 4.76
The standard assay was carried out on lOpl aliquotes of 10-fold diluted 
samples in phosphate protection buffer.
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fold ( x )
20-40%
ASP
6.1 5.400 3.11 0.576 158.00 8.06
aliquot 
of ASP
1.0 0.885 0.51 0.576 100.00 1.00
Supernatants obtained after 1.0 ml aliquot was heat treated at 50°C
5 min 1.0 0.325 0.868 2.672 170.3 4.64
10 min 1.0 0.158 0.504 3.191 98.9 5.54
15 min 1.0 0.120 0.483 4.023 94.7 6.98
Supernatants obtained after 1.0 ml aliquot was heat treated at 55°C
5 min 1.0 0.161 0.708 4.398 138.8 7.64
10 min 1.0 . 0.150 0.324 2.160 63.5 3.75
PMSF was freshly added to 0.5mM final concentration in the phosphate 
protection buffer used in the resuspension of the ammonium sulphate pellet (AS 
P ). One ml of that preparation was heat treated and the denatured protein 
removed by centrifugation at 4°C in a bench centrifuge. The activity of PRPP 
synthetase is expressed as mUnits which is the amount of enzyme required to 
produce 1 nmole of PRPP per minute at 37°C in the standard assay used.
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fold ( x )
crude 16.70 76.82 8.61 0.112 100.00 1.00
20K sn 14.47 49.82 6.78 0.136 78.75 1.21
20-40%
ASP




6.00 1.14 7.00 6.140 81.30 54.82
dialysed
enzyme.
1.62 0.59 4.84 8.203 56.21 73.24
The dialysed enzyme preparation represents the product of overnight 
dialysis against 500 volumes of phosphate protection buffer with 20% (v/v) 
glycerol and concentrated with polyethylene glycol (20,000). The samples were 
diluted 10 fold in phosphate protection buffer and lOjil aliquots assayed by the 
standard assay.
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Table 3.7. Removal of an endogeneous inhibitor and activation of enzyme 













fold ( x )
Crude 4.44 34.74 3.93 0.113 100.00 1.00




7.38 20.57 7.37 0.358 187.81 3.17
The crude preparation was obtained by disrupting the cells with 3 cycles 
of freezing and thawing in liquid nitrogen and 37°C respectively. The cell debris 
was spun down at 20Kxg at 4°C for 20 minutes to give the 20K sn fraction. This 
was passed through a Pharmacia G-25 column. All the samples were assayed 
using the standard assay..
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3.4.7. Cibachron Elug-Ligand chromatographs
Elution of PRPP synthetase with 6mM ATP at pH 7.6.
The result is shown in figure 3.3. This procedure gave a recovery of 
PRPP synthetase units of 15% and of protein of 75%. The purification fold of 
fraction 26 was 27 fold.
This method was not used further due to the low enzyme recovery.
Elution of PRPP synthetase with 2mM ATP at different pH.
The results of this experiment arc presented in Table 3.8. The system of 
pH 6.5 gave the highest percentage recovery of units and purification fold but not 
of any great significance so dye-ligand chromatography was abandoned as a 



































Figure 3.3. Elution of PRPP synthetase from Cibacron-blue affinity 
chromatography column with 6mM ATP at pH 7.6. A Cibacron Blue-Sepharose 
column (20 x 1.6 cm) was equilibrated with phosphate protection buffer, pH 7.6 
and 7ml of 1% sn from streptomycin sulphate precipitation (2.417 mg protein of 
0.307 mUnits/mg specific activity) were applied; the column was eluted with 132 
fimoles of ATP in phosphate protection buffer. The ATP was applied between 
the two arrows. A flow rate of 0.62 ml/min was used and fractions collected 
every 10 minutes. The standard assay was used with 38|il samples of each 
fraction.
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Table 3.8. Elution of PRPP synthetase from Cibacron-blue affinity 













fold ( x )
20K sn 
loaded
1.17 12.40 1.58 0.127 100.00 1.00
PHJ15
W 11.13 8.510 0.38 0.044 23.81 0.35
E 6.05 0.256 0.12 0.481 7.81 3.79
pH 7.0
W 11.02 7.600 0.44 0.058 28.00 0.46
E 5.80 0.260 0.06 0.239 3.94 1.88
PIL7.5
W 11.02 8.375 0.50 0.060 31.94 0.47
E 5.95 0.402 0.06 0.157 4.00 1.24
pH AO
W 11.02 8.10 0.66 0.082 42.16 0.65
E 5.95 0.39 0.06 0.144 3.56 1.13
Where W and E correspond to washing and elution fractions respectively.
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3.4.8. Detection of PRPPsvnthetase in bloodstream and cultured procvclic 
Tbbrucei cells.
In Table 3.9 the ontent of PRPP synthetase expressed in munits from 
bloodstream forms (BS) vas found to be considerably lower than that of the 
same number of cultured procyclic (CP) forms. The difference might reflect 
genuine differences in the PRPP requirements of the CP forms for growth and 
replication. The estimation for the CP forms was carried out only once so it was 
not possible to derive mu:h information from it. From the raw data (counts per 
minute) it was immediately obvious how the observed difference arose since the 
CP crude extract gave a very low blank value compared to the consistently high 
value of the BS form cruce extract
The attempted estimation of the sum total of PRPP and R5P 
concentrations may not have been accurate due to the lack of boiling the enzyme 
extract to kill the PRPP synthetase. This was not done because PRPP is very 
easily destroyed by extensive heating. From Table 3.9, it appeared that the sum 
content of PRPP and R5P concentrations in the two forms was very similar.
3.4.9. Validity of the coupled-enzvme assay.
In determinations of catalytic activity, the task of the coupling (indicator) 
reaction is to indicate at any time point the amount of reaction product of the 
primary reaction. The rate of the coupled overall reaction is followed on the basis 
of the increase of the reaction product of the indicator reaction with time 
(Bergmeyer, 1983).
In the coupled reaction:
Eprim.
Si + S2 > p i +P2
Eind.
P1 + S3 -----------> P3 + P4
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Table 3.9. PRPP synthetase and the sum of PRPP and R5P in the 
bloodstream and cultured pnocyclic Tbbrucei cells.
Form of 
Tbbrucei
[PRPP + R5P1 content 
(nmoles/l(r cells)






0.368 1  0.193 
1.593
BS (bloodstream form of Tbbrucei)
CP (cultured procyclic form of Tbbrucei).
The [PRPP + R5P] content was obtained from the standard assay carried 
out in the absence of added
R5P. Any activity observed would be due to PRPP or/and R5P already present in 
the extract.
The activity of PRPP synthetase is expressed as mUnits of enzyme which 
is the amount of enzyme required to produce 1 nmole of PRPP per minute in the 
standard assay.





In the steady-state, (veff.)ind. = Vprim. and 
Q' = (Km)pj/[Pj] is a constant From this it follows that
Vind. x [S3]
(ve f f .W  = ----------------------------------VP™-
( l + Q ) x [ S 3] + (Km)S3 
This is the equation of a one-substrate reaction. If it is assumed that, in addition, 
(Km)p^/[Pj] = Q’ must have a particular value, then (1 + Q') x [S3] »  (Km)53, 
the equation becomes:
1
(V rff)inrf =  Vprim . =  x Vind
(1 + Q')
or
Vind. = (1 + Q’) x Vprim.
The condition (1 + Q') x [S3] »  (Km)33 should always be satisfied.
In the present PRPP synthetase (Eprim.) standard 
assay,S1 can be MgATP^"; S2 can be R5P; Pj can be MgPRPP; P2 can be 
AMP; Eind. can be HGPRTase; S3 can be [^C]Hypoxanthine; P3 can be [^C] 
5'IMP and P4 can be PPi.
The Km of the yeast HGPRTase for PRPP is less than 4x10"  ^M, as 
described by Komberg, Lieberman, and Simms (1955).
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3.4.10. Rate of overall reaction at two r14ClHvpoxanthine concentrations in the 
assay,
From the results in Table 3.10, there is very little difference in the rate of 
the overall reaction at the two final [^CJHypoxanthine concentrations in the 
assay. The [^C]Hypoxanthine concentration used in subsequent standard assays 
was about 7|iM.
3.4.11. Overall rate of reaction with increasing amounts of HGPRTase units in 
the assay,
From the results in Figure 3.4, it was apparent that the chosen 2munits of 
HGPRTase activity in the standard assay was adequate for ensuring that the 
PRPP formed in the PRPP synthetase reaction was converted to IMP by the 
coupling enzyme HGPRTase.
3.4.12. Percentage conversion of hypoxanthine to IMP as a function of protein 
cpnccntratminihe assay.
The concentration of PRPP synthetase is proportional to the protein 
concentration in the preparation used in the assay (Figure 3.5).
The standard assay was valid for up to 8% conversion of hypoxanthine to 
IMP under the conditions of the assay.
3.4.13. The percentage of hypoxanthine converted to product (IMP) as a function
of assay tirog,
The reaction is linear with up to at least 15 minutes of incubation at 37°C. 
The chosen reaction time for all subsequent standard assays was 10 minutes at 
37°C (Figure 3.6).
This allowed the assaying of 22 separate assays in each run since the 
assays were carried out in duplicate, the number of assays was up to 5 including 
the standard assay which always accompanied the different investigations. Since
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Table 3.10. Rate of overall reaction at two [ ^ C]Hypoxanthine concentrations 
in the assay.
Experimental conditions as in Figure 3.4.
Concentration of 
[ ^ C]hypoxanthine in 
the assay (p.M)
cpm [14C] 5’IMP formed 
in 10 minutes with 
1.7 jig protein in assay
cpm [^C] 5'IMP formed 
in 10 minutes with 
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Figure 3.4. Overall reaction rate with increasing amounts of HGPRTase units 
in the assay.
The standard assay was carried out using lmunit, 2munits, 3munits, 
4munits and 6munits of HGPRTase per 70|il assay. The volume of the assay was 
kept at 70jil. One munit of HGPRTase is defined as the amount of enzyme that 
catalyses the formation of one nmole of GMP per minute under the defined 
conditions. PRPP synthetase concentration was kept constant at 0.6 |ig 
protein/assay (specific activity of 1.14 mUnits/mg protein). The reaction was 
earned out at 37°C for 10 minutes. The [^C] Hypoxanthine concentration in the 
assay was 5.7 pM (48,738 cpm=100%). The arrow indicates the number of 













Protein concentration ( |jg/assay)
Figure 3.5. Percentage conversion of hypoxanthine to IMP as a function of 
protein concentration in the assay.
The assay was allowed to take place over 10 minutes at 37°C. 100% 
represents all the [ ^ CJHypoxan thine supplied in the 70pl assay (56089.2 cpm). 
A crude preparation was used which was first passed through a Sephadex G-25 
column (specific activity o f PRPP synthetase 0.605 mUnits/mg protein). The 
concentration of HGPRTase was kept constant throughout at 2mUnits in the 
assay. The bars represent tlhe mean and the error bars the standard error of the 
















Figure 3.6. The percentage of hypoxanthine converted to product (IMP) as a 
function of assay time.
The reaction was carried out at 37°C for different incubation times. The 
55°C heat treated partially purified PRPP synthetase preparation was used which 
had specific activity of 2.874 mUnits/mg protein and 0.32pg protein used in the 
standard assay.
100% substrate was 64358.2 cpm [^CJHypoxanthine in 70jil of the 
standard assay.
The error bars represent the standard error of the mean. Where the error 
bars are not obvious, they are encompassed within the markers. The markers 
represent the mean of two separate experiments carried out in dublicate.
there was always a standard assay carried out it was possible to account for loss 
of PRPP synthetase activity during the time required to complete all the runs and 
to standardise experiments carried out on different enzyme preparation batches.
3.4.14. The effect of inorganic pyrophosphatase (PPiasel to the overall reaction 
rate.
The amount of PRPP produced, equals the amount of PPi, since for every 
molecule of PRPP produced, one molecule each of IMP and PPi is formed as 
long as PRPP synthetase is th e limiting enzyme reaction. From this result it is 
possible to speculate that the amount of PPi produced, which in this experiment 
amounted up to 0.2|iM in the assay, was not high enough to cause any inhibition 
by reversing the HGPRTase reaction (Table 3.11).
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Table 3.11. The effect of inorganic pyrophosphatase (PPiase) to the overall 
reaction rate.
Assay -R5P + R5P A (cpm) [Protein]
(lig/assay)
- PPiase 421.1 2188.85 1767.75 9.0
+ PPiase 348.6 2166.10 1817.50 9.0
- PPiase 197.9 1592.50 1394.60 4.5
+ PPiase 187.6 1434.70 1247.10 4.5
The total counts of hypoxanthine included in the standard assay were 
56288 cpm, corresponding to a hypoxanthine concentration of 6.59 |iM.
The standard assay was earned out with and without lOjil (2units) of 
PPiase solution. The enzyme solution consisted of a crude 20K sn enzyme 
preparation. The amount of PRPP produced, equals the amount of PPi, since for 
every molecule of PRPP produced, one molecule each of IMP and PPi is formed 
as long as PRPP synthetase is the limiting enzyme reaction. From this result it is 
possible to speculate that the amount of PPi produced, which in this experiment 
amounted up to 0.2|iM in the assay, was not high enough to cause any inhibition 
by reversing the HGPRTase reaction.
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3.4.15. Stability of PRPP synthetase in the presence and absence of inorganic 
phosphate (Pil at 0°C.
The percentage of PRPP synthetase remaining after incubating at certain 
time intervals at 0°C is shown in Figure 3.7. The activity at the start of the 
incubation is denoted as 100%. The rate of loss of activity is very similar for both 
systems. At the start, the system in the absence of phosphate had only 60% of the 
activity as in its presence. So Pi activated the enzyme without stabilising it to any 
extent in the system used.
3.4.16. Stability of PRPP synthetase in the presence and absence of inorganic 
phosphate (Pi) at 37°C.
The results are shown in Figure 3.8. At 37°C PRPP synthetase quickly 
became inactive irrespective of the presence or absence of Pi in the storage 
buffer. Up to 80% of the activity of the enzyme was lost after the first hour of 
incubation at 37°C in the phosphate and TEA-HC1 buffers used.
3.4.17. Stability of PRPP synthetase in the presence and absence of glycerol. 
There was a rapid loss of activity in the first two days of storage with and
without glycerol in the enzyme preparation (Figure 3.9). The rapid loss of 
activity continued in the absence of glycerol. Glycerol, at 20% (v/v) stabilises the 
enzyme for up to a week from the day of preparation and therefore was included 
in the end of all subsequent purification procedures which involved storage of the 
partially purified enzyme preparation prior to characterisation.
3.4.18. Stability of PRPP synthetase in the presence and absence of ATP in the 
protection buffer.
The activity remaining after a day's storage at 4°C is shown in Table 3.12. 
On the day of preparation the addition of ATP in the standard assay 
appears to have an inhibitory effect on the activity of the enzyme. However, after 















Figure 3.7. Stability of PRPP synthetase in the presence and absence of
inorganic phosphate (Pi) at 0°C.
■------■ represent incubations in the presence of inorganic phosphate
[20mM potassium phosphate (pH 7.6), 6mM MgC^, O.lmM EDTA (disodium),
2.5mM mercaptoethanol and 0.5mM PMSF]. While, Q □ represent
incubations with 20mM TEA-HC1 (pH 7.6) instead of the phosphate.
Equal samples of 20K sn were passed through Pharmacia Sephadex G-25 
columns pre-equilibrated in the appropriate buffer. The enzyme preparations 
were stored on ice. Aliquots of lOfil were assayed for enzyme activity using the 
standard assay. The error bars represent the standard error of the mean from 
duplicate results from two separate experiments. Where the error bars are not 






' C  










Figure 3.8. Stability of PRPP synthetase in the presence and absence of 
inorganic phosphate (Pi) at 37°C.
The enzyme preparations were incubated at 37°C in a temperature- 
controlled water-bath. The enzyme was quickly inactivated at 37°C irrespective 
of the presence or absence of inorganic phosphate in the incubation medium. The 
activity at the start of the incubation in the absence of phosphate was only 41% 







Days of storage at 4®C.
Figure 3.9. Stability of PRPP synthetase in the presence and absence of
glycerol.
■ ■ represent incubations in the presence of 20% (v/v) glycerol
□------ □ represent the absence of glycerol from the protection buffer.
The bars represent the standard error of the mean. When the error bars are not 
visible, they are encompassed within the marker.
Concentrated heat treated (5 minutes at 55°C) enzyme preparation 
(specific activity of 3.676 mUnits/mg protein and 1.36 mUnits/ml) had been 
dialysed against protection buffer with and without 20% (v/v) glycerol and stored 
at 4°C. The samples were diluted lOx in protection buffer and lOpl assayed using 
the standard assay. Error bars stand for standard error of the mean.
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Table 3.12. Stability of PRPP synthetase in the presence and absence of ATP 
in the protection buffer.
The 5 minute 55°C treated sn preparation was stored in the presence and 
absence of 0.3mM ATP in protection buffer and kept at 4°C overnight
The activity remaining after a day's storage at 4°C is shown in the table
below:





0 -ATP 5.728 100.00
0 + ATP 4.201 100.00
1 -ATP 1.970 34.39
1 + ATP 1.973 46.97
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ATP in the buffer was greater than that with ATP. It would seem therefore that 
ATP has a stabilising effect on the enzyme although the extent seems not to be so 
pronounced since both enzyme preparations lost up to 50% of the enzyme 
activity during overnight storage at 4° C in phosphate protection buffer, pH 7.6.
3.4.19. The effect of the presence or absence of EDTA in the presence and 
absence of Pi.
EDTA (disodium) was excluded from both the protection and the 
standard assay cocktail, in order to see the effect its absence might have on the 
reaction rate observed.
From the results in Table 3.13, it appears that the presence of phosphate 
in the enzyme buffer causes the enzyme activity to remain equally high in the 
presence and absence of EDTA and phosphate in the assay. The absence of 
phosphate in the enzyme preparation, causes the loss of about 50% of the activity 
but additional absence of EDTA causes an extra 10% loss of enzyme activity. 
Phosphate and EDTA have synergistic effects in activating the enzyme.
3.4.20. The effect of inorganic phosphate (TO on activity of trvpanosomal PRPP 
synthetase.
In order to assess the effect of inorganic phosphate on enzyme activity (as 
opposed to stability) the enzyme was assayed at various concentrations of Pi. The 
results are given in Figure 3.10.
It was repeatedly observed that the PRPP synthetase activity decreased 
rapidly at phosphate concentrations higher than 40mM. In order to see if this 
effect was due to enzyme inhibition by inorganic phosphate, the experiment was 
repeated with rat liver enzyme. PRPP synthetase requires phosphate for activity 
and for the rat liver enzyme the activity should increase with increasing 
phosphate concentration up to a maximum at lOOmM (Roth et a i, 1974). It was 
repeatedly observed that the PRPP synthetase activity decreased rapidly at 
phosphate concentrations higher than 40mM, irrespective of the source of PRPP
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Table 3.13. The effect of the presence or absence of EDTA in the presence 
and absence of Pi.
Half the enzyme preparation had been passed through a Sephadex G-25 
column pre-equilibrated with TEA-HQ protection buffer in order to investigate 
the effect of EDTA in the absence of Pi. The results obtained were tabulated 
below:







The enzyme preparation used in this experiment was a partially purified 







Figire 3.10. The effect of inorganic phosphate (Pi) on activity of trypanosomal 
PRF synthetase. Potassium phosphate solutions were made up in 50mM TEA- 
H Q buffer, pH 7.6 and the pH adjusted when neccesary to 7.6. PRPP synthetase 
activity was corrected for the blank (no R5P in the assay). ■— ■ represent the 
trypaiosomal PRPP synthetase system (specific activity 0.288 mUnits/mg 
proton; 5.87 jiM hypoxanthine concentration in the assay). While,n— □ re- 
presnt the rat liver PRPP synthetase system (specific activity 1.465 mUnits/mg 
proton; 4.32 pM hypo-xanthine concentration in the assay). The trypanosomal 
PRP synthetase preparation (4.5 fig protein /assay) consisted of a crude 
hoirogenate whose buffer was exchanged for 50mM TEA-HC1 (pH 7.6) through 
passige through a Sepharose G-25 column. The rat liver PRPP synthetase 
prepuation consisted of a crude lOOKxg supernatant (1.17 \ig protein/assay), 
whose buffer was also exchanged for 50mM TEA-HC1 (pH 7.6) through passage 
throigh a Sepharose G-25 column. The standard assay was carried out with 10p.l 
of diuted enzyme preparations. The error bars represent the standard error of the 
meai of three separate experiments. Where the error bars are not visible, they are 
encompassed within the markers.
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synthetase. From this result it was possible to exclude the possibility of PRPP 
synthetase inhibition as a potential cause for the decrease in activity observed 
and to assign it to an inherent limitation of the standard assay, likely to be due to 
competition of the Pi with IMP binding onto the DE-81 filters.
It was realised that the Pi effect may have been observed by an 
experimental artefact resulting from interference of Pi in binding of IMP to the 
DEAE filters in the assay. This was investigated by testing for the effect of Pi in 
the binding of IMP (Table 3.14) and the effect of altering the protocol of filters 
for the effect of the number of filters on the binding of IMP in the presence of Pi 
(Table 3.15). The effect of pre-soalting the filters in 4mM hypoxanthine solution 
in 20mM phosphate buffer (pH 7.6) was also investigated for its effect on the 
binding of IMP to the filters (Table 3.16).
From the data in Table 3.14 it is clear that Pi interferes with [^^C] IMP 
binding on the DE-81 filters.
With just IMP added to the filters, there is an improvement in binding 
with the stacked filters which is reduced by addition of Pi. It might be possible to 
improve the binding of the IMP onto the filters if the filters were not pre-soaked 
in the adenosine in 20mM potassium phosphate (pH 7.6) buffer before use (See 
Table 3.16).
It was found (Table 3.16) that the non-specific binding of 
[^C] hypoxanthine was high with filters which were not pre-soaked, but not 
more than 0.5% of the total counts filtered through as opposed to the 0.3% of the 
total counts in non-specifically bound onto the pre-soaked filters. The stacking of 
3 unsoaked filters was therefore used in Figure 3.10, as the binding improved to 
95% of the total IMP counts produced under those conditions.
It was suggested that a callibration curve of % CPM bound at different 
concentrations of Pi be constructed, so that the effect of the interference of Pi 
with IMP binding might be corrected for.
141
Table 3.14. The effect of phosphate on IMP binding onto the DE-81 disc.
A standard assay was set up as usual and allowed to proceed with the 
formation of [^C] IMP. The reaction was stopped by heating in a boiling water- 
bath for 3 minutes and the denatured proteins spun down and removed.
A suitable sample was deposited into Eppendorf tubes and to a third of 
the tubes, lOOmM phosphate was added (assay+Pi) and to the third lOOmM 
phosphate and lOjil of 0.1 M cold IMP (assay+IMP+Pi) added and to the third 
lOjil of 0.1 M cold IMP was added (assay+IMP) as usual. The contents of the 
tubes were filtered through DE-81 filters and the results obtained as follows:





Table 3.15. The effect of the number of filters on the amount of [ ^ C] IMP 
binding in the presence of Pi.
A suitable amount of [^C] IMP was produced as described in Table
3.14. The same number of counts were passed through one and through 3 filters 
both stacked and separate (one third of the sample each) and the results were as 
follows:
System cpm on filter % total cpm
one filter 4512.7 63.51
3 stacked 7105.6 100.00
1/3 on 3 filters 
in total
5979.6 84.15
with added Pi and cold IMP,
one filter 2793.6 39.30
3 stacked 5706.4 80.31




Table 3.16. The effect of pre-soaking of filters to the binding of IMP.
The filters were not soaked in the adenosine solution in 20mM phosphate 
buffer, pH 7.6 as usual, but used directly from the packet to see if that would 
make any difference to the IMP binding onto the DE-81 filters.
System cpm on filter 
which was soaked
cpm on filter 




no Pi 1876.2 2137.6 100.00
+ Pi 1409.2 1594.2 75.00
3 stacked filters,
no Pi 2421.9 2589.9 100.00
+ Pi 2238.4 2537.2 95.00
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3.4.21. Substrate specificity of T.b.brucei PRPP synthetase.
Nucleotide specificity.
From the results in Table 3.17 T.bJbrucei PRPP synthetase is highly 
specific for ATP as the pyrophosphoiyl donor. Except for dATP which can 
replace ATP (relative activities 100:75), the other nucleotides (NTP) tested, viz., 
GTP, CIP, and UTP, gave less than 1% of the activity as compared to ATP.
With 1TP the rate was within approximately 80% of the rate with ATP, however, 
the blank (no R5P) was as high as the test, which was equal to about 71% of the 
activity as compared to ATP. The difference resulted in percentage activity for 
HP of 7.7% compared to that with ATP as substrate.
Pentose phosphate specificity.
The investigation of pentose phosphate specificity of trypanosomal PRPP 
synthetase was impared due to the lack of pure enzyme, and the limitations of the 
coupling assay. However, the conversion of ribulose-5-phosphate and ribose-1- 
phosphate directly into PRPP or first into ribose-5-phosphate was investigated.
Ribulose-5-phosphate as substrate for trypanosomal PRPP synthetase.
From Table 3.18, it appeared that the assay system converted ribulose-5- 
phosphate to IMP with the same rate as it converted R5P. The extent of product 
formation increased with the time of incubation in a linear way. From these 
results it appeared that the trypanosomal PRPP synthetase preparation may have 
had contaminating D-ribose-5-phosphate ketol-isomerase activity or that 
ribulose-5-phosphate acted as a substrate with similar affinity to R5P.
Ribose-1 -phosphate as substrate for trypanosomal PRPP synthetase.
In this experiment ribose-5-phosphate (standard assay concentration 
2.87mM) was substituted with ribose-1-phosphate (ImM in the assay) in the 
standard assay. A crude trypanosomal extract was used. There was a small 
increase in the activity of the blank (no R5P in the assay) when ribose-1-
Table 3.17. Nucleotide triphosphate specificity of T.b.brucei PRPP 
synthetase.
The standard assay was carried out with dATP, CTP, GTP, ITP and UTP 
at final concentration of 0.302 mM [MgNTP^"] in the assay. Excess MgCl2  
concentration of 10 mM in the assay was used.
The results were expressed as % of PRPP formed as compared to that 
observed with ATP which was 8.46 nmoles PRPP formed/5 minutes. Each 
incubation medium contained 0.6 fig protein.
NTP + R5P - R5P A (cpm) % ATP
dATP 2182.4 118.8 1939.3 75.000
1928.0 113.0
UTP 98.8 65.0 14.9 0.576
81.6 85.6
CTP 65.8 63.0 1.6 0.062
52.2 51.8
ITP 2123.0 1869.0 199.1 7.700
1968.8 1824.6
GTP 67.2 57.4 19.4 0.750
82.4 53.4
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Table 3.18. Ribulose-5-phosphate as substrate for trypanosomal PRPP 
synthetase.
The data were obtained with Ribulose-5-phosphate, at ImM 
concentration in the assay. For Ribose-5-phosphate, the standard assay 
concentration of 2.87mM was used. In the blank assays the sugar phosphate is 










10 minutes 4906.5 231.9 4677.4 3.831
5042.0 226.3 4812.9 3.942
30 minutes 15535.5 349.3 15202.7 12.451
12673.5 316.3 12340.7 10.107
with Ribose-5-phosphate.
10 minutes 4329.9 224.6 4119.95 3.374
4723.1 195.3 4513.15 3.696
The standard assay contained [^C]hypoxanthine concentration of 9p.M 
and 2.16fig of partially purified enzyme preparation with specific activity of 
1.527 nmoles PRPP formed/minute/mg protein, in the standard assay.
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phosphate was present (from 307 to 864 counts on the DE-81 filters per 10 
minutes), but the results were not clear. A small increase in the blank was not 
conclusive of ribose-1-phosphate being the substrate for PRPP synthetase and the 
activity observed could have been due to some ribose-5-phosphate contamination 
of the ribose-1-phosphate preparation.
3.4.22. The effect of Mg2* concentration on HGPRTase activity.
From Figure 3.11 it is seen that HGPRTase requires Mg^+ for activity as 
reported already for phosphoribosyltransferases. The activity increased with 
increasing Mg^+ concentration with plateau at Mg^+ concentration higher than 
5mM in the assay.In the standard assay for PRPP synthetase activity Mg^+ is 
included at a final concentration of 5mM.
3.4.23. The effect of cations on HGPRTase activity.
From the data in Table 3.19 it could be seen that HGPRTase activity with 
magnesium was as high as with calcium. Manganese however seemed to activate 
the enzyme 3 fold while cobalt (divalent) also activated HGPRTase by increasing 
its activity 2 fold to that with magnesium. Copper, nickel and zinc were less 
effective at substituting for magnesium and inactivated the enzyme by 20%. The 
effect of the different cations on HGPRTase was therefore not prohibiting the 
investigation of the effect of cations on trypanosomal PRPP synthetase.
3.4.24. The effect of cations on trypanosomal PRPP synthetase.
In order to make sure that the effect observed was due to the PRPP 
synthetase reaction, two concentrations of PRPP synthetase enzyme preparation 
were assayed and only when the doubling of the enzyme resulted in twice the 
amount of product being produced the result was considered valid. Unfortunately 
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Figure 3.11. The effect of Mg^+ concentration on HGPRTase activity.
In a final volume of 70pl, the concentration of reagents was: 20mM 
potassium phosphate, pH 7.6,0.143mM EDTA, 7.5|iM [^C]hypoxanthine, 
lOmM PRPP, lmunit of HGPRTase, Mg^+ at 0, 0.5, 2 and 5mM and water to 
make up the volume. The reaction was initiated by the addition of HGPRTase 
and carried out at 37°C for 10 minutes.
The results were obtained after subtraction of the activity in the control 
assay which was carried out without any PRPP. The presence of divalent cations 
such as Mg2+ was compulsory for activity. The rate of HGPRTase reaction 
increases with increasing Mg^+ concentration to a plateau at > 5mM Mg^+ in 
the assay.
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Table 3.19. The effect of cations on the HGPRTase activity.
All metals are used as the chloride salt and are present in the HGPRTase 
assay at 2mM (see legend of Figure 3.11. for assay details). The MgCl2 sample 
gave 4.21 pmoles PRPP per 10 minutes. Values shown for other divalent cations 
represent percent activity in the assay in which divalent cation has supplimented 










The effect of cations on trypanosomal PRPP synthetase is presented in 
Table 3.20. For the trypanosomal PRPP synthetase, the activity with magnesium 
was maximal and similar to that with manganese as for PRPP synthetases from 
other sources studied to date. Nickel had a very high inhibitory effect. The 
inhibitory effect of zinc and cobalt was nearly 50%.
3.4.25. Kinetic studies of trypanosomal PRPP synthetase.
The partially purified enzyme preparation was used for the investigation 
of the kinetic behaviour of trypanosomal PRPP synthetase. The activity and 
stability of the enzyme was sufficient for kinetic studies to be carried out Each 
point was repeated in duplicate, with less than 5% difference between the two 
repeats.
The validity of the kinetic studies was checked by assaying two 
concentrations of enzyme preparation for every parameter changed and only 
when the doubling of the enzyme concentration resulted in the doubling of 
counts (product) formed, were the results accepted as valid.
3.4.26. Considerations for experimental protocol with Mg ATP2' as substrate.
It is well-known that most enzymes that are ATP-dependent also require 
Mg^+ for formation of the true substrate, MgATP^". It is impossible to prepare a 
solution of pure MgATP^' without a number of other ions also being present An 
equimolar mixture of ATP and MgCl2 at pH 7 contains appreciable proportions 
of MgATP^', ATP^-, HATP^", Mg^+ and Cl", as well as traces of MgHATP", 
Mg2ATP and MgCl+. Moreover, the proportions of each species vary with the 
total MgCl2 and ATP concentrations, the pH, the ionic strength and the 
concentrations of other species (such as buffer components) that may be present 
(Comish-Bowden, 1979). When studying the effect of increasing MgATP^' 
concentrations in the assay, it is important to ensure that the variation in the 
Mg2* and ATP4- concentrations is minimal.
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Table 3.20. The effect of cations on trypanosomal PRPP synthetase.
All metals are used as the chloride salt and present in the standard assay 
at 2mM final concentration. The MgCl2 sample gave 46.3pmoles PRPP per 10 
minutes. The specific activity of the partially purified preparation after heat 
treatment, dialysis and concentration, measured with standard assay (5mM 
Mg2+) was 3.32mUnits/mg protein. Values shown for other divalent cations 
represent percent activity in the assay in which divalent cation has supplimented 










A ’badly' designed experiment involves the variation of the total 
concentrations of ATP and MgCl2 in constant ratio. Whether this ratio is 1:1 or 
any other, it leads to wild variations in the proportion of ATP existing in any 
particular form, and should be avoided. Somewhat less objectionable, is to keep 
the total MgCl2 concentration constant at a value that exceeds the highest ATP 
concentration by about 2-5 mM. Although this design does ensure that ATP 
exists largely as MgATP^", it can produce undesirably large variations in the 
concentrations of free Mg^+ and of Mg2ATP.
Storcr and Comish-Bowden (1976) found that ATP exists in a high and 
nearly constant proportion (about 80%) as MgATP^" in solutions in which the 
total MgCl2 concentration exceeds the total ATP concentration by 1-10 mM.
This was taken into consideration in the kinetic studies of trypanosomal PRPP 
synthetase and the concentration of Mg^+ exceeded the concentration of ATP by 
1 or 2mM throughout these experiments.
3.4.27. Substrate saturation experiments with trypanosomal PRPP synthetase 
with Mg ATP2' as the varying substrate.
In this investigation the total MgATP^" concentration in the assay was 
varied while keeping the R5P concentration fixed at 2.87mM and the Mgx 
concentration in excess of the ATP concentration in the assay. The MgATPx" 
concentration was calculated as 84.1% of the ATP added, since Mg^+ was in 
excess by 2mM over the ATP concentration in the assay.
The rate of reaction of trypanosomal PRPP synthetase increased with 
increasing MgATP^- concentrations up to about 0.35 mM MgATP^', after which 
the reaction rate decreased. The data were fitted to a standard substrate inhibition 
equation, v= Vmax/(1 + Km/[S] + [S]/Ki), and presented in Figure 3.12. From a 
computer program for high substrate inhibition written by Ian Goodyear, 
Biochemistry Department, Bath University, the kinetic parameters for 
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Figure 3.12. Substrate saturation experiments with trypanosomal PRPP 
synthetase with MgATP^' as the varying substrate.
The investigation was carried out using partially purified enzyme 
preparation (1.23{ig protein in the assay with specific activity of 1.024 
mUnits/mg protein in the standard assay), and 8|iM [^Cjhypoxanthine in the 
assay. The experiment was done with fixed R5P concentration of 2.87mM and 
2mM MgCl2 (excess of ATP) concentration, using the standard assay, with 
TEA-HC120mM (pH 7.6) instead of the usual 20mM KH2P04 (pH 7.6) buffer.
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KiaPP MgATP^" of 0.25mM and VmaxaPP of 2.23 munits enzyme/ml enzyme 
preparation (specific activity of PRPP synthetase of 2.04 munits/mg protein).
3.4.28. Substrate saturation experiments with trypanosomal PRPP synthetase 
with R5P as the varying substrate.
Figure 3.13 shows the substrate saturation curve for ribose-5-phosphate. 
The data were fitted to the Michaelis-Menten enzyme rate equation, 
v= Vmax [S]/([S]+Km) and the apparent kinetic parameters were estimated using 
the Direct-Linear plot of Eisenthal and Comish-Bowden (1974). The calculated 
K m aPP of trypanosomal PRPP synthetase for R5P was 27 ± 9|iM for the 
trypanosomal PRPP synthetase. The calculated Vmax of trypanosomal PRPP 
synthetase for R5P was 1.55 ± 0.3 munits/mg protein in the partially purified 
PRPP synthetase preparation.
It was considered as unlikely that the physiological concentration of R5P 
would be higher than 5 mM so this was the highest R5P concentration assayed.
3.4.29. Effect of Mg^+ on enzvme activity.
The efect of Mg^+ concentration on the activity of the partially purified 
trypanosomal PRPP snthetase was investigated at a R5P concentration of 
2.87mM and 3 fixed MgATP^" concentrations. At this R5P concentration the 
activity is maximal as shown in Figure 3.13. A magnesium concentration of 
OmM excess denotes that magnesium was present in the assay at the same 
concentration as ATP (1.43mM, the concentration of ATP of the standard assay). 
The concentrations of MgATP^" were chosen to represent different aspects of the 
substrate/activity profile as shown in Figure 3.12. From figure 3.12 it is seen that 
MgATP^' concentration at 0.0202 mM and 0.101 mM is at the ascending branch 
of the high substrate inhibition curve while 2.06mM MgATP^" is at an inhibitory 
concentration of MgATP^".
It was found that excess Mg^+ (above ATP concentration) was 
inhibitory. The activity of PRPP synthetase was plotted against excess
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Figure 3.13. Substrate saturation experiments with trypanosomal PRPP 
synthetase with R5P as the varying substrate.
The magnesium concentration throughout the assay was kept at ImM 
excess over the [MgATP^-] concentration which was constant at 0.101 mM at all 
the R5P concentrations assayed. The absence of [MgATP^-] constituted the 
blank. The assay was carried out for 10 minutes at 37°C as usual. The specific 
activity of the partially purified PRPP synthetase used was 1.93 munits/min/mg 
protein and 1.08|ig protein was included in each assay.
The data were fitted to the Michaelis-Menten enzyme rate equation, v= 
Vmax [S]/([S]+Km) and the kinetic parameters were estimated using the Direct- 
Linear plot of Eisenthal and Comish-Bowden (1974).
magnesium concentration and presented in Figure 3.14. The results were 
expressed as fractional inhibition, i, defined as:
i = 1 ...........
v0
where v q 1 and v q  are the reaction rates in the presence and absence of inhibitor 
respectively.
The insert to Figure 3.14 shows the results plotted as fractional inhibition 
against excess magnesium concentration at the 3 fixed MgATP^" concentrations. 
The calculated values for the 'operational' inhibition constant are presented in 
Table 3.21. It appears that the decrease in activity of the partially purified PRPP 
synthetase preparation did not differ (within experimental error) with the 
concentration of MgATP^" in the assay.
The results were plotted as activity versus MgATP^" concentration at the 
five excess magnesium concentrations and presented in Figure 3.15 as hyperbolic 
curves after the data had been fitted to the Michaelis-Menten enzyme rate 
equation as for the substrate saturation graphs. The computer programme was 
also used to obtain the apparent kinetic parameters, Km and Vmax from the 
Direct Linear Plot of Eisenthal and Comish-Bowden (1974). The apparent 
kinetic parameters Km and Vmax so obtained are presented in Table 3.22. From 
the data in Table 3.22 it appears that excess magnesium (over ATP) is a 
competitive inhibitor with respect to MgATP^', since increasing excesses of 
magnesium gave unaltered (within experimental error) apparent Vmax values 
and increasing apparent Km values. The secondary plots of the ratio of apparent 
Km and Vmax against excess magnesium concentration and of the reciprocal of 
the apparent Vmax against excess magnesium concentration are presented in 
Figures 3.16 and 3.17 respectively. From figure 3.16, a plot of apparent 
Km'/Vmax' against Mg^+ excess, a straight line was obtained with x-axis 







Excess Magnesium concentration (mM).
Figure 3.14. Activity of trypanosomal PRPP synthetase plotted against excess 
Mg2+ concentration in the assay at 3 fixed concentrations of MgATP^'.
The [R5P] was fixed at 2.87mM throughout the experiment.
■-------■ represent the assay with [MgATP^"] = 0.0202mM,
□-------□ represent the assay with [MgATP^"] = O.lOlmM and
▲------▲ represent the assay with [MgATP^-] = 2.06mM.
In the insert the data are presented as fractional inhibition plotted against excess 
[Mg^4]. The curves were fitted by computer to the Michaelis - Menten enzyme 
rate equation.
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Table 3.21. The ’operational' inhibition constant of excess magnesium 
concentration for trypanosomal PRPP synthetase.
[R5P] [MgATP2"] 'Operational' inhibition constant
(mM) (mM) (mM)
2.87 0.0202 5.320 ± 1.485
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Figure 3.15. Activity of trypanosomal PRPP synthetase plotted against 
MgATP2' concentration. The curves were fitted by a computer program for 
Michaelis - Menten rate equation with apparent Km and Vmax values calculated 
from the Direct Linear Plot as quoted in text
■------■ represent the assay with OmM Mg^+ excess over [ATP],
□------□ represent the assay with ImM Mg^+ excess over [ATP],
▲------▲ represent the assay with 2mM Mg^+ excess over [ATP],
O-----O represent the assay with 5mM Mg^+ excess over [ATP] and
a a  represent the assay with lOmM Mg^+ excess over [ATP].
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Table 3.22. The calculated apparent kinetic parameters for inhibition by five 







0 0.0179 ± 0.0045 2.91 ±0.115
1 0.0266 ± 0.0053 2.99 ±0.060
2 0.0390 ± 0.0077 2.84 ±0.115
5 0.1010 ±0.0940 2.88 ±0.125
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Figure 3.16. Secondary plot of apparent Km/Vmax (from Direct Linear plot 
estimates of data presented in Figure 3.15) against excess Mg concentration 







Excess Magnesium concentration (mM).
Figure 3.17. Secondary plot of reciprocal of apparent Vmax (from Direct
O I
Linear plot estimates of data presented in figure 3.15) against excess Mg^ 
concentration over ATP concentration in the assay.
plot of l/VmaxaPP the estimate of the inhibition constant Ki for the enzyme- 
substrate complex was obtained as 54.9 ±15 mM.
The free concentration of magnesium was likely to have been 
overestimated since no consideration was given to the binding of magnesium to 
R5P and PRPP, as well as for the magnesium interaction with the coupling 
enzyme HGPRTase. The discrepancy in the concentration of free magnesium is 
likely to be small and fairly constant so patterns gave a reasonable approximation 
to the true effect of free Mg^+ on trypanosomal PRPP synthetase.
3.4.30. ADP inhibition studies of trypanosomal PRPP synthetase.
ADP inhibition was investigated at two fixed concentrations of each 
substrate while varying the other. The MgATP^" concentrations were 0.036mM 
and 0.36mM, chosen so as to represent ascending and maximal activities 
respectively as shown in Figure 3.12. The R5P concentrations chosen were 
0.057mM (near the Km) and 2.87mM (saturating) (See Figure 3.13). The assays 
were essentially the standard assay but with lOmM MgC^, instead of the 5mM 
final concentration. The partially purified enzyme preparation (1.23fig 
protein/assay), which had a specific activity of 1.024 mU/mg protein and 0.37 |ig 
protein/p.1 was used for the kinetic studies.
The results are shown in Figures 3.18 and Figure 3.19 as plots of activity 
versus ADP concentration. It can be seen that ADP acts as an inhibitor for all 
four concentrations of MgATP^' and R5P. In order to assess more quantitatively 
the effect of substrate (S) concentration on the ADP inhibition, the results are 
expressed as fractional inhibition (i) and are plotted against ADP concentration 
in the inserts of Figures 3.18 and Figure 3.19. From these plots an 'operational’ 
inhibition constant, ig 5 is obtained by fitting the data to the Michaelis-Menten 
equation by the computer programme also used for the substrate saturation 
experiments. The 'operational' inhibition constants are tabulated in Table 3.23.
The nature of ADP inhibition was assessed from Dixon and Comish- 










Figure 3.18. Activity against ADP concentration at fixed low R5P 
concentration 0.057mM and varied MgATP^" concentrations.
Insert shows the data plotted as fractional inhibition,i, against ADP concentration
at low (□----- □ ) and high ( ■----- ■ ) MgATP^‘ concentrations, at a fixed low


















Figure 3.19. Activity against ADP concentration at fixed high R5P 
concentration 2.87mM and varied MgATP^” concentrations.
Insert shows the data plotted as fractional inhibition,i, against ADP concentration
at low (□ □) and high ( ■ ■ ) MgATP^- concentrations, at a fixed high
R5P concentration of 2.87mM.
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Table 3.23. Apparent kinetic parameters for the 'operational' inhibition 





'Operational' inhibition constant 
(mM)
0.057 0.036 0.00646 ±0.0144
0.057 0.360 0.03890 ±0.0215
2.87 0.036 0.02050 ±0.0087










Figure 3.20. Dixon plot of 1/v against inhibitor (ADP) concentration, at a fixed 
low R5P concentration of 0.057mM and varying MgATP^" concentrations, at a 
total concentration of Mg^+ in the assay of lOmM.
□------ □ represents the assay with [MgATP^']= 0.036mM,
■ ■ represents the assay with [MgATP^"]= 0.36mM.
and figure 3.21 are the results plotted as Dixon plots for R5P fixed at low and
high concentration respectively while MgATP^" was varied. In both cases the
lines cross in the second quadrant (above the x-axis). Similarly Figures 3.22 and
3.23 present the data as Dixon plots at fixed low and high MgATP^"
concentrations while varying R5P. In both cases the lines cross in the third
quadrant (below the x-axis). Figures 3.24 and 3.25 present the data as Comish-
Bowden plots at fixed low and high R5P concentrations and varying MgATP^’
concentration respectively. In these cases, the lines cross in the third quadrant
(below the x-axis). Similarly Figures 3.26 and 3.27 present the data as Comish-
Bowden plots at fixed low and high MgATP^" concentrations and varying the
R5P concentration respectively. In these cases the lines cross in the second
quadrant (above the x-axis).
From the Dixon and Comish-Bowden plots it appears that ADP acts as a
mixed inhibitor with respect to both substrates. The inhibitor constants Ki (for
✓
the free enzyme) and Ki (for the substrate-enzyme complex) were estimated
using the Dixon and Comish-Bowden plots respectively. The slopes and
intercepts of the computed ’best-fit* staight lines through the data were used to
calculate the inhibition constants. The x-coordinate of the intersection point of
the two lines in the Dixon plot, gives the value of -Ki, while the respective point
✓_
from the Comish-Bowden plot gives the value of the -Ki. The estimates of the 
inhibition constants are given in Table 3.24.
✓
In the case of R5P, the mixed inhibition is R5P-inhibited (Ki<Ki), while
in the case of MgATP^" the mixed inhibition by ADP appears to be MgATP^"- 
✓
enhanced (Ki>Ki). Further experiments need to be carried out with more R5P 
concentrations to clearly determine whether at low R5P concentrations the ADP 
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Figure 3.21. Dixon plot of 1/v against inhibitor (ADP) concentration, at a fixed 
high R5P concentration of 2.87mM and varying MgATP^" concentrations, at a 
total concentration of Mg^+ in the assay of lOmM.
o □ represents the assay with [MgATP^"]= 0.036mM,










Figure 3.22. Dixon plot of 1/v against inhibitor (ADP) concentration, at a fixed 
low MgATP^" concentration of 0.036mM and varying R5P concentrations, at a 
total concentration of Mg^+ in the assay of lOmM.
□------□ represents the assay with [R5P]= 0.057mM,






Figure 3.23. Dixon plot of 1/v against inhibitor (ADP) concentration, at a fixed 
high MgATP^- concentration of 0.36mM and varying R5P concentrations, at a 
total concentration of Mg^+ in the assay of lOmM.
□----- □ represents the assay with [R5P]= 0.057mM,







Figure 3.25. Comish-Bowden plot of [MgATP^‘]/v against inhibitor (ADP) 
concentration at fixed high R5P concentration of 2.87mM and varying MgATP^" 
concentrations, at a total concentration of Mg^+ in the assay of lOmM.
D-------o represents the assay with [MgATP^“]= 0.036mM,





Figure 3.24. Comish-Bowden plot of [MgATP^"]/v against inhibitor (ADP) 
concentration at fixed low R5P concentration of 0.057mM and varying 
MgATP^" concentrations, at a total concentration of Mg^+ in the assay of 
lOmM.
□ □ represents the assay with [MgATP^"]= 0.036mM,








Figure 3.26. Comish-Bowden plot of [R5P]/v against inhibitor (ADP) 
concentration at fixed low MgATP^" concentration of 0.036mM and varying 
R5P concentrations, at a total concentration of Mg^+ in the assay of lOmM.
□ □ represents the assay with [R5P]= 0.057mM,









Figure 3.27. Comish-Bowden plot of [R5P]/v against inhibitor (ADP) 
concentration at fixed high MgATP^' concentration of 0.36mM and varying R5P 
concentrations, at a total concentration of Mg^+ in the assay of lOmM.
D------ D represents the assay with [R5P]= 0.057mM,
■------ ■ represents the assay with [R5P]= 2.870mM.










0.057 varied 0.122 ±0.084 0.772 ±1.591
2.870 varied 0.056 ±0.089 0.074 ±0.104
varied 0.036 0.149 ±0.098 0.050 ±0.081
varied 0.360 0.261 ±0.063 0.057 ±0.0238
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3.4.31. Results on localisation study .of T.b.brucei PRPP synthetase.
Distribution patterns of marker enzymes, PRPP synthetase and protein 
were carried out by the group in Brussels, as previously described by Steiger et 
al. (1980). Since density boundaries are not strictly reproducible, the histograms 
were normalised over 15 fractions. The density scale, divided into 15 normalised 
fractions of identical increment, extends from 1.07 to 1.27 g/cm^. The surface 
area of each histogram section is equivalent to the fractional amount of 
constituent present within each normalised fraction (Steiger, Opperdoes and 
Bontemps, 1980).
The PRPP synthetase activity was expressed in milliunits, that is the 
amount of enzyme catalysing the formation of 1 nmole of PRPP per minute 
under the standard assay conditions employed. The results, which are presented 
in table 3.25 are expressed as relative activity in each fraction as a percentage of 
the activity of fraction 14 and sent to the laboratory of origin.
The data were analysed in Brussels, using a subcellular fractionation 
computer programme and the results presented in Figure 3.28, where the 
distribution of the PRPP synthetase was compared with those of a number of 
marker enzymes. The abbreviations used were as follows: prot, protein; manno, 
a-D-mannosidase (lysosomes); AcPase, acid phosphatase (flagellar pocket); a- 
gluco, a-D-glucosidase (plasma membrane); ALAT, alanine aminotransferase 
(cytosol); HK, hexokinase (glycosomes); ICDH-P, NADP-linked isocitrate 
dehydrogenase (mitochondrion); 3-AMPase, 3-nucleotidase (plasmamembrane); 
PRPP, phosphoribosylpyrophosphate synthetase. The recovery (R) is indicated 
within parenthesis. In the case of PRPP synthetase, the recovery is 89.7%. PRPP 
synthetase behaves as a soluble enzyme. The peak of PRPP synthetase activity is 
extremely sharp and the fraction with the highest activity was at a sucrose 
density of around 1.11 to 1.13 g crn’3
From figure 3.28 it is clear that PRPP synthetase sediments much faster 
than alanine aminotransferase or the soluble components of a-D-glucosidase or 
3-nucleotidase. As discussed by Dr.F.R. Opperdoes (personal communication),
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Table 3.25. Phosphoribosylpyrophosphate synthetase (EC 2.7.6.1) activity in 
subcellular fractions of bloodstream form of Tbrucei.
Gradient TR 21A (STE-GRADIENT 211083)


















The activity of PRPP synthetase in each fraction where,
* milliunits are nmoles of PRPP produced per minute.
** relative activity is expressed as a percentage of the activity of fraction 14. 
The assay contained twice the units of HGPRTase (4munits/assay) and 12|iM 
[ * ^ C] hypoxanthine in the assay. All the other variables of the assay were the 
same as in the standard assay.
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D E N S IT Y
Figure 3.28. Isopycnic centrifugation in sucrose of a large-granule fraction 
(65.3mg protein) from T.b.brucei. The percentage of recovery (sum of the 
activity of all fractions with respect to the activity of the layered sample) for each 
protein is given within parentheses. Frequency, on the ordinate, is defined as the 
percentage of recovered activity in a fraction divided by the density range 
covered by the same fraction. The results are duplicates of a single experiment 
(See text for abbreviations).
this is a peculiar behaviour for a soluble enzyme unless it has a very high 
molecular weight due to aggregation. An alternative explanation offered, would 
be that the enzyme was associated with membrane vesicles equilibrating at a 
density of around 1.11 to 1.13 g cm"^ . As pointed out, membrane vesicles 
normally give a very broad distribution due to their heterogeneity, rendering this 
explanation less likely. It is reported in the literature that PRPP synthetase from 
other sources, such as, rat liver (Roth et a i, 1974), Salmonella typhimurium 
(Switzer, 1969) and human erythrocytes (Fox and Kelley, 1971), exists as a low 
solubility enzyme with a large molecular weight The size of the respective 
enzyme from the bloodstream form of T.brucei was investigated both in the 
crude extract and in the partially purified preparation (see following section).
3.4.32. Gel filtration of PRPP synthetase from T.bruceL 
Calibration of Superdex S-200 column.
Figure 3.29 shows the graph of elution volume plotted against the log molecular 
weight of standard proteins on the Superdex S-200 column which was 
equilibrated with 50mM potassium phosphate, pH 7.6,6mM magnesium 
chloride, ImM EDTA (disodium salt) and 2.5mM mercaptoethanol.
Partially purified PRPP synthetase from T.bruceL
In the partially purified enzyme preparation, PRPP synthetase activity 
eluted from Superdex S-200 column after 59ml (figure 3.30). From figure 3.29 
this elution volume corresponds to a molecular weight of about 193,000.
The specific activity of the partially purified heat treated enzyme 
preparation was 0.421 munits/mg protein. The enzyme recovery in fraction 59 
was 4% of total units loaded but the specific activity enrichment was 18.9x to 
7.957 munits/mg protein.
Crude homogenate of T.brucei.
The elution profile of PRPP synthetase activity from Superdex S-200 gel 
filtration column in a crude T.b.brucei homogenate is presented in Figure 3.31.
With crude homogenate the PRPP synthetase activity eluted as a large 
peak in the void volume of the column. The exclusion limit of the column was 
600,000. The Dextran blue 2000 eluted after 38ml, the void volume of the 
column. The molecular weight of the PRPP synthetase in the crude homogenate 
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Figure 3.29. Gel filtration of PRPP synthetase from Tbrucei.
Calibration of Superdex S-200 (16/60) gel filtration column with known 
molecular weight marker proteins. The equilibration and elution buffer was 
50mM potassium phosphate, pH 7.6,6mM magnesium chloride, ImM EDTA 
(disodium salt) and 2.5mM mercaptoethanol. The least square regression 
indicates a molecular weight of about 193,000 for partially purified Tbrucei 
PRPP synthetase preparation (position marked with a filled square).
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Figure 3.30. Elution of PRPP synthetase activity from Superdex S-200 gel 
filtration column using a partially purified enzyme preparation.
The equilibration and elution buffer was 50mM potassium phosphate, pH 
7.6, 6 mM magnesium chloride, ImM EDTA (disodium salt) and 2.5mM 
mercaptoethanol. Fraction volume was 1ml. The enzyme activity is expressed as 











































Figure 3.31. Elution of PRPP synthetase activity from Superdex S-200 gel 
filtration column in a crude T.bbrucei homogenate.
Blue dextran elution is marked with □------□ . The equilibration and
elution buffer was 25mM Tris-HCl, pH 7.2, ImM EDTA (disodium salt) and 
0.25 M sucrose. The fraction volume was lml. The enzyme activity was 
expressed as counts per 10 minutes per 10pl of fraction assayed with the standard 
method. Both dextran blue and PRPP synthetase eluted in the void volume of the 
colume which is 38ml. The molecular weight of the enzyme was therefore 
greater than the column exclusion limit of 600,000.
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3.5. Discussion.
From the data described in Chapter 2 it was confirmed that the 
bloodstream forms of T.b.brucei converted a small, but significant proportion of 
the metabolised glucose to C5 carbohydrate which was incoiporated into the 
RNA of the cells. PRPP synthetase is the sole enzyme responsible for formation 
of PRPP which gets converted into nucleotide building blocks through the action 
of phosphoribosyltransferases. A number of phosphoribosyltransferases had been 
detected and quantitated in crude extracts of T.b.brucei by other workers 
(Gutteridge and Davies, 1982 and Davies et al., 1983). The detection of the sole 
enzyme responsible for the formation of the key metabolite PRPP was therefore 
pursued beyond the initial failure to detect it by the orotate removal assay. The 
sensitivity of the orotate removal assay was inadequate for detection of the 
enzyme from the trypanosomes. Equally limited was the use of the ^ P  transfer 
assay due to the inadequate purification of the enzyme from T.b.bruceL As it was 
shown in the pentose phosphate specificity experiments the partially purified 
trypanosomal PRPP synthetase preparation contained other contaminating 
enzymatic activities that did not allow the use of the ^ P  transfer assay. The 
method was tried on the partially purified enzyme preparation but found to yield 
very high blanks that made the assay impossible to use. This assay is ideal 
because it is the only direct assay to measure PRPP synthetase and because it is 
fast and very accurate, it is preferred for kinetic assays of highly purified enzyme 
preparations. Its drawback is the requirement for pure enzyme preparations free 
from ATPase-like activities such as ribose-5-phosphate kinase, ribulose-5- 
phosphate kinase, and ribokinase.
It was found that the coupling of PRPP synthetase to HGPRTase resulted 
in a useful and reliable method for assaying the activity of PRPP synthetase from 
trypanosomes. The purification protocol resembled that of the same enzyme from 
different sources but with the inherent problem of very low specific activity. As 
for the same enzyme from rat liver the extent of purification depended on the 
specific activity of the crude extract (Roth et al. , 1974). The yield of partially
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purified PRPP synthetase was adequate for a simple kinetic study and for 
comparison of some of the properties of the trypanosomal enzyme to those of the 
enzyme from other sources.
The large number of potential inhibitors of PRPP synthetase from other 
sources (Fox and Kelley, 1971) makes speculation regarding the endogeneous 
inhibitor present in the crude extract difficult. It must be of small size since it 
was removable by dialysis and gel filtration by passing the extract through a 
Sephadex G-25 column. The endogeneous inhibitor may have been ADP, since 
this was found to be inhibitory to trypanosomal PRPP synthetase. Further work 
would be required to isolate and characterise the endogeneous substance of 
inhibitory action on trypanosomal PRPP synthetase.
Inorganic phosphate activates all known PRPP synthetases including the 
trypanosomal one. Inorganic phosphate activated the trypanosomal PRPP 
synthetase but was not an absolute requirement for its stability since in its 
absence the enzyme remained stable. This is in contrast to the situation with 
human erythrocyte and the S.typhimurium PRPP synthetases which have an 
absolute requirement for phosphate for both stability and catalytic activity (Fox 
and Kelley, 1971; Switzer, 1969). However, the rate of decay of activity of PRPP 
synthetase on storage at 0° and 37°C was unaffected by Pi. The trypanosomal 
PRPP synthetase is similar to the rat liver enzyme (Roth et al. , 1974), in not 
requiring phosphate for stability, as shown by the failure of phosphate-free buffer 
to inactivate the enzyme.
The rat liver enzyme has been found to be stabilized by albumin 
(50|ig/ml), EDTA (ImM), or dithiothreitol (ImM) and loses activity when 
assayed at low protein concentration (Roth et al. , 1978). Iodoacetamide and p- 
chloromercuribenzoate abolish the effect of these compounds, suggesting that 
stabilisation of the enzyme is due to the protection of an essential sulphydryl 
group on the enzyme (Roth and Deuel, 1974). Stabilisation of PRPP synthetase 
by EDTA could result from chelation of contaminating heavy metals present 
during the assay.
Fox and Kelley (1971) showed that ATP (0.3mM) and 6mM MgCl2 
stabilised the human erythrocyte enzyme at -70°, 4°, and 60°C. These substances 
also partially protected the enzyme from inactivation by dithiothreitol at -70°C. 
MgATP^", which is the true substrate for the trypanosomal PRPP synthetase, 
was found to be highly inhibitory at concentrations above about 0.36mM.
The substrate specificity of trypanosomal PRPP synthetase was strict as 
would have been expected for a tightly regulated enzyme that supplies the cell 
with such a key metabolite as PRPP. Although there was no substantial activity 
with any of the nucleotide triphosphates or pentose phosphate species other than 
R5P, the blank was as high as the test in the ITP experiment This could be due 
to the presence of ITP hydrolysis products which equilibrated with the 
radioactive IMP pool or which were generated by some contaminating enzyme 
activities in the partially purified preparation used. Because the test was as high 
as the blank, this was not due to net PRPP synthesis, since the blank contains no 
R5P which is required for PRPP synthetase activity.
T.b.brucei PRPP synthetase, like the rat liver (Roth et al., 1974), 
S.typhimurium ( Switzer, 1969) and human erythrocyte (Fox and Kelley, 1971) 
PRPP synthetase has strict structural requirements for the pyrophosphoryl donor. 
The relative unimportance for the 2-hydroxyl position of the ribose moiety of the 
purine nucleotides, was demonstrated in the similar activities with ATP and 
dATP as substrates.
The enzyme preparation utilised ribulose-5-phosphate with a similar rate 
as it utilised ribose-5-phosphate, suggesting the ribulose-5-phosphate could have 
been a substrate for PRPP synthetase or that it was converted to ribose-5- 
phosphate first. The first suggestion involves the formation of PPRuP which is 
not a substrate for HGPRTase, which has a strict substrate specificity for PRPP 
(Flaks, 1963a). The second explanation is more likely especially as D-ribose-5- 
phosphate ketol-isomerase (EC 5.3.1.6) activity may have co-purified with PRPP 
synthetase. As reported by Cronin et al. (1989), bloodstream Tbrucei forms have 
D-ribose-5-phosphate ketol-isomerase activity with specific activity in a crude
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extract of 144 nmoles/min/mg protein. This specific activity is much higher than 
that of PRPP synthetase, indicating that ribose-5-phosphate derived from 
ribulose-5-phosphate is supplying the PRPP synthetase and that ribose-5- 
phosphate formation is not rate limiting. The reaction continues as ribose-5- 
phosphate continues to be available to PRPP synthetase in the 30 minute 
incubation. From the specific activity of 144 nmoles/minute/mg protein it can be 
estimated that the partially purified PRPP synthetase preparation contained 
1.06% of protein as D-ribose-5-phosphate ketol-isomerase.
Ribose-5-phosphate is the preferred and possibly the only pentose- 
phosphate substrate for trypanosomal PRPP synthetase. The lack of pure PRPP 
synthetase preparation makes it impossible to conclude whether the activity 
observed with ribulose-5-phosphate is due to PRPP synthetase or D-ribose-5- 
phosphate ketol-isomerase activity, which remained in the partially purified 
PRPP synthetase preparation.
Hypoxanthine-guanine phosphoribosyltransferase (EC 2.42.8) from 
Brewer's yeast, which was the enzyme supplied by Sigma, has a specific 
requirement for PRPP which cannot be replaced with ATP, ribose-1,5- 
diphosphate, ribose-5-phosphate, ribose-1-phosphate or combinations of the 
latter two substrates with ATP (Flaks, 1963b). Because of the indirect assay for 
PRPP synthetase activity used, involving the coupling to HGPRTase activity, the 
mechanism of PRPP synthetase with pentose phosphate substrate, would have to 
be such that PRPP is always produced, if the activity is to be so measured.
It is therefore likely that the partially purified trypanosomal PRPP 
synthetase preparation has both D-ribose-5-phosphate ketol-isomerase and 
phosphoribomutase contaminating activities, since incubations with ribulose-5- 
phosphate as well as with ribose-1-phosphate resulted in PRPP synthetase 
activity.
PRPP synthetases from Salmonella typhimurium (Switzer and Gibson, 
1978) and from rat liver (Roth et al. , 1974) have a strict specificity for ribose-5- 
phosphate. Purified human erythrocyte PRPP synthetase has been reported to
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exhibit 34% activity with ribulose-5-phosphate as substrate compared to activity 
with ribose-5-phosphate (Fox and Kelley, 1971). Because of possible 
contamination of commercial ribulose-5-phosphate preparations with ribose-5- 
phosphate, the activity may not reflect the formation of PPRuP (Roth et al. , 
1974). It is most likely that trypanosomal PRPP synthetase shares in the strict 
substrate specificity.
It is possible that the apparent activity with ribose-1-phosphate could 
have arisen from the conversion of ribose-1-phosphate and [^C] hypoxanthine 
to [^C] inosine, by the action of purine-nucleoside phosphorylase (EC 2.4.2.1), 
followed by nucleoside kinase to [^C] IMP.
It is unlikely that PRPP synthetase can utilise ribose-1-phosphate as a 
substrate, although it would seem advantageous to the parasite if it could use 
(recycle) the ribose-1-phosphate produced by nucleoside phosphorylases to form 
nucleotides through PRPP synthetase. Phosphoribomutase activity is distinct 
from phosphoglucomutase and exists in many cells such as Baker's and Brewer's 
yeast, uterine muscle (rabbit, bovine, human) and in human blood (Guarino and 
Sable, 1956), and might also exist in trypanosomes. It would be interesting to 
find out if such activity exists in T.brucei.
Unlike PRPP synthetase of human erythrocytes (Fox and Kelley, 1971), 
Ehrlich ascites tumor cells (Wong and Murray, 1969) and the S.typhimurium 
enzyme (Switzer, 1969), the T.b.brucei enzyme showed activity with calcium. In 
the copper system, there was a precipitate formed. The activity with Cu^+ was as 
high as for the blank and very high for test up to 200% of that with Mg^+ alone.
For the Salmonella enzyme, Mg^+ is required for formation of the 
bidentate MgATP^' complex, which serves as the substrate for the enzyme and 
for the true product MgPRPP (Li et al. , 1978). Excess Mg^+ is also required for 
binding to the subunits of PRPP synthetase and activating the enzyme when 
MgATP^" is available. For the trypanosomal PRPP synthetase excess magnesium 
over that of ATP was found to be a competitive inhibitor with respect to 
MgATP^“, suggesting the binding of magnesium at the active site of PRPP
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synthetase at the binding site of MgATP^*. Because of the coupling assay used, 
the magnesium concentration was kept at SmM in the standard assay since 
HGPRTase activity was enhanced by free magnesium.
PRPP synthetase from TJbrucei showed a high affinides for its substrates, 
R5P and MgATP^“ with apparent Km of 27jiM and 63|iM respectively. The Km 
values for the trypanosomal PRPP synthetase arc comparable to the Km values 
for this enzyme from other sources as shown in Table 3.26. The Km values for 
R5P and MgATP^" of the trypanosomal enzyme resemble those of the Ehrlich 
ascites tumor cells and the human erythrocytes.
The trypanosomal enzyme showed high substrate inhibition by MgATP^" 
as the Salmonella enzyme, but with higher Ki. High substrate inhibition by 
MgATP^" is also reported for the pigeon liver PRPP synthetase where ATP 
levels greater than 2mM (Flaks, 1963b). The falling off of the rate at MgATP^" 
concentrations greater than 0.35mM thus indicates that trypanosomal PRPP 
synthetase has a sensitivity to substrate concentration not shown by PRPP 
synthetase from other sources. Whether this represents a control feature of this 
enzyme in the metabolic pathway leading to RNA ribose must await future 
studies. These studies would have to involve a detailed analysis of the subcellular 
concentrations of ATP, Mg^+ and R5P, and studies of MgATP^' and R5P 
kinetics.
The most potent inhibitor of human, Ehrlich ascites tumor cell, and rat 
liver PRPP synthetases is ADP, a competitive inhibitor of the enzyme with 
respect to MgATP^' (Fox and Kelley, 1972; Wong and Murray, 1969; and Roth 
and Deuel, 1974). ADP was found to be an inhibitor of trypanosomal PRPP 
synthetase with a Ki of about 0.055mM. Although the inhibition seems to show 
trends of mixed inhibition in nature, it appears from the inhibition constants 
obtained that within experimental error the inhibition may be competitive with 
respect to both R5P and MgATP^\ Further work is required to give a better 
understanding of the system. The human erythrocyte enzyme shows an inhibition 
constant (Ki) for ADP of 10'^ M, a value well below the intracellular ADP
Enzyme source Km for MgATP2" Km for R5P Additional comments.
T.brucei bloodstream 
forms (This work)
63 pM 27 pM Substrate inhibition 
by MgATP2" with 
Ki 250 pM
Human erythrocytes 
(Fox and Kelley, 1971)
14 pM 33 pM
S. typhimurium 
(Switzer, 1971)
46 pM 160 pM Substrate inhibition 
by MgATP2” with 
Ki 64 pM
Ehrlich Ascites tumor cells 
(Wong and Murray, 1969)
60 pM 50 pM
Rat liver
(Roth et al. , 1974)
220 |JJV1 290 pM Substrate inhibition 
at R5P concentration 
> 1.5 mM
Table 3.26. Kinetic parameters of PRPP synthetase from various sources. 191
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concentration for human erythrocytes (Fox and Kelley, 1972). This finding 
suggests a physiological role for the competitive interaction of adenylates in 
controlling enzyme activity and supports the proposal of Atkinson and Fall 
(1967). Atkinson and Fall (1967) proposed that the potent inhibition of E.coli 
PRPP synthetase by ADP may be part of a general ATP conservation system that 
causes the rate of expenditure of ATP to be curtailed when the "energy charge" 
of the cell decreases slightly; and that such ATP conservation control may be 
superposed on product negative feedback regulation of PRPP synthetase. The 
"energy charge" of the adenylate system, defined as (ATP + 1/2 ADP)/(AMP + 
ADP + ATP), has been proposed by Atkinson and Walton (1967) as a 
fundamental metabolic control parameter.
"Energy charge" studies would have to be acompanied by 
compartmentalisation studies because the energy charge of the glycosomes 
would be expected to be markedly different to the energy charge of the cytosol.
The detection of PRPP synthetase in combination with the incorporation 
of glucose into the ribose moiety of RNA, gives good evidence for the formation 
of PRPP in vivo, presumably from R5P precursor. The R5P precursor may not be 
exclusively supplied from an active pentose phosphate pathway, but certainly a 
fraction of it is.
Cronin et al. (1989) mentioned that all the enzymes of the pentose 
phosphate pathway in bloodstream forms of T.brucei are present in the cytosol, 
although no direct evidence for this was given. The behaviour of PRPP 
synthetase as a soluble enzyme is consistent with the results of Cronin et al. 
(1989), in view of R5P being the substrate of the PRPP synthetase reaction as 
well as the end-product of the classical oxidative pentose phosphate pathway.
Trypanosomes depend on active salvage and interconversion pathways 
for both purine bases and nucleosides since they are incapable of de novo purine 
synthesis. Incorporation of purine bases and nucleosides has been demonstrated 
in mammalian host forms of T.b.brucei (James and Bom, 1980). Three 
phosphoribosyltransferase activities with fairly high levels of activity
(0.6 - 5.6 nmole/min/mg protein ; for T.brucei trypomastigotes), capable of 
salvaging adenine, hypoxanthine and guanine were reported (Davies et al. , 
1983). Higher rates were found for these activities than for the purine nucleoside 
kinases(0.045 - 0.4 nmole/min/mg protein). The same workers failed to detect 
inosine phosphorylase activity and suggested that hypoxanthine salvage occurs 
only via the phosphoribosyltransferase route, while there were detectable 
adenosine and guanosine phosphorylase activities (2.9 and 0.36 nmole/min/mg 
protein, respectively). Purine metabolism of the bloodstream forms of African 
trypanosomes is still poorly understood.
Gutteridge and Davies (1982) showed that purine phosphoribosyl­
transferase activity in the culture epimastigote forms of T.cruzi involves two 
separate enzyme proteins: one, active with adenine as substrate, occurs in the 
cytosol; the other, active with both hypoxanthine and guanine, occurs in the 
glycosomes. The activities with hypoxanthine and probably guanine were found 
to be particulate but not latent. Isopycnic centrifugation in sucrose gradients 
confirmed the particulate nature of the activities with hypoxanthine and guanine 
and showed that they banded in the density range 1.23 - 1.25 g/cm^, identical to 
that of glycolytic enzymes such as hexokinase and phosphofructokinase 
(Gutteridge and Davies, 1982). Whether HGPRTase activity is located on the 
outside of or within the glycosome is not clear. The apparent lack of latency 
compared with glycolytic enzymes is not significant since overall rates of 
reaction are lower and therefore it is unlikely that penetration of substrates would 
be limiting as it is with glycosomal enzymes. If it occurs within the glycosome, it 
is most likely to occur in the lumen or loosely attached to the membrane since it 
can easily be solubilised by freezing and thawing (Hammond and Gutteridge, 
1980).
Hammond et al. (1981) showed that the last two enzymes of UMP 
synthesis de novo, OPRTase and ODCase, co-sedimented with glycosomal- 
(microbody-)marker enzymes such as hexokinase (see figure 1.13 in the 
introduction section).
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The relevance of the glycosomal location of purine and pyrimidine 
phosphoribosyltransferases (PRTases) is unclear, but the common requirement of 
the enzymes for PRPP suggests that glycosomes may have a transport system for 
this compound or that the purine PRTases may be located on the surface of the 
organelle as has been suggested for orotate PRTase (Hammond and Gutteridge, 
1983). From similar studies on the purine metabolising enzymes of promastigote 
forms of Lmmexicana (Hassan et al. , 1985) it is suggested that channelling of 
purines, nucleosides and nucleotides between subcellular compartments is an 
integral part of purine metabolism in T.b.brucei, T.cruzi and Lmmexicana.
Another possibility would be that if cytosolic R5P is the substrate for at 
least part of PRPP synthetase activity, and if glucose is the source for this R5P 
then this may suggest a source of phosphorylated intermedeates to serve as 
substrate for the pentose phosphate enzymes in the cytosol which in turn suggests 
hexokinase activity in the cytosol as well as glycosome, or transport of 
phosphorylated hexose from the glycosome to the cytosol.
Initially, partially purified enzyme preparation of PRPP synthetase from 
the bloodstream form of T.brucei, was found to have a molecular weight of about 
193,000.
From the localisation study, T.brucei PRPP synthetase behaves as a 
soluble enzyme. However PRPP synthetase sediments much faster than alanine 
aminotransferase or the soluble components of a-D-glucosidase or 3'- 
nucleotidase. As discussed by Dr.F.R. Opperdoes (personal communication), this 
is a peculiar behaviour for a soluble enzyme unless it has a very high molecular 
weight due to aggregation.
This was found to be the case in subsequent gel filtration experiments 
with T.brucei crude extract, prepared in the same way as for the localisation 
study, which resulted in PRPP synthetase eluting in the void volume with 
molecular weight greater than 600,000. This finding explaines the sedimentation
behaviour of the enzyme. It also indicates another similarity of T.brucei PRPP 
synthetase to PRPP synthetase from other sources, such as, rat liver (Roth et al. , 
1974), Salmonella typhimuriwn (Switzer, 1969) and human erythrocytes (Fox 
and Kelley, 1971), which is reported in the literature to exist as a low solubility 
enzyme with a large molecular weight
PRPP synthetase from all the sources studied this far, appears as a 
multimeric enzyme that exists in various states of subunit aggregadon.Results 
from gel filtration and sedimentation behaviour in localisation studies showed 
that PRPP synthetase from T.brucei also exists in more than one state of 
aggregation. In the crude homogenate which was prepared in the absence of 
magnesium, the enzyme exists as an aggregate of high molecular weight During 
the partial purification, the aggregate dissociates to an enzyme species of about
193.000 molecular weight which is catalytically active.
The subunit structure of human PRPP synthetase purified to apparent 
homogeneity, was found by Fox and Kelley (1971) to consist of a single subunit 
of molecular weight 33,200, which underwent reversible association to 
aggregated forms composed of 2,4, 8,16 and 32 subunits in response to the 
addition of Pi, MgATP^' or Mg^+. Similarly, Salmonella PRPP synthetase has a 
subunit molecular weight of 31,000 and the native enzyme exists in several states 
of aggregation with the predominant form having a molecular weight of about
160.000 (Switzer and Gibson, 1978). The enzyme from rat liver also has a 
complex molecular weight of subunit molecular weight of 40,500 enzyme 
molecules stacked together in long, linear aggregates as reported by Roth et al. 
(1974).
PRPP synthetase from T.b.brucei appears to be very similar in nature to 
the same enzyme from other sources possibly due to its tight regulation in order 




The misunderstanding that existed long in the literature on the lack of the 
pentose phosphate pathway as part of the carbohydrate metabolic capacity of 
trypanosomes has finally been put right. It was during the period of this research 
that the presence of the enzymes of the classical pentose phosphate pathway was 
published by Cronin et al. (1989). The present work has confirmed that in 
bloodstream forms of T.b.brucei there functions an oxidative pentose phosphate 
pathway that forms a small, but significant, proportion of glucose metabolism.
The detection of PRPP synthetase activity in the bloodstream and 
cultured procyclic trypanosomes has also been of importance. The doubling time 
of the bloodstream forms of trypanosomes in vivo was used in combination with 
the RNA yield as estimated in Chapter 2 to calculate the specific activity of 
PRPP synthetase in relation to the cells requirement for RNA ribose synthesis 
(Table 3.27). The activity of PRPP synthetase in the crude extract of bloodstream 
forms appears not to be sufficient for RNA ribose synthesis and supply of PRPP 
for the trypanosomal phosphoribosyl pyrophosphate utilising salvage enzymes. 
Therefore, there need to be other sources of the carbohydrate moiety of RNA for 
synthesis, possibly through the action of phosphorylases and nucleoside kinases 
which would also yield the monophosphate blocks for RNA synthesis.
The properties of the trypanosomal PRPP synthetase studied in the 
partially purified preparation have been found to be similar to the properties of 
the same enzyme from other sources. The main differences have been the high 
substrate inhibition observed by MgATP^" of the enzyme from bloodstream 
forms of T.b.brucei, the inhibitory effect of excess (over ATP) concentration of 
magnesium and the lack of requirement of inorganic phosphate for stability 
during storage. Compartmentalisation of certain enzymes into intracellular 
organelles is considered as a peculiarity of trypanosomes. The cytosolic 
localisation of PRPP synthetase makes it possible for the R5P produced by the 
enzymes of the oxidative branch of the pentose phosphate pathway to be 
accessible to PRPP synthetase. It also requires the availability of hexose
Table 3.27. Calculation of specific activity of trypanosomal PRPP synthetase 
and requirement for nucleotide synthesis for replication.
The long slender bloodstream forms of T.b.brucei are the forms which 
multiply in vivo in rats. The observed doubling time of these organisms in vivo in 
rats is 6-8 hours (Balber, 1972).
The RNA yield of 4x10^ bloodstream forms of T.b.brucei was calculated 
as 782.12 ± 470.19 pg RNA (from 17 separate estimations) from the data 
obtained in the experiments presented in chapter 2.
Taking the average molecular weight of a monophosphate component of 
RNA as 339.45, and dividing the pg of RNA by this value, the rate of RNA 
synthesis in bloodstream forms of T.b.brucei is calculated to be approximately 
1.37 nmoles RNA/min/lO^ cells, based on a doubling time of 7 hours.
The activity of PRPP synthetase in crude extracts of bloodstream forms 
of T.b.brucei is 0.625 nmoles PRPP formed/mi n/10^ cells from data presented in 
chapter3.
It appears that there is insufficient PRPP synthetase activity in 
bloodstream forms of T.b.brucei to account for RNA ribose synthesis, and that 
there must also be other source(s) of the carbohydrate moiety of RNA for 
synthesis, such as phosphorylases and nucleoside kinases (Fish et al. , 1982a), 
which would also yield the monophosphate building-blocks.
phosphate in the cytosol either produced directly by the action of cytosolic 
hexokinase or transported to the cytosol through a transporter located on the 
glycosomal membrane.
3.7. Suggestions for future >vprk,
Although the work described here seems to have no direct application to 
drug development, the detection, subcellular localisation and unfolding of some 
of the peculiar properties of trypanosomal PRPP synthetase such as high 
substrate inhibition by MgATP^', could prove useful to future workers in the 
search for safe and effective trypanocidal drugs.
It would be interesting to see if there is switching-on of the gene for 
PRPP synthetase when the availability of extracellular nucleic acid bases and 
nucleosides changes. This could be done by incubating bloodstream and 
procyclic forms of T.b.brucei in vitro in a defined medium with controlled 
additions of purine and pyrimidine nucleotide precursors and measuring the 
PRPP synthetase content to see if it changes. The PRPP synthetase gene may be 
part of an operon with the phosphoribosyltransferases, nucleoside kinases and 
other salvage enzymes constituents of the trypanosomes' complex nucleic acid 
metabolism.
Since trypanosomal PRPP synthetase is cytosolic it does not impose the 
additional problems of glycolytic enzymes for pharmacological inhibitors to get 
access to it and inhibit i t  It might be possible to find an inhibitor for 
trypanosomal PRPP synthetase and so inhibit nucleotide synthesis due to 
inhibition of the salvage pathways which require PRPP.
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